CURRICULUM VITAE (4.17.2025)

NAME: William John Gradishar, M.D., FACP, FASCO

CURRENT POSITION: Betsy Bramsen Professor of Breast Oncology &
Professor of Medicine
Director, Maggie Daley Center for Women's Cancer Care
Deputy Director, Clinical Network, Robert H. Lurie Comprehensive Cancer Center

ADDRESS

Work: Northwestern University Feinberg School of Medicine
Division of Hematology / Oncology
Department of Medicine
676 N. St. Clair Street, Suite 850
Chicago, IL 60611
Phone: (312) 503-1114
Fax: (312) 695-6189
E-mail: w-gradishar@northwestern.edu
Twitter: @drwgradishar
Admin: Erika Perez, erika.perez@northwestern.edu

Home: 321 North Euclid Avenue
Oak Park, IL 60302

CURRENT AFFILIATIONS: Northwestern Medicine
Maggie Daley Center for Women's' Cancer Care
Prentice Women's Hospital
250 East Superior, 4th floor
Chicago, IL 60611

Northwestern Memorial Hospital
251 E. Huron Street
Chicago, IL 60611

CITIZENSHIP: USA

DATE OF BIRTH: July 29, 1956

PLACE OF BIRTH: Chicago, IL

SPOUSE: Cynthia Boyd, MD, MBA
Children: Zachary Gradishar, Nicholas Gradishar

2. EDUCATION

1978 BA Chemistry, Northwestern University
Chicago, IL

1982 MD University of Illinois, Abraham Lincoln School of Medicine

Chicago, IL

3. GRADUATE MEDICAL EDUCATION (if applicable)

N/A

4. POSTDOCTORAL RESEARCH TRAINING (if applicable):

Internships and Residencies:

1982-1985	Michael Reese Hospital, Chicago	Residency in Internal Medicine
1985-1986	Michael Reese Hospital, Chicago	Chief Medical Resident

Clinical and Research Fellowships:

1986-1990	University of Chicago	Fellowship, Hematology/Oncology

5. BOARD CERTIFICATION and MEDICAL LICENSURE

1983 Diplomate, National Board of Medical Examiners Parts I, II, III

1985 Diplomate, American Board of Internal Medicine, #105684

1989 Diplomate, American Board of Internal Medicine, Medical Oncology

6. MILITARY SERVICE (N/A)

7. FACULTY APPOINTMENTS

1985-1986	Clinical Instructor	University of Chicago Department of Medicine
1990-1996	Assistant Professor of Medicine	Northwestern University Feinberg School of Medicine, Department of Medicine
1997-2005	Associate Professor of Medicine	Northwestern University Feinberg School of Medicine, Department of Medicine
2005-present	Professor of Medicine	Northwestern University Feinberg School of Medicine, Department of Medicine
2010-present	Endowed Chair: Betsy Bramsen Professor of Breast Oncology	Northwestern University Feinberg School of Medicine, Department of Medicine
2017-2024	Chief, Division of Hematology/Oncology	Northwestern University Feinberg School of Medicine, Department of Medicine

8. HOSPITAL APPOINTMENTS

1990-present	Attending Physician	Northwestern Memorial Hospital
1990-present	Attending Physician	Lakeside Veterans Administration Hospital

9. ADMINISTRATIVE APPOINTMENTS

1992-2011	Director,	Hematology-Medical Oncology Fellowship Training Program Department of Medicine Northwestern University
1992-present	Director,	Breast Medical Oncology, Multidisciplinary Breast Cancer Program Department of Medicine, Northwestern University
1999-2009		Associate Director, Lynn Sage Breast Program Northwestern University
2010-present		Director, Maggie Daley Center for Women's Cancer Care Northwestern University, Northwestern Memorial Hospital
2010-2017		Deputy Chief, Division of Hematology-Oncology Department of Medicine, Northwestern University (under Drs. Licht and Giles)
2016-present		Deputy Director (Network), Robert H. Lurie Comprehensive Cancer Center, Northwestern University
2017-2018		Acting Chief, Division of Hematology-Oncology, Dept. of Medicine, Northwestern University Feinberg School of Medicine
2018-2024		Chief, Division of Hematology-Oncology, Dept. of Medicine, Northwestern University Feinberg School of Medicine

10. COMMITTEE SERVICE

<u>Hospital</u>

1990-1992	Director, Thoracic Oncology Northwestern Memorial Hospital
1991-1996	Quality Assurance Committee, Department of Medicine Northwestern Memorial Hospital
1991-1992	Vascular Access Subcommittee, Practice Committee Northwestern Memorial Hospital
1991-1994	1/6/17Research Review Committee, Northwestern Memorial Foundation Northwestern Memorial Hospital
1995-1998	Member, Institutional Review Board (IRB) Northwestern Memorial Hospital

1995-1999 Committee on Cancer
Northwestern Memorial Hospital

2017- Committee on Cancer
Northwestern Memorial Hospital

Feinberg School of Medicine

1991-1993 Chairman, Thoracic Oncology Committee, Northwestern Cooperative Oncology Group, Robert H. Lurie Cancer Center

1991-1993 Scientific Review Committee, Robert H. Lurie Comprehensive Cancer Center

1993-2010 Education Committee, Robert H. Lurie Comprehensive Cancer Center, Northwestern University

1993-1995 Admissions Interview Committee, Northwestern University Medical School

1999-present Chair, Annual Lynn Sage Breast Cancer Symposium

2007-present Executive Committee, Division of Hematology-Oncology, Northwestern University

2009-present Executive Leadership Committee, Robert H. Lurie Comprehensive Cancer Center, Northwestern University

2013-present Clinical Cancer Center Senior Leadership Committee

2013-present Clinical Cancer Center Executive Council

2015-present Deputy Director (Network), Robert H. Lurie Comprehensive Cancer Center

2016-2017 Lead Director, Cancer Tanzania Project 2017

2016-2017 eHealth Cancer Distance Learning Director

2020 Internal Reviewer, Department of Radiation Oncology

Northwestern University

2002-2005 General Faculty Committee (GFC), Northwestern University

11. AWARDS, HONORS, DISTINCTIONS

1996	Fellow	American College of Physicians
2002	Visiting Professor	University of Pittsburgh
2004	Advances in Breast Cancer	National Breast Cancer Awareness Month (NBCAM)

2008 Arthur G. Michel Award Y-Me; Breast Cancer: Network of Strength

2008 Statesman Award/Fellow American Society of Clinical Oncology

2010 Betsy Bramsen Professor of Breast Oncology- Endowed Chair

2020 Visiting Professor University of Florida, Gainesville

2022 Roger Winn Award National Comprehensive Cancer Network (NCCN)

12. PROFESSIONAL SOCIETY MEMBERSHIPS

1986-present Member, American College of Physicians (see Professional Service)

1990-present Member, American Society of Clinical Oncology (see Professional Service)

1991-present Member, American Association for Cancer Research

1991-present Member, Illinois Medical Oncology Society

1991-present Member, American Federation for Clinical Research

1993-2011 Member, American Society of Hematology

1994-2000 Member, Association of Subspecialty Professors (see Professional Service)

1995-present Member, American Society of Breast Disease (see Professional Service)

13. PROFESSIONAL and SCIENTIFIC SERVICE

Local Committees

1991-1992 Co-Chair, Sarcoma Committee, Illinois Cancer Council

1992-1995 Chairman, Professional Education Committee, American Cancer Society, State of Illinois, Loop Division

1995-1996 Board of Directors, American Cancer Society, Loop Division, Illinois Division

1995-1996 Vice-President, Greater Downtown Unit Board, American Cancer Society

1996-1998 Council of the Northern Illinois Chapter, American College of Physicians

1996-1998 Chair, Scientific Program Committee, Northern Illinois Chapter, American College of Physicians

National Committees

1990-1993 Lung and Sarcoma Committee, Eastern Cooperative Oncology Group

1995-present Breast Cancer Core Committee, Eastern Cooperative Oncology Group

1995-present	National Comprehensive Cancer Network, Breast Cancer Practice Guideline Task Force
1997-1999	Member Cancer Communication Committee, American Society of Clinical Oncology
1997-1999	Oncology Training Programs Committee, American Society of Clinical Oncology
1997-1999	Publications Committee, American Society of Clinical Oncology
1998-1999	Program Committee, Association of Subspecialty Professors
1999-2000	Vice Chair, Cancer Communications Committee, American Society of Clinical Oncology
1999-present	National Comprehensive Cancer Network, Breast Cancer Risk Reduction Subcommittee
1999-2003	Board of Directors, American Society of Breast Disease
2000-2002	Chair, Cancer Communication Committee, American Society of Clinical Oncology
2001-2003	Clinical Trials Committee, Association of American Cancer Institutes
2001-2003	Chair, Communications Committee, American Society of Breast Disease
2002-2004	Program Committee, American Society of Clinical Oncology
2002-2008	Executive Committee, Commission on Cancer, American College of Surgeons (Representing the American Society of Clinical Oncology)
2002-2008	Quality Integration Committee, Commission on Cancer, American College of Surgeons
2003-2004	Chair-Elect, Oncology Training Programs Committee, American Society of Clinical Oncology
2004-2005	Chair, Oncology Training Programs Committee, American Society of Clinical Oncology
2003-2004	Councilor At-large, Association of Subspecialty Professors
2003-2007	Advocacy Committee, Association of Subspecialty Professors
2004-2007	Councilor Medical Oncology, Association of Subspecialty Professors
2004-2008	Multidisciplinary Cancer Management Course (Development of Curriculum for Breast Cancer Management for underserved countries), American Society of Clinical Oncology
2005	National Comprehensive Cancer Network, Taxane Scientific Advisory Board
2005-2008	Data Monitoring Committee of ACOSOG
2006	National Comprehensive Cancer Network, HER2 Task Force
2006	National Comprehensive Cancer Network, Pain DSEC
2006-2009	Board Member, National Accreditation Program for Breast Centers

2006-2008	Member, American College of Surgeons Oncology Group Data Monitoring Committee
2007	Breast Cancer DataMart Scientific Review Committee, National Cancer Institute
2007-2009	Executive Committee, National Accreditation Program for Breast Centers (American College of Surgeons)
2007-2008	NCCN Task Force: Breast Cancer in the Older Woman
2010-2013	Co-Chair, Developmental Therapeutics Working Group, Eastern Cooperative Oncology Group
2010-present	Advisory Board, Lynn Sage Breast Cancer Research Foundation
2010-2011	Chair, Professional Development Committee, American Society Clinical Oncology
2011	Program Committee, American Society of Breast Diseases
2013-present	Chair, National Comprehensive Cancer Network (NCCN) Breast Cancer Practice Guideline Panel
2013-2016	Steering Committee, Novartis BOLERO-4 study (CRAD001y24135)
2013-2017	Chair, IDMC, Kaitlin (T-DM1) adjuvant study
2013-2015	NCCN Taxane Scientific Advisory Board
2014-2015	ASCO Breast Cancer Symposium Program Committee
2014-2015	Chair, Nominating Committee, American Society Clinical Oncology
2014-2015	Board of Directors, Oncofertility Consortium National Physicians Cooperative
2014-2015	NCCN GSK MEK Scientific Review Committee
2014-present	NCCN Resource Stratification Working Group
2015-2019	Chair, NCCN-Pfizer Metastatic Breast Cancer Grant Program
2015-2018	Member, DSMB Mylan Heritage Study
2017-present	Member, DSMB, Alliance Foundation Trials
2020-present	Medical Oncology Board, American Board of Internal Medicine
2023-present	ASCO Scientific Program Committee
2023-present	San Antonio Breast Cancer Symposium Scientific Program Committee

<u>International Committees</u>

1998-2006	Scientific Advisory Board, Breast Cancer International Research Group (BCIRG)
2000-2001	Sponsoring/Funding Activities Subcommittee, World Society for Breast Health
2013	Peer Review Panel, Irish Collaborative Research Centers, Dublin
2013-2019	International Advisor, Japanese Breast Cancer Society
2014-2019	Steering Committee Advisor, Hong Kong Oncology Group
2014-present	NCCN International Program Steering Committee
3/2019-present	Panel Member, St. Gallen International Consensus Panel on Early Stage Breast Cancer, Vienna, Austria
2/2021	Panel Member, WHO Global Breast Cancer Initiative- Technical Consultation
2023	NCCN Poland Breast Cancer Guideline Adaptation Panel
2024	NCCN/ACS – Sub-Saharan Africa Breast Cancer Guideline Adaption Panel Nairobi, Kenya
2024-present	European Society of Medical Oncology (ESMO) Scientific Program Committee

Study Section/Review Panels

1994	Epidemiology Study Section, Department of Defense Breast Cancer Research Program
1994	Scientific Advisory Committee on Personnel for Research, American Cancer Society, Atlanta
1995	National Action Plan on Breast Cancer (NAPBC) Study Section National Institutes of Health, Office of Women's Health
1995-1996	Cell Biology Study Section, American Cancer Society, Atlanta
1996-present	Clinical Research Study Section, Susan G. Komen Breast Cancer Foundation
1996-present	Epidemiology Study Section, Department of Defense Breast Cancer Research Program
1997-1999	Peer Review Committee on Cell Structure and Metastasis, American Cancer Society, Atlanta
1998	Ad Hoc Reviewer - Study Section on Angiogenesis, New Zealand Heart Association
1997-1998	Clinical and Experimental Therapeutics Study Section, Department of Defense Breast Cancer Research Program
1998-2000	Chemoprotectant Expert Panel, American Society of Clinical Oncology

1999-2005 Ad-hoc Consultant, Oncology Drug Advisory Committee (ODAC), Food and Drug Administration

2000-2001 Ad Hoc Reviewer, Committee on Cell Structure and Metastases, American Cancer Society, Atlanta

2000-2002 National Committee Chair, Data Monitoring Committee, Genentech, Inc., Phase III trial on rhuMAb VEGF (bevacizumab)

2003-present Study Section, Clinical Breast Cancer Trials Group, Cancer Research Campaign, United Kingdom

2004 Wake Forest University Breast Cancer Center of Excellence, NCI Site Visit

2005 Ad Hoc Reviewer, Irish Health Review Board Study Section

2005-2009 Chair, Data Safety Monitoring Board, RAD001 Program, Novartis Pharmaceuticals

2005-2008 Chair, Data Safety Monitoring Board, XPR Program, Aventis-Sanofi Pharmaceuticals

2006 Member, Data Monitoring Committee, Genentech, Inc., AVF3694g/AVF3693g

2006 Ad Hoc Reviewer, Concept Review Committee, NCI CTEP

2006 Member, NCI Special Emphasis Panel, P4 Concept Review

2006 Ad Hoc Reviewer, AVON-NCI, "Progress for Patients" Award Panel

2006 Ad Hoc Technical Reviewer, Maryland Industrial Partnerships (MIPS) Program University of Maryland

2006-present Member, Data Monitoring Committee, International Breast Cancer Study Group (IBCSG)

2006-2008 Member, Alberta Cancer Board Breast Cancer Review Committee

2006-2009 Data Monitoring Committee, American College of Surgeons Oncology Group (ACOSOG)

2008-2013 Member, *Susan G. Komen for the Cure* Study Section, Endocrine Therapy

2008 Subcommittee H – Clinical Groups, National Cancer Institute Initial Review Group, National Cancer Institute, NIH-NCI Subcommittee H (CALGB)

2009-2011 Chair, IDMC, EMD-Serono; Stimuvax Breast Cancer Program

2009-2013 Chair, IDMC, AZ09831 Program in Breast Cancer

2008-2013 Steering Committee TIES Program, Bayer-Onyx

2011-2015 Steering Committee, Alternative Study (Sorafenib)

2013-2017 Steering Committee, Neratanib Development Program, PUMA Pharmaceutical

2012-2015 Member, DSMB, International Breast Cancer Study Group (IBCSG)

2013-2020 Chair, DMC- KAITLIN study (TDM-1), Genentech

2014-2015 Member Komen Breast Cancer Study Section, Systemic therapy

2015-2019 Chair, DMC- Oncothyreon ONT- 380 study (HER2 specific TKI)

2017 Chair, NCCN/Pfizer Clinical Pathways in Breast Cancer Program, Peer Review

2017 Adhoc Member, NCI Specialized Program of Research Excellence (SPORE)

2019-present 2 IDMC-TRIO033 NATALEE

2022-2024 ASCO Conquer Cancer Grant Selection Committee

2022-present Steering Committee, Harmonia Study

2023-present Independent Data Monitoring Committee, Roche B041843 Study

2023-present Independent Data Monitoring Committee, Destiny Breast-05 (DB-05)

2023-present Steering Committee, EMBER 4

2023-present Member, Oncology Drug Advisory Committee (ODAC), FDA

2024 Member, Precision Medicine Academic Consortium (PMAC)

Editorial Boards

1996-1998 Year Book of Oncology 1996, Mosby-Year Book, Inc.

1997 Breast Cancer Lifeline

1997-present Oncology

2000-present Current Treatment Options in Oncology, Section Editor, Breast Carcinoma

2004-2006 Academic Internal Medicine Insight, AAIM Newsletter

2004-present Clinical Breast Cancer

2006-2010 Clinical Cancer Research

2007-present Clinical Advances in Hematology & Oncology™

2007-present Editor in Chief, NEJM Journal Watch Hematology-Oncology (Founding Editor)

2009-present European Journal of Clinical and Medical Oncology

2010-2015 Journal of Clinical Oncology

2011-present Breast Cancer Management, Future Medicine, London, UK

2014-present Journal of the National Comprehensive Cancer Network

2014-present Breast Cancer Research and Treatment

2015-2018 Journal of Global Oncology (ASCO)

2019-present St. Gallen International Breast Cancer Census Panel, Vienna, Austria

2019-present NCCN Pfizer EMBRACE Grant Review Committee

2019-present Alliance Foundation Trials (AFT) Data Safety Monitoring Board

2019-present Editor in Chief, Breast Cancer Research and Treatment

2020-present Annals of Breast Surgery

Reviewer

JAMA, Journal of Clinical Oncology, Clinical Cancer Research, European Journal of Cancer, Lancet Oncology, Clinical Breast Cancer, Journal of the National Cancer Institute, Annals of Oncology, Breast Cancer Research and Treatment, New England Journal of Medicine, Journal of Clinical Investigation

14. TEACHING

Ongoing

- Course Developer/Course Director – Annual Lynn Sage Breast Cancer Symposium; National Meeting over 4 days; 1000 Registrants; CME; since inception 26 yrs.

- Course Developer/Course Director – Annual ASCO Review (American Society of Clinical Oncology); 300 Registrants; CME; since inception 20 yrs.

- Course Developer/Course Director – Annual Review of the San Antonio Breast Cancer Symposium; 150 Registrants; CME; since inception 20 yrs.

- Curriculum Development Committee/Faculty – Annual School of Breast Oncology; Emory University; 250 Registrants; CME; since inception 23 yrs.

- Supervisor/Mentor – 2 surgical breast fellows annually; each fellow spends 3 months with me in the Outpatient Breast Clinic; 21 yrs.

- Weekly Virtual Molecular Tumor Board; Cancer Expert Now (CEN) at Chinese Academic Centers; 2019-present

Previous

- Course Director – Novel Frontiers on Breast Cancer Research; Northwestern University Chicago; 2007

- Program Director – Hematology/Oncology Fellowship Training Program, Department of Medicine, Northwestern University; 16-18 trainees, in position - 20 yrs.

15. RESEARCH GRANTS/CONTRACTS

1992 Young Investigator Award, The Northwestern Memorial Foundation, A Quantitative Assay of Tumor Angiogenesis Based on a Model of Wound Healing.

1993 NIH # R21 CA 64487-01, Exploratory/Development Grant, Suramin: Inhibition of Angiogenesis in Breast Cancer, $122,568; Principal Investigator - William J. Gradishar, M.D.

1994 NIH # 1 P20 CA 65764-01, Exploratory Grant, Robert H. Lurie Cancer Center, Breast Cancer Program, Program Principal Investigator - V. Craig Jordan, Ph.D., 4 year project - $270,000/year. Project 3: Endocrine status of premenopausal, node-negative breast cancer patients who become amenorrheic following treatment with tamoxifen, Principal Investigator - William J. Gradishar, M.D.

1995 State of Illinois - Department of Public Health - Breast and Cervical Cancer Research Program - Suramin: Inhibition of Angiogenesis in Breast Cancer, $12,500.

1995 Washington Square Health Foundation - Does Tamoxifen Prevent Skeletal and Cardiovascular Morbidity of Chemotherapy in Premenopausal Patients? Principal Investigator - Monica Morrow, M.D.; Co-Principal Investigator - William J. Gradishar, M.D., $200,000.

1996 Department of Defense - Increasing Access to Modern Multidisciplinary Breast Cancer Care. Principal Investigator - Monica Morrow, M.D.; Project 6: Multidisciplinary Networked Breast Cancer Conferences. Principal Investigator - William J. Gradishar, M.D., $870,504.

2000 NIH P50 CA089018. SPORE in Breast Cancer. Principal Investigator – Craig Jordan; Project Principal Investigator – Gerald Soff, MD; Co-Investigator - William Gradishar, MD. Project Period: 9/30/00 – 8/31/05.

2002 ASCO/Hartford Geriatric Fellowship Training Grant. Principal Investigator – William Gradishar, MD. Project Period: 7/1/2002-6/30/2005. Direct: $75,000/yr1, $50,000/yr2, $25,000/yr3

2003 A102713. Principal Investigator – Charles Bennett, MD; Co-Investigator – William Gradishar, MD. Project Period: 9/15/2003-8/31/2005.

2003 Amgen Fellowship. Project Period: 7/1/2002-6/30/2005. Direct: $40,000

2003 Ortho-Bio Tech Fellowship. Project Period: 7/1/2003-6/30/2004

2003 NIH U10-CA017145. Project Period: 5/1/2004-4/30/2010

2005-2010 NIH Nano-materials for Cancer Diagnostic and Therapeutics. Project Period: 9/30/2005-8/31/2010

2006-present Breast Cancer Research Foundation. Targeting □B-Crystallin and the MEK-ERK Pathway in Basal-like Breast Cancer. Principal Investigator - Vincent L. Cryns, M.D., Co-Principal Investigator - William J. Gradishar, MD, $225,000/year

2015-2020 Support of Training and Mentoring in Nigeria for Academics (STAMINA). University of Jos/Fogarty International Center NIH. Project Period: 09/09/2015-07/31/2020. Effort on Project- 5%. Annual Cost: $101,401.

16. SCHOLARLY BIBLIOGRAPHY

A. Original, peer-reviewed research articles

1. **Gradishar WJ,** Vokes EE, Kies M. Phase II trial of etoposide and doxorubicin in advanced head and neck cancer. Med Pediatr Oncol, 18:489-490, 1990.

2. **Gradishar WJ,** Vokes EE, Schilsky RL, Weichselbaum R, Panje W. Catastrophic events in patients receiving 5-fluorouracil based chemotherapy: The University of Chicago experience. Med Pediatr Oncol, 19:8-15, 1991.

3. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, **Gradishar WJ,** Yahanda A, Vincent M, Stewart M, Glaspy J. Reduction in the Incidence of Chemotherapy-Induced Febrile Neutropenia in patients with small cell lung cancer by Granulocyte Colony-Stimulating Factor (r-metHuG-CSF). N Engl J Med, 325:164-70, 1991.

4. **Gradishar WJ,** Mick R, Hoffman PC, et al. The impact on survival by adjuvant chemotherapy and radiation therapy in stage II non-small cell lung cancer. Am J Clin Oncol, 15:405-411, 1992.

5. **Gradishar WJ,** O'Laughlin R, LeBeau MM, Vardiman JW, Larson RD. Clinical and Cytogenetic Responses to Granulocyte-Macrophage Colony Stimulating Factor in the Therapy-Related Myelodysplastic Syndrome. Blood, 80:2463-2470, 1992.

6. Schiller JH, Ettinger DS, Larson MM, **Gradishar WJ,** et al. Phase II trial oral etoposide plus cisplatin in extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group Study. Eur J Cancer, 30A:158-161, 1994.

7. **Gradishar WJ,** Haraf DJ, Hoffman PC, et al. A Phase II trial of neoadjuvant chemotherapy and concomitant chemoradiotherapy for the treatment of locally advanced non-small lung cancer. Oncology Reports, 1:957-962, 1994.

8. Athanasiadis I, Kies MS, Miller M, Ganzenko N, Joob A, Marymont M, Rademaker A, **Gradishar WJ**. A phase II study of all-trans retinoic acid (TRA) and interferon-alpha (IFN-α) in patients with advanced non-small cell lung cancer (NSCLC). Clinical Cancer Res, 1:973-979, 1995.

9. **Gradishar WJ,** Vogelzang N, Kilton LJ, Leibach SJ, Rademaker AW, French S, Benson, AB, III. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma: An Illinois Cancer Center study. Investig New Drugs 13:171-174, 1995.

10. Tallman M, Rademaker A, Jahnke L, Brown S, Bauman A, Mangan C, Kelly C, Rubin H, Kies M, Shaw J, Kiel K, Gordon L, **Gradishar W**, Winter J. High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer. Bone Marrow Transplantation, 20:721-729, 1997.

11. **Gradishar WJ**. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer: interim results of a phase II study. Oncol 11(suppl. 8):15-18, 1997.

12. Cristofanilli, M, Bryan, WJ, Miller, LL, Chang, AY, **Gradishar, WJ**, Kufe, DW, Hortobagyi, GN. Phase II study of adozelesin in untreated metastatic breast cancer. Anticancer Drugs, 9: 779-82, 1998.

13. Tallman MS, **Gradishar WJ**. High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer. Cancer Chemo Pharm, 42:560-567, 1998.

14. Sparano JA, Speyer J, **Gradishar WJ** et al. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol, 17:880-886, 1999.

15. O'Regan RM, Jordan VC, **Gradishar, WJ**. Tamoxifen and contralateral breast cancer. J Am Col Surg, 188:678-683, 1999.

16. Noe LL, Becker RV, **Gradishar WJ**, Gore M, Trotter JP. The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Managed Care, 5 (suppl):S389-S406, 1999.

17. Carlson, RW, Anderson, BO, Bensinger, W, Cox, CE, Davidson, NE, Edge, SB, Farrar, WB, Goldstein, LJ, Gradishar, WJ, et al. National Comprehensive Cancer Network. NCCN Practice Guidelines for Breast Cancer. Oncology, 14: 33-39, 2000.

18. **Gradishar WJ**, Soff G, Liu J, Cisneros A, French S, et al. A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. Oncology 58:324-333, 2000.

19. **Gradishar WJ,** Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88:2047-2053, 2000.

20. O'Regan RM, **Gradishar WJ**. Selective estrogen –receptor modulators in 200. Oncology (Williston). 2001;15(9):1177-85, 1189-90 discussion 1190-4.

21. **Gradishar WJ**. Clinical status of capecitabine in the treatment of breast cancer. Oncology (Williston). 2001;15(1 Suppl 2):69-71 discussion 72

22. **Gradishar WJ**, Jordan VC. The evolving role of endocrine therapy for treatment and prevention of breast cancer. Cancer Chemother Biol Response Modif. 2001;19:215-36.

23. **Gradishar WJ.** Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer. Clin Breast Cancer 2(suppl 1):S31-S35, 2001.

24. Piro SM, Zeldow PB, Knight SJ, Mytko JJ, **Gradishar WJ**. The relationship between agentic and communal personality trains and psychosocial adjustment to breast cancer. J Clin Psychol Med Set 8:263-271, 2001.

25. **Gradishar WJ**, Glover DJ, Stephenson P, et al. A phase II trial of cis-platinum plus WR-2721I for metastatic breast cancer. Cancer 92:2517-2222, 2001.

26. **Gradishar WJ,** Hellmund R. A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. Clin Breast Cancer 2:282-286, 2002.

27. Miller KD, **Gradishar W,** Schuchter L, Sparano J, Cobleigh M, Robert N, Rasmussen H, Sledge GW. A randomized phase II pilot trial of adjuvant marimastat in patients with early stage breast cancer. Ann Oncol 13:1220-1224, 2002.

28. **Gradishar WJ**, Morrow M. Advances in endocrine therapy of metastatic breast cancer. Br J Surg. 2002;89(12): 1489-92

29. Forbes JF, **Gradishar WJ**, Ravdin PM. Choosing between endocrine therapy and chemotherapy or is there a role for combination therapy? Breast Cancer Res Treat. 2002;75 Suppl 1:S37-44; discussion S57-9

30. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, **Gradishar WJ,** et al. Randomized trial of dose dense vs. conventionally scheduled and sequential vs. concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup C9741 – CALGB 9741. J Clin Oncol 21:1431-1439, 2003.

31. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, **Gradishar WJ,** et al. Phase III study of conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem cell transplantation in patients with stage II or III breast cancer at high risk of recurrence (INT 0121). N Engl J Med 349 (1):17-26, 2003.

32. Tedesco KL, Johnson DH, Thor AD, Shyr Y, Blum KA, Goldstein LJ, **Gradishar WJ,** et al. A multi-institutional phase II pilot trial with weekly docetaxel and Trastuzumab as first or second line therapy for HER-2 over expressing metastatic breast cancer. Journal of Clinical of Oncology 22:1071-7, 2004.

33. Sparano JA, Bernardo P, Stephenson P, **Gradishar WJ,** et al. Randomized phase III trial of Marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: an Eastern Cooperative Oncology Group Trial (E2196). Clin Oncol; 22:4631-4638, 2004.

34. Gra**dishar WJ**, Meza L, Samid D, Hill T, Chen Y-M, and Amin B. A Multicenter Phase II Study of Capecitabine plus Paclitaxel in metastatic Breast Cancer: Survival Update. Clin Oncol; 22(12): 2321-7, 2004

35. O'Regan R, Von Roenn J, Carlson R, Malik U, Sparano J, Staradub V, Khan S, Jovanovic B, Morrow M, **Gradishar WJ**. Final Results of a Phase II Trial of Preoperative TAC (Docetaxel, Doxorubicin, Cyclophosphamide) in Stage III Breast Cancer. Clin Breast Cancer, 6(2): 163-168, 2005.

36. Norton L, Hudis C, Gralow J, Perez E, Henderson C, **Gradishar WJ.** Dose-Dense Adjuvant Chemotherapy in Breast Cancer: Treatment-related Hematology Toxicities and Management Considerations. Clinical Breast Cancer (in press), 2004

37. **Gradishar W**J, Wedam SB, Jahanzeb M, Erban J, Limentani S, Tsai KT, Olsen SR, Swain SM. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol, 16(8): 1297-304, 2005.

38. **Gradishar WJ**, Sahmoud T. Current and Future Perspectives on Fulvestrant. Clinical Breast Cancer 6 (suppl 1): S23-S29, 2005.

39. **Gradishar WJ**. Clinical Value of Fulvestrant in Breast Cancer: Forward. Clinical Breast Cancer, 6(Suppl 1): S4, 2005.

40. Wolff AC, O'Neil A, Kennedy MJ, Stewart JA, **Gradishar WJ**, Lord RS, Davidson NE, Wood WC. Single Agent Topotecan as First-Line Chemotherapy in Women with Metastatic Breast Cancer: Final Results of Eastern Cooperative Oncology Group Trial E8193. Clin Breast Cancer, 6(4):334-9, 2005.

41. **Gradishar WJ**, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE, Marcom PK. Capecitabine Plus Paclitaxel as Front-line Combination Therapy for Metastatic Breast Cancer: a multicenter Phase II Study. Clin Oncol; 15:22(12): 2321-7, 2004.

42. **Gradishar WJ**, Tjulandin S, Davidson N, Shaw H, Desai PB, Hawkins M, O'Shaughnessy J. Superior Efficacy of Nanoparticle Albuman-Bound Paclitaxel (Abraxane, ABI-007) Compared with Cremophor-Based Paclitaxel (Taxol) in Women with metastatic Breast Cancer: Results of a Phase III Trial. Clin Oncol, 23(31): 7794-7803, 2005.

43. **Gradishar WJ**. The Future of Breast Cancer: the Role of Prognostic Factors. Breast Cancer Research and Treatment, 89: (Suppl 1) S17-S26, 2005.

44. **Gradishar, WJ**. Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal Women. Oncology, 69: 1-9, 2005.

45. **C**arlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, **Gradishar WJ**, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Breast Cancer. J National Comprehensive Cancer Network, 3: 238-289, 2005.

46. Sokolowicz LE, **Gradishar WJ**. Hormonal Therapy for Primary Breast Cancer: Scientific Rationale and Status of Clinical Research. Curr Oncol Rep, 7(1): 31-37, 2005.

47. Kaklamani V, **Gradishar WJ**. Adjuvant Therapy of Breast Cancer. Cancer Invest. 23: 548-559, 2005.

48. Videnovic A, Semenov I, Chua-Adajar, Baddi L, Blumenthal, Beck AC, Simuni T, Futterer S, **Gradishar WJ**, Tellez, C, Raizer JJ. Capecitabine-induced multifocal leukoencephalopathy: A report of five cases. Neurol, 65: 1-1, 2005.

49. Zucker S, Wang M, Sparano JA, **Gradishar WJ**, Ingle JN, Davidson NE. Plasma MMP-7 and MMP-9 in Patients with Metastatic Breast Cancer Treated with Marimastat or Placebo: Eastern Cooperative Oncology Group Trial E2196. Clin Breast Cancer, 6(6):525-529, 2006.

50. Carlson RW, Brown, Burstein HJ, **Gradishar WJ**, Hudin CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Journal of the National Comprehensive Cancer Network, 4: (Suppl 1) S1-S27, 2006.

51. **Gradishar WJ**, Vishalpura T, Franklin M, Nightengale B, Bramley T. Cost-effectiveness Analysis of Antineoplastic Therapy Using nab-Paclitaxel or solvent-based Docetaxel in Patients with Metastatic Breast Cancer.

52. Bangash AK, Atassi B, Kaklamani V, Rhee KT, Yu M, Lewandowski RL, Sato KT, Ryu RK, Gates VL, Newman S, Mandal R, **Gradishar WJ**, et al. ^{90}Y Radioembolization of Metastatic Breast Cancer to the Liver: Toxicity, Imaging Response, Survival. J Vasc Interv Radiol 2007; 18:621-628

53. Chia S**, Gradishar WJ,** Mauriac L, et al., Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results from EFECT. Clin Oncol; 26: 1664-70, 2008

54. Chia S**, Gradishar WJ**. Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer. Breast. 17 (Suppl.3): 516-21, 2008.

55. Desai NP, Treiu V, Hwang LY, Wu R, Soon-Shiong P, **Gradishar WJ.**Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anti-Cancer Drugs. 19(9) 899-909, 2008.

56. Dranitsaris G, **Gradishar WJ**, Coleman R. *nab*-Paclitaxel Weekly or Every 3 Weeks Compared to Standard Docetaxel as First-line Therapy in Patients with Metastatic Breast Cancer: An Economic Analysis of a Prospective Randomized Trial. *Breast Cancer Res Treat*., 119: 717-24, 2010.

57. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, **Gradishar WJ,** R. Mitchell B, et al., American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants. Clinical Oncol, 7(1): 127-145. 2009.

58. Engel RH, Brown JA, Von Roenn J, O'Regan RM, Bergan R, Badve S, **Gradishar WJ**. A Phase II Study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest. 25(8) 733-7, 2007.

59. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, **Gradishar WJ**, et al. Breast Cancer Risk Reduction. Journal of the National Comprehensive Cancer Center Network, 5(8): 676-701, 2007

60. Cianfrocca M, **Gradishar WJ**, Counterpart: the argument for combination chemotherapy in the treatment of metastatic breast cancer. Journal of the National Comprehensive Cancer Center Network, 5(8): 673-5, 2007

61. Carlson RW, Andresen BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, **Gradishar WJ** et al. Invasive Breast Cancer. Journal of the National Comprehensive Cancer Center Network, 5(3): 246-312, 2007

62. Hazard HW, Gorla SR, Scholtens D, Kiel K, **Gradishar WJ** et al. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer 113(8) 2011-9, 2008

63. **Gradishar WJ**, Bellon WJ, Gadd MA et al. Case records of the Massachusetts General Hospital. Case 30-2008. A 47-year old woman with a mass in the breast and a solitary lesion the spine. N Engl J Med 359(13): 1382-91, 2008

64. Ivanov O, Chen F, Wiley EL, Keswori A, Diaz LK, Memmel HE, Rademaker A, **Gradishar WJ** et al. alpha B- crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 111(3): 411-7, 2008

65. Carlson RW, Moerch S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, **Gradishar WJ** et al. NCCN Task Force Report: breast cancer in older women. Journal of National Comprehensive Cancer Network. 4: S1-S25, 2008

66. Carlson RW, Allred PC, Andersen DO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, **Gradishar WJ** et al. Breast Cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 7(2): 122-92, 2009

67. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, CohenGI, Emami B, **Gradishar WJ**, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM. American Society of Clinical Oncology 2008 clinical practice guidelines update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27(1):127-145, 2009.

68. **Gradishar WJ**, Krasnojon D, Cheporov S et al. Significantly longer progression-free survival with *nab*-paclitaxel compared with docetaxel as first line therapy for metastatic breast cancer. J Clin Oncol 27(22):3611-3619, 2009.

69. **Gradishar W.** Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther 3:163-171, 2009.

70. **Gradishar W.** Skeletal issues and bone health in patients with cancer: introduction. Oncology 23(14 Suppl 5):7-8, 2009.

71. Dranistsaris G, **Gradishar WJ.** Overmoyer B. Abraxane for Breast Cancer Therapy. American Health & Drug Benefits 2 (3 Suppl 4):126-137. 2009.

72. **Gradishar WJ**, Hansen NM, Susnik B. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice. Clin Adv Hematol Oncol 7(4):1-7, 2009.

73. Bevers, TB, Armstrong, DK, Arun, B, Carlson, RW, Cowan, KH, Daly, MB, **Gradishar, WJ**, et al. Breast cancer risk reduction. J Natl Comp Canc Net. 8:1112-46, 2010.

74. Dranitsaris G, Coleman R, **Gradishar W.** *nab*-paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 119(3):717-724, 2010.

75. Kaklamani V, Cianfrocca M, Ciccone J, Kindy K, Rademaker A, Wiley E, **Gradishar W**, O'Regan R. Increased HER 2- neu expression in recurrent hormone receptor positive breast cancer. Biomarkers 15(2):191-193, 2010.

76. Moulder S, Li H, Wang M, **Gradishar WJ**, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in

patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat 119(3):663-671, 2010.

77. **Gradishar WJ.** Adjuvant endocrine therapy for early breast cancer: the story so far. Cancer Invest 28(4):433-442, 2010.

78. Aapro M, Tjulandin S, Bhar P, **Gradishar WJ.** Weekly nab-paclitaxel is safe and effective in >65 years old patients with metastatic breast cancer: a post-hoc analysis. BREAST 20(5):468-74, 2011.

79. Edwards, BJ, Raisch, DW, Shankaran, V, McKoy, JM, **Gradishar, WJ**, et al. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res., 17: 560-8, 2011.

80. Barrios C, Forbes JF, Jonat W, Corte P, **Gradishar W**, et al. The sequential use of endocrine treatment for advanced breast cancer: Where are we? Ann Oncol 23: 1378-86. 2012.

81. Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Edge, SB, Farrar, B, Forero, A, Giordano, SH, Goldstein, LJ, **Gradishar, WJ**, et al. National Comprehensive Cancer Network. Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines. J Natl Comp Canc Netw. 10: 821-9, 2012.

82. Li T, Guo M, **Gradishar WJ**, et al. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). Breast Cancer Res Treat. 2012;134(1):345-52.

83. Goss, Smith, O'Shaughnessy, Ejlertsen, Kaufmann, Boyle, Buzdar, Fumoleau, **Gradishar**, Martin, Moy, Piccart-Gebhart, Pritchard, Lindquist, Chavarri-Guerra, Aktan, Rappold, Williams, Finkelstein; on behalf of the TEACH investigators*. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14: 88-96, 2012.

84. **Gradishar WJ**, Krasnojon D, Cheporov S, et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer. 2012;12(5):313-21.

85. **Gradishar W.** Phase II trial nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer 12: 313-321, 2012.

86. **Gradishar, WJ**, Krasnojon, D, Cheporov, S, Makhson, A, Manikhas, G, Clawson, A, Bhar, P, McGuire, J, Iglesias, J. Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival. Clinical Breast Cancer, 12: 313-21, 2012.

87. Hornberger, J, Alvarado, MD, Rebecca, C, Gutierrez, HR, Yu, TM, **Gradishar, WJ**. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst. 104: 1068-79, 2012.

88. Kaklamani, V, Siziopikou, K, Scholtens, D, Lacouture, M, Gordon, J, **Gradishar, W**, et al. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Res Treat. 132: 833-42, 2012.

89. Weldon C, Trosman J, **Gradishar W,** et al. Barriers to the use of personalized medicine in breast cancer. J Oncol Pract 8: 24-31, 2012.

90. **Gradishar WJ,** Kaklamani, V, Sahoo, TP, et al. A double-blind, randomized, placebo-controlled, phase 2B study evaluating sosafenib in coubretion with paclitaxel as a first-line therapy in patients with HER-2 negative advanced breast cancer. Eur J. Cancer 49: 312-22, 2013.

91. Somlo, G, Atzori, F, Strauss, LC, Geese, WJ, Specht, JM, **Gradishar, WJ**, Rybicki, A, Sy, O, Vahdat, LT, Cortes, J. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res. Apr 2013.

92. **Gradishar WJ**, Gralow J, Jones S, Collins H. Minimizing cancer's impact on bone with denosumab: current and future perspectives. Community Oncol 10: 235-43, 2013.

93. Kumthekar P, Grimm SA, Avram MJ, Kaklamani V, Helemowski I, Rademaker A, Ciandrocca M, **Gradishar WJ,** Patel J, Mulcahy M, McCarthy K, Raizer JJ. Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. J Neurooncol 112: 247-255, 2013.

94. Trosman, JR, Weldon, CB, Schink, JC**, Gradishar, WJ**, Benson, AB III. What do providers, payers and patients need from comparative effectiveness research on diagnostics? The care of HER3/Neu testing in breast cancer. J Compar Effect Res 2(4), 1-17, 2013.

95. Tamer Refaat, Mehee Choi, Germaine Gaber, BPharm,z Krystyna Kiel, Minesh Mehta, **William Gradishar**, and William Small, Jr. Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer. Am J Clin Oncol 37: 480-5, 2014.

96. Baselga, J, Costa, F, Gomez, H, Hudis, CA, Rapoport, B, Roche, H, Schwartzberg, LS, Petrenciuc, O, Shan, M and **Gradishar, WJ.** A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatic HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials. 2013, 14:228.

97. **Gradishar, WJ.** Barriers to and Opportunities for the Use of Personalized Medicine in Patients with Breast Cancer: American Health & Drug Benefits 6 (1): S25-S27, 2013.

98. **William J. Gradishar, MD**, Julie Gralow, MD, Stephen Jones, MD, and Helen Collins, MD. Minimizing cancer's impact on bone with denosumab: current and future perspectives. Community Oncol 10 (8): 235-241, 2013.

99. A phase 3Trial comparing capecitabinE in combination with Sorafenlb or Placebo for treatment of locally advanced or metastatic HER2-Negative breast CanceEr (the RESILIENCE study): study protocol for a randomized controlled trial. Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartzberg LS, Petrenciuc O, Shan M, **Gradishar WJ**. Trials 14:228, 2013.

100. Breast cancer, version 3.2013: featured updates to the NCCN guidelines.

Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, **Gradishar WJ,** Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. J Natl Compr Canc Netw. 1: 753-60, 2013.

101. **Gradishar WJ**, Anderson BO, Blair S, et al. Breast Cancer Version 3.2014: Clinical Practice Guidelines in Oncology JNCCN 12:542-589, 2014

102. Gordon, AC, **Gradishar**, WJ, Kaklamani, VG, Thuluvath, AJ, Ryu, RK, Sato, KT, Gates, VL, Salem, R and Lewandowski, RJ. Yttrium-90 Radioembolization Stops Progression of Targeted Breast Cancer Liver Metastases after failed Chemotherapy. J Vasc Inter Rediol 25: 1523-32, 2014.

103. Jain S, **Gradishar W**. The application of Oncotype DX in early-stage lymph node positive disease. Curr Oncol Rep. 2014;16:360.

104. Schink, HC, Trosman, JR, Weldon, CB, Siziopilou, KP, Tsongalis, GJ, Rademaker, AW, Patel, JD, Benson, AB, Perez, EA, **Gradishar, WJ**. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. J Natl Cancer Inst (2014) 106(10).

105. Shanafelt TD, **Gradishar WJ**, Kosty M, et al. Burnout and career satisfaction among US oncologists. J Clin Oncol. 2014;32(7):678-86.

106. Shanafelt, TD, Raymond, M, Horn, L, Moynihan, T, Collichio, F, Chew, H, Kosty, MP, Satele, D, Sloan, J, **Gradishar, WJ**. Oncology fellows' career plans, expectations, and well-being: Do fellows know what they are getting into? J Clin Oncol. 32: 2991-7, 2014.

107. Boyle, FM, Smith, IE, O'Shaughnessy, J, Ejlertsen, B, Buzdar, AU, Fumoleu, P, **Gradishar, W**, et al. Health related quality of life of women in TEACH, a randomized placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 51: 685-96, 2015.

108. Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms K, Gutin A, Abkevich V, Sangale Z, Solimeno C, Jones J, Hartman A, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, **Gradishar W**. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579). Breast Cancer Res Treat. 2015;151:629-38.

109. Malin D, Strekalova E, Petrovic V, Rajanala H, Sharma B, Ugolkov A, **Gradishar WJ**, Cryns VL. ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo. Oncogene. 34: 5626-5634, 2015.

110. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, **Gradishar W**, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 17: 56-63, 2015.

111. Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, **Gradishar W**, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D,

Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015 Jun 25;107(9).

112. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, **Gradishar WJ**, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast Cancer Risk Reduction, Version 2.2015. J NCCN 13: 880-915, 2015.

113. Jain S**,** Santa-Maria C, **Gradishar W**. The role of ovarian suppression in premenopausal women with hormone receptor-positive early stage breast cancer. Oncology 29: 473-8, 2015.

114. Santa-Maria CA, Park SJ, Jain S, **Gradishar WJ**. Breast cancer and immunology: biomarker and therapeutic developments. Expert Rev Anticancer Ther. 15: 1215-22, 2015.

115. **Gradishar WJ**, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015; 13:1475-85.

116. Giordano, S, Garrett-Mayer, E, Navdha, M, Smith, K, Shulman, L, Passaglia, C, **Gradishar, W**, and Pavone, M. Journal of Adolescent and Young Adult Oncology. December 2016, 5(4): 337-343.

117. Vahdat, L. T., Layman, R., Yardley, D. A., **Gradishar, W**., Salkeni, M. A., Joy, A., Garcia, A. A., Ward, P., Khatcheressian, J., Sparano, J., Rodriguez, G., Tang, S., Gao, L., Dalal, R. P., Kauh, J., Miller, K. (2017). Randomized phase II study of ramucirumab or icrucumab in combination with capecitabine in patients with previously treated locally advanced or metastatic breast cancer. *Oncologist, 22*(3), 245-254. doi:10.1634/theoncologist.2016-0265

118. Giordano, S, Garrett-Mayer, E, Milttal, N, Smith, K, Shulman, L, Passaglia, C, **Gradishar, W**, Pavone, ME. Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection between Infertility and Breast/Ovarian Cancer Risk. J Adolesc Young Adult Oncol. 5: 337-343, 2016.

119. **Gradishar WJ,** Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P. Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. Clin Cancer Res. 2016; 22:301-9.

120. **Gradishar WJ,** Melisko ME, Moy B. Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications. Am Soc Clin Oncol Educ Book. 2016;35:e22-9.

121. Liu, M, Pitcher, BN, Mardis, ER, Davies, SR, Friedman, PN, Snider, JE, Vickery, TL, Reed, JP, DeSchryver, K, Singh, B, **Gradishar, WJ**, et al. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer, 2: 2344-47, 2016.

122. Nye L, Mutonga MB, Jain S, **Gradishar WJ**. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here? Santa-Maria CA, Oncology (Williston Park). 2016; 30:148-55.

123. Trosman, J, Carols, R, Simon, M, Madden, D, **Gradishar, W**, Benson, A, Rapkin, B, Weiss, E, Gareen, I, Wagner, L, Khan, S, Bunce, M, Small, A, Weldon, C. Care for a patient with cancer as a project management of complex task interdependence in cancer care delivery. J of Oncol Pract. 12:11101-1113, 2016.

124. Woodruff TK, Smith K, **Gradishar W**. Oncologists' Role in Patient Fertility Care: A Call to Action. JAMA Oncol. 2016; 2:171-72.

125. Edwards BJ, **Gradishar WJ**, Smith ME, Pacheco JA, Holbrook J, McKoy JM, Nardone B, Tica S, Godinez-Puig V, Rademaker AW, Helenowski IB, Bunta AD, Stern PH, Rosen ST, West DP, Guise TA.Elevated incidence of fractures in women with invasive breast cancer. Osteoporos Int. 2016; 27:499-507.

126. **Gradishar WJ,** Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14:324-54.

127. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, **Gradishar W**, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016; 56:85-92.

128. **Gradishar W**, Salerno KE. NCCN Guidelines Update: Breast Cancer. J Natl Compr Canc Netw. 2016 May;14(5 Suppl):641-4. PMID: 27226503

129. Baselga, J, Zamagni, C, Gomez, P, Bermejo, B, Nagai, S, Melichar, B, Chan, A, Mangel, L, Bergh, J, Costa, F, Gomez, H, **Gradishar, W**, et al. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib with Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clin Breast Cancer, 2017.

130. Costa, R, Santa-Maria, C, Scholtens, D, Jain, S, Flaum, L, **Gradishar, W**, Clevenger, C, Kaklamani, V. A pilot study of cabergoline for the treatment of metastatic breast cancer. Breast Cancer Res Treat, 165: 585-592, 2017.

131. Davis, A, Chae, Y, Jain, S, Santa-Maria, C, Flaum, L, Beaubier, N, Platanias, L, **Gradishar, WJ**, Giles, F, Cristofanilli, M. Concordance of genomic alterations by next generation sequencing (NGS) in tumor tissue vs. cell-free DNA in advanced breast cancer. Proc Ann Mtg Am Soc Clin Oncol, 2016 (abs 11528).

132. **Gradishar W**, Johnson K, Brown, K, Mundt E, Manley S. Clinical variant classification: a comparison of public databases and a commercial testing laboratory. Oncologist, 2017; 22:797-803.

133. **Gradishar, W**, Anderson, B, Balassanian, R, et al. NCCN Guidelines. Insights: Breast Cancer, Version 1.2017. J Natl Comp Canc Netw. 15:433-451, 2017.

134. Han HS, Dieras V, Robson M, Palacova M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli, Domchek S, Friedlander M, Kaufman B, Garber J, Shparyk Y, Chmielowska E, Jacobsen EH, Kaklamani V, **Gradishar W**, et al. Veliparib with temozolomide or carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II Brocade study. Ann Oncol, 2017.

135. Hortobagyi GN, Lipton A, Chew, HK, **Gradishar WJ**, et cl Sauter NP, Mohanlal RW, Zhen M, McGrain B, Van Poznak C, Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. JAMA Oncol, 3: 906-912, 2017.

136. Johnston, S, Hegg, R, Im, S, Park, I, Burdaeva, O, Kurteva, G, Press, M, Tjulandin, S, Iwata, H, Simon, S, Kerry, S, Izguierdo, M, Williams, L, **Gradishar, WJ**. A phase 3, randomized study of dual HER2-blockade with lapotinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with human epidermal growth factor receptor-2 positive, hormone rec. J Clin Oncol 2017.

137. Nunes A, Liang C, **Gradishar WJ**, Dalvi T, Lewis J, Jones N, Green E, Doherty M, Seeger J. A real-world evidence study to define the prevalence of endocrine therapy-naïve hormone receptor-positive locally advanced or metastatic breast cancer in the US, Oncology Ther. 2017.

138. Nye L, Rademaker A, **Gradishar WJ**. Breast cancer outcomes after diagnosis of hormone positive breast cancer and subsequent pregnancy in the tamoxifen era. Clin Breast Cancer, 17:185-89, 2017.

139. Traina T, Miller K, Yardley D, Eakle J, Schwartberg L, O'Shaughnessy J, **Gradishar WJ**, Schmid P, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Traudeau M, Steinberg J, Uppall H, Tudor I-C, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing, Triple-Negative Breast Cancer. J Clin Oncol 2017.

140. Trosman, J, Weldon, C, **Gradishar, WJ**, Benson, A, Cristofanilli, M, Kurian, A, Ford, J, Balch, A, Watkins, J, Phillips, K. Modernizing the framework for insurance coverage policy for contemporary precision medicine – the case of next-generation cancer sequencing. Health Affairs. 2017.

141. Jain, S, Santa-Maria, C, Rademaker, A, Giles, F, Cristofanilli, M, **Gradishar, WJ**, Phase 1 study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy. Journal of Clinical Oncology. 2018.

142. Miller, KD, O'Neill, A, **Gradishar, WJ**, et al. A double-blind phase III trial of doxorubicin and cyclophosphamide followed by paclitaxel with bevacizumab or placebo in patients with lymph node positive and high risk lymph node negative breast cancer: A trial of the ECOG-ACRIN cancer research group (E5103). New England Journal of Medicine. 2018.

143. Robertson, J, Raizer, J, Hodges, JS, **Gradishar, WJ**, and Allen, JA. Risk factors for the development of paclitaxel induced neuropathy in breast cancer patients. Journal of the Peripheral Nervous System. 2018.

144. Zizani, P. L., Dreyling, M., **Gradishar, WJ**, Andre, M., Esteva, F.J., Boulos, S., Barca, E. G., Benn, K., Curigliano, G. Are biosimilars the future of oncology and hematology? A Narrative Review. Annals of Internal Medicine. 2018.

145. Wagner, L.I., Tooze, J.A., Levine, B. J., Beaumont, J., Duffecy, J., Victorson, D., **Gradishar, WJ**, Leach, J., Saphner, T., Surz, K., Smith, M.L., Penedo, F., Mohr, D. C., Cella, D. F. Randomized trial to evaluate an eHealth Intervention to reduce fear of recurrence among breast cancer survivors: Results from the FoRtitude trial. Journal of Clinical Oncology. 2018.

146. Soliman, H., Wagner, S., Flake II, D.D., Robson, M., Schwartzberg, L., Sharma, P., Magliocco, A., Kronenwett, R., Lancaster, J.M., Lanchbury, J., Gutin, A., **Gradishar, W.J.**, Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer. Breast Cancer Research. 2019.

147. Trosman, J., Weldon, C., Kircher, S., **Gradishar, W.J.**, Benson III, A., Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients. Current Treatment Options in Oncology. Crossmark. 2019.

148. Soliman, H., Wagner, S., Flake, D.J., Robson, M., Schwartzberg, L., Sharma, P., Magliocco, A., Kronenwett, R., Lancaster, J.M., Lanchbury, J.S., Gutin, A., **Gradishar, W.J.** Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Annals of Surginal Oncology. 2020.

149. Dietz, J. R., Moran, M. S., Isakoff, S. J., Kurtzman, S.H., Willey, S.C., Burstein, H.J., Bleicher, R.J., Lyons, J.A., Sarantou, T., Baron, P.L., Stevens, R.E., Boobol, S.K., Anderson, B.O., Shulman, L.N., **Gradishar, W.J**., Monticciolo, D.L., Plecha, D.M., Nelson, H., Yao, K.A. Recommendations for Prioritization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic. The COVID-19 Pandemic Breast Cancer Consortium. Accepted to Breast Cancer Research and Treatment. 2020.

150. Phillips, S.M.,Welch, W.A., Fanning, J., Santa Maria, C. A., Gavin, K.L., Auster-Gussman, L.A., Solk, P., Cullather, E., Khan, S, Kulkarni, S., **Gradishar, W**.& Siddique, J. (In Press) Daily Physical Activity and Symptom Reporting in Breast Cancer Patients Undergoing Chemotherapy: An Intensive Longitudinal Examination. Cancer Epidemiology, Biomarkers & Prevention. 2020.

151. Saura, C., Matito, J., Oliveira, M., Wildiers, H., Brufksy, A.M., Waters, S.H., Hurvitz, S.A., Moy, B., Kim, S., **Gradishar, W.J**., Queiroz, G.S., Cronemberger, E., Wallweber, G.L., Bebchuk, J., Keyvanjah, K., Lalani, A.S., Bryce, R., Vivancos, A., Eli, L.D., Delaloge, S. Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer, Clin Cancer Res September 22 2021 DOI: 10.1158/1078-0432.CCR-21-1584.

152. Weiser R, Polychronopoulou E, Kuo YF, Haque W, Hatch SS, Tyler DS, **Gradishar WJ,** Klimberg VS. De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough? Ann Surg. 2021 Oct 1;274(4):654-663. doi: 10.1097/SLA.0000000000005064. PMID: 34506321.

153. Wagner, L.,Tooze, J., Hall, D., Levine, B., Beaumont, J., Duffecy, J., Victorson, D., **Gradishar, W**., Leach, J., Saphner, T., Smith, M. Penedo, P., Mohr, D., Cella, D. (2021) Targeted eHealth intervention to reduce breast cancer survivors fear of recurrence: Results from the FoRtitude randomized trial. Journal of the National Cancer Institute. 113(11): 1495-1505. DOI: 10.1093/jnci/djab100.

154. Moreno, P. I., Horner, F. S., Torzewski, J. B., Thomas, J. L., **Gradishar, W.**, Victorson, D., & Penedo, F. J. (in press). Study design and protocol for tailored Acceptance and Commitment Therapy (ACT) to optimize quality of life in women living with metastatic breast cancer. Contemporary Clinical Trials Communications.

155. Wagner, L.I., Tooze J.A., Hall, D.L., Levine, B.J., Beaumont, J., Duffecy, J., Victorson, D., Gradishar, W., Leach, J., Saphner, T., Sturtz, K., Smith, M.L., Penedo, F., Mohr, D.C., & Cella. D. (2021). Evaluating a targeted eHealth intervention to reduce fear of recurrence among breast cancer survivors: Results from the FoRtitude randomized trial. Journal of the National Cancer Institute, 113, 1495-1505. PMCID: PMC8244801.

156. Whitaker, M., Welch, W.A., Fanning, J., Santa-Maria, C.A., Auster-Gussman, L.A., Solk, P., Khan, S.A., Kulkarni, S.A., **Gradishar, W.**, Siddique, J. and Siobhan M. Phillips. Using ecological momentary assessment to understand associations between daily physical activity and symptoms in breast cancer patients undergoing chemotherapy. Accepted to Journal of Supportive Care in Cancer. (2022).

157. Hall DL, Levine BJ, Jeter E, Chandler A, Tooze JA, Duffecy J, Victorson D, **Gradishar W**, Leach J, Saphner T, Smith ML, Penedo F, Mohr DC, Cella D, Wagner LI. A spotlight on avoidance coping to manage fear of recurrence among breast cancer survivors in an eHealth intervention. Journal of Behavioral Medicine. In press. 2022.

158. Hophan, S. L., Odnokoz, O., Liu, H., Luo, Y., Khan, S., **Gradishar, W**., Zhou, Z., Badve, S., Torres, M. A., & Wan, Y. (2022). Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management. Endocrinology, 163(4), bqac027. https://doi.org/10.1210/endocr/bqac027

159. Davis, A. A., Gerratana, L., Clifton, K., Medford, A. J., Velimirovic, M., Hensing, W. L., Bucheit, L., Shah, A. N., D'Amico, P., Reduzzi, C., Zhang, Q., Dai, C. S., Denault, E. N., Bagegni, N. A., Opyrchal, M., Ademuyiwa, F. O., Bose, R., **Gradishar, W. J**., Behdad, A., Ma, C. X., … Cristofanilli, M. (2022). Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer. *EBioMedicine*, *86*, 104316. https://doi.org/10.1016/j.ebiom.2022.104316

160. Fu, Z., Chen, S., Zhu, Y., Zhang, D., Xie, P., Jiao, Q., Chi, J., Xu, S., Xue, Y., Lu, X., Song, X., Cristofanilli, M., **Gradishar, W.J.**, Kalinsky, K., Yin, Y.,

Zhang, B., Wan. Y. Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity. Science Advances. 2023

161. Esquives, B.S.N., Walsh, E.A., Penedo, F.J., Thomas, J.L., Horner, F.S., Torzewski, J.B., **Gradishar, W.J.**, Victorson, D., Moreno, P. Coping Strategies and Psychosocial Resources among Women Living with Metastatic Breast Cancer: A Qualitative Study. Submitted 2023.

162. Shah, A.N., Santa-Maria, C.A., Mukhija, D., Shah, N., Kang, A.K., Kumthekar, P., Burdett, K., Chandra, S., Chang, J., Tsarwhas, D., Woodman, J., Jovanovic, B., Gerratana, L., **Gradishar, W.**, Cristofanilli, M. A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases. Clin Breast Cancer. 2023. 23(3):324-329.

163. Santaliz-Casiano, A., Mehta, D., Danciu, O.C., Patel, H., Banks, L., Zaidi, A., Buckley, J., Rauscher, G.H., Schulte, L., Weller, L.R., Taiym, D., Liko-Hazizi, E., Pulliam, N., Friedewald, S.M., Khan, S., Kim, J.J., **Gradishar, W.**, Hegerty, S., Frasor, J., Hoskins, K.F., Madak-Erdogan, Z. Identification of metabolic pathways contributing to ER+ breast cancer disparities using a machine-learning pipeline. Sci Rep 13, 12136. 2023.

164. Lenz, L., Neff, C., Solimeno, C., Cogan, E.S., Abramson, V.G., Boughey, J.C., Falkson, C., Goetz, M.P., Ford, J.M., **Gradishar, W.J.**, Jankowitz, R.C., Kaklamani, V.G., Marcom, P.K., Richardson, A.L., Storniolo, A.M., Tung, N.M., Vinayak, S., Hodgson, D.R., Lai, Z., Dearden, S., Hennessy, B.T., Mayer, E.L., Mills, G.B., Slavin, T.P., Gutin, A., Connolly, R.M., Telli, M.L., Stearns, V., Lanchbury, J.S., Timms, K.M. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. Breast Cancer Research and Treatment (2023). 10.1007/s10549-023-07046-3.

165. Noriega Esquives, B.S., Walsh, E.A., Penedo, F.J., Thomas, J.L., Horner, F.S., Torzewski, J.B., **Gradishar, W.J.**, Victorson, D.E., Moreno, P.I. Coping strategies and psychosocial resources among women living with metastatic breast cancer: A qualitative study. Journal of Psychosocial Oncology. 2023. DOI: 10.1080/07347332.2023.2254754.

166. Zhu, Y., Benerjee, A., Xie, P., Ivanov, A., Amaduddin, F., Jiao, Q., Chi, J., Zeng, L., Xue, Y., Lu, X., Cristofanilli, M., **Gradishar, W.J.**, Henry, C., Gillespie, T.W., Bhave, M.A., Kalinsky, K., Fu, H., Bahar, I., Zhang, B., Wan, Y. Multiomics unravels suppression of the OTUD4-CD73 axis in restoring antitumor immunity for immune-cold breast cancers. Submitted 2023.

167. Goetz, M.P., Bagegni, N.A., Batist, G., Brufsky, A., Cristofanilli, M.A., Damodaran, S., Daniel, B.R., Fleming, G.F., **Gradishar, W.J.**, Graff, S.L., Grosse Perdekamp, M.T., Hamilton, E., Lavasani, S., Moreno-Aspitia, A., O'Connor, T., Pluard, T.J., Rugo, H.S., Sammons, S.L., Schwartzberg, L.S., Stover, D.G., Vidal, G.A., Wang, G., Warner, E., Yerushalmi, R., Plourde, P.V., Portman, D.J., Gal-

Yam, E.N. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized phase II ELAINE 1 trial. Annals of Oncology 34(12): 1141-1151. December 2023.

168. Gerratana, L., Davis, A.A., Foffano, L., Reduzzi, C. Rossi, T., Medford, A., Clifton, K., Shah, A., Bucheit, L., Velimirovic, M., Bandini, S., Dai, C.S., Wehbe, F., **Gradishar, W.J.**, Behdad, A., Ulivi, P., Ma, C.X., Puglisi, F., Bardia, A., Cristofanilli, M. Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling. Submitted 2024.

169. Phillips, S.M., Starikovsky, J., Solk, P., Desai, R., Reading, J.M., Hasanaj, K., Wang, S.D., Cullather, E., Lee, J., Song, J., Spring, B., **Gradishar, W.J**. Feasibility and preliminary effects of the Fit2ThriveMB pilot physical activity promotion intervention on physical activity and patient reported outcomes in individuals with metastatic breast cancer. Breast Cancer Res Treat (2024). DOI: 10.1007/s10549-024-07432-5.

170. Chi JJ, Xie P, Cheng MH, Zhu Y, Cui X, Watson J, Zeng L, Uddin A, Nguyen H, Li L, Moremen K, Reedy A, Wyatt M, Marcus A, Dai M, Paulos CM, Cristofanilli M, **Gradishar W.J.**, Zhao S, Kalinsky K, Hung MC, Bahar I, Zhang B, Wan Y. MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer. Nat Commun. 2025 Apr 15;16(1):3552. DOI: 10.1038/s41467-025-58524-9. PMID: 40229283; PMCID: PMC11997035.

B. Editorials, Reviews, Chapters, Books, Commentaries

Book Chapters

1. Combined modality therapy for stage III non-small cell lung cancer: The University of Chicago experience. Bitran JD, Vokes EE, Hoffman PC, Ellis E, **Gradishar WJ,** English C, Golomb HM. In Neoadjuvant Chemotherapy, Barzetl LP, Holland JF, Khayat D, Weil M (eds). Springer-Verlag, Paris, France, pp 427-431, 1991.

2. The Oncologic Emergencies. **Gradishar WJ,** Hoffman PC. In Principles of Critical Care Medicine, Hall JB, Schmidt GA, Wood LDH (eds). 1st edition, McGraw-Hill, New York, pp 1847-1863, 1992.

3. Lung carcinoma. **Gradishar WJ,** Bitran JB. In Medicine for the Practicing Physician, 3rd edition, Hurst JW (ed). Butterworth, Boston, pp 70-74, 1992.

4. Neoadjuvant therapy for stage III non-small-cell lung cancer: A review. In Lung Cancer Differentiation. Implications for Diagnosis and Treatment. Bitran JD, Vokes EE, Hoffman PC, **Gradishar WJ,** English C, Golomb HM. Marcel Dekker, Inc, pp 293-304, 1992.

5. Lung cancer. Filderman AE, **Gradishar WJ,** Matthay RA. In Annual Review of Pulmonary and Critical Care Medicine, 1993, Twelfth Edition, Matthay RA, Wiedman HP (eds). Hanley and Belfus, pp 25-44, Philadelphia, 1993.

6. Clinical aspects of breast cancer. **Gradishar WJ,** Morrow M. In Hormones and Cancer, Vedeckis WV (ed). Birkhauser Publishing Co., pp 147-196, 1996.

7. Tumor Angiogenesis, Current Concepts and Clinical Implications. **Gradishar WJ,** Bouck N. In Comprehensive Textbook of Oncology Updates. Moosa AR, Schimpff SC, Robson MC (eds). Williams and Wilkins, 1996.

8. The Oncologic Emergencies. **Gradishar WJ,** Hoffman PC. In Principles of Critical Care Medicine, Hall JB, Schmidt GA, Wood LDH (eds). 2nd edition, McGraw-Hill, New York, pp. 1075-1090, 1998.

9. Endocrine Therapy of Breast Cancer. **Gradishar WJ,** Jordan VC. In The Breast: Comprehensive Management of Benign and Malignant Diseases. Bland KI, Copeland EM (eds). W.B. Saunders, Philadelphia, pp. 1350-1372, 1998.

10. A 42-year-old premenopausal woman with a painless right breast lump. **Gradishar, WJ**, Morrow, M, Watson, JD, Dixon, JM. In Breast Disease: A Problem-Based Approach. Dixon JM, Morrow M (eds). WB Saunders, London, UK, pp. 93-114, 1999.

11. A 45-year-old premenopausal women who presents with a 3.2 cm mass in the right breast with skin dimpling. **Gradishar, WJ**, Morrow, M. In Breast Disease: A Problem-Based Approach. Dixon JM, Morrow M (eds). WB Saunders, London, UK, pp. 117-127, 1999.

12. A 48-year-old presents with a 6-month history of a lump in the left breast and increasingly severe pain in the midthoracic region. **Gradishar, WJ**. In Breast Disease: A Problem-Based Approach. Dixon JM, Morrow M (eds). WB Saunders, London, UK, pp. 162-168. 1999.

13. Pharmacology and Use of Antiestrogens in Treatment and Chemoprevention of Breast Cancer. **Gradishar WJ**, Jordan VC. In Endocrinology of the Breast. Manni A (ed). Humana Press, New Jersey, pp. 283-312, 1999.

14. Surrogate Endpoints as a Measure of Efficacy in Clinical Trials of Angiogenesis Inhibitors. Twardowski PT, Gately S, **Gradishar, WJ**. In Therapeutic Implications of Angiogenesis Inhibitors & Stimulators: Current Status & Future Directions. Mousa S (ed). Landes Bioscience, TX, in press, 1998.

15. Tamoxifen. **Gradishar WJ** in Oncology Therapeutics: A Quick Reference Guide. Ratain MJ, Tempero M, Skosey C (eds). WB Saunders, Orlando, in press.

16. Toremifine. **Gradishar WJ** in Oncology Therapeutics: A Quick Reference Guide. Ratain MJ, Tempero M, Skosey C (eds). WB Saunders, Orlando, in press.

17. Endpoints for Determination of Efficacy of Antiangiogenic Agents in Clinical Trials. **Gradishar WJ**. In Antiangiogenic Agents in Cancer. Discovery Drug Series. Teicher BA (ed). Humana Press, New Jersey, pp. 341-344, 1999.

18. Male Breast Cancer. **Gradishar WJ**. In Diseases of the Breast. Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Second edition, Lippincott Williams & Wilkins, Philadelphia, PA, pp 661-667, 2000.

19. Breast Cancer and Hormonal Management. **Gradishar WJ,** Jordan VC. In Endocrinology, DeGroot LJ, Jameson JL (eds), 4th Edition. WB Saunders, Philadelphia, PA, pp 2199-2208, 2000.

20. The Evolving Role of Endocrine Therapy for the Treatment and Prevention of Breast Cancer. **Gradishar WJ** and Jordan VC. In Cancer Chemotherapy and Biological Response Modifiers – Annual 19, Schilsky R, Sondel P, Giaccone G (eds.). Elsevier Science Ltd., Oxford, England, pp 215-236, 2001.

21. Breast Cancer. Bines J, **Gradishar WJ.** In Oncology/Hematology Handbook: A Primary Reference for House Staff and Medical Students, Rosen ST, Kuzel TM (eds). PRR, Inc: Melville, NY, pp 63-81, 2001.

22. Adjuvant Systemic Therapy for Primary Breast Cancer. **Gradishar WJ.** In Manual on Breast Diseases, Jatoi I (ed.). Lippincott Williams & Wilkins, Philadelphia, pp 309-328, 2002 .

23. Hormonal Therapy. Jordan VC, **Gradishar WJ.** In Cancer Handbook, Alison M (ed.). Nature Publishing Group, Washington, DC, in press, 2001.

24. Male Breast Cancer. **Gradishar WJ.** In UpToDate, Rose BD (ed.). UpToDate, Wellesley, MA, in press, 2001.

25. The Evolving Role of Endocrine Therapy for the Treatment and Prevention of Breast Cancer. **Gradishar WJ** and Jordan VC. In Cancer Chemotherapy and Biological Response Modifiers – Annual 20, Schilsky R, Sondel P, Giaccone G (eds.). Elsevier Science Ltd., Oxford, England, pp 227-238, 2002.

26. Endocrine Therapy of Breast Cancer. **Gradishar WJ,** Jordan VC. In The Breast: Comprehensive Management of Benign and Malignant Diseases (3rd Edition), Bland KI, Copeland EM III (eds.). W.B. Saunders, Philadelphia, PA, in press, 2003.

27. Steroid Hormone Receptors. O'Regan RM, Badve S, **Gradishar WJ.** The Breast: Comprehensive Management of Benign and Malignant Diseases (3rd Edition), Bland KI, Copeland EM III (eds.). W.B. Saunders, Philadelphia, PA, in press, 2003.

28. Advances in Endocrine Therapy for the Treatment and Prevention of Breast Cancer. **Gradishar WJ** and Jordan VC. In Cancer Chemotherapy and Biological Response Modifiers – Annual 21, Schilsky R, Sondel P, Giaccone G (eds.). Elsevier Science Ltd., Oxford, England, pp 211-222, 2003.

29. The Role of Taxanes in Early Breast Cancer. Kaklamani VG, **Gradishar WJ.** In Diseases of the Breast Updates (2nd Edition), Harris JR, Lippman ME, Morrow M, Osborne CK (eds.). Lippincott Williams & Wilkins, New York, NY, pp 1-15, in press, 2003.

30. SERMs Other Than Tamoxifen for Chemoprevention. O'Regan RM, **Gradishar WJ.** In Managing Breast Cancer Risk, (eds.). BC Decker, Inc., Ontario, Canada, in press, 2003.

31. Chemotherapy Guidelines for Metastatic Breast Cancer. **Gradishar WJ,** Jorgensen CW. In Advanced Therapy in Breast Disease (2nd Edition), Singletary SE, Robb GL, Hortobagyi GN (eds.). BC Decker Inc., Hamilton, Ontario, Canada, pp 557-566, 2004.

32. Adjuvant Hormonal Therapy in Early Breast Cancer. Buzdar A, **Gradishar WJ.** In Advanced Therapy of Breast Disease (2nd Edition), Singletary SE, Robb GL, Hortobagyi GN (eds.). BC Decker Inc., Hamilton, Ontario, Canada, pp 459-466, 2004.

33. Inhibitors of Tumor Angiogenesis. Zakarija A, **Gradishar WJ**. In Principles of Cancer Chemotherapy and Biological Response Modifiers, Chabner BA, Longo DL (eds.). pp 605-620, 2005.

34. Surveillance Strategies for Breast Cancer Survivors. McGartland L, **Gradishar WJ**. In Breast Cancer (2nd Edition), BC Decker Inc., Hamilton, Ontario, Canada, pp 575-582, 2006

19. Adjuvant Therapy for Breast Cancer. Kaklamani V, **Gradishar WJ.** In The Breast: Comprehensive Management of Benign and Malignant Diseases. Bland KI, Copeland EM (eds). Fourth Edition, W.B. Saunders, Philadelphia, in press, 2009.

35. Male Breast Cancer. Wisinski KB, **Gradishar WJ**. In Diseases of the Breast. Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Fourth edition, Lippincott Williams & Wilkins, Philadelphia, PA, pp 775-780, 2009.

36. Huyck TK, **Gradishar WJ.** Metastatic Breast Cancer.10:173, 2011.

37. **Gradishar W.** Anti-HER-2 Therapy and Endocrine Therapy. J Jap Society of Clinical Oncology.46:1167-71, 2011.

38. **Gradishar W.** Emerging Approaches for treating HER-2 positive metastatic breast cancer beyond trastuzumab. Annals of Oncology, 2011.

39. **Gradishar, WJ**, Twelves, C, Rugo, HS. Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer. Clin Adv Hematol Oncol., 12: 3-21, 2014.

40. Jain S, **Gradishar W**. Male Breast Cancer. Diseases of the Breast, 5th Ed. 2014.

41. Costa, R, Hansen, N, **Gradishar, W**. Locally advanced breast cancer. The Breast, 5th Ed, Bland, Copeland, Klimberg, Gradishar (ed). Elservier, Philadelphia 2017.

42. Costa, RLB, **Gradishar, WJ**. Differences are important: Breast cancer therapy in different ethnic groups. J Global Oncol, 2017.

43. Flaum, L, **Gradishar, WJ**. Advances in Endocrine Therapy for Postmenopaulsal Metastatic Breast Cancer in Optimizing Breast Cancer Management. 1st Ed, Gradishar (ed), 1st Edition, Springer International Publishing AG: Cha, Switzerland 2018.

44. Jain, S, **Gradishar, WJ**. Male Breast Cancer. The Breast, 5th Ed, Bland, Copeland, Klimberg, Gradishar (ed). Elsevier, Philadelphia 2017.

45. Santa-Maria, C. **Gradishar, WJ**. Adjuvant and Neoadjuvant Systemic Therapies for Early Stage Breast Cancer. The Breast, 5th ed. Bland, Copeland, Klimberg, Gradishar (ed). Elsevier, Philadelphia 2017.

Books

1. **Gradishar WJ**, Wood WC (eds.). Advances in Breast Cancer Management. Kluwer Academic Publishers: Norwell, MA. 2000.

2. **Gradishar WJ**, Wood WC (eds.). Advances in Breast Cancer Management, Second Edition. Springer: New York, NY. 2008.

3. Bland KI, Copeland EM (eds.). Barsky SH, **Gradishar WJ**, Recht A, Unst MM (Assoc Ed.) The Breast: Comprehensive Management of Benign and Malignant Disorders, 4th Edition, Saunders Elsevier, Philadelphia, 2009.

4. Bland KI, Copeland EM, Klimberg V, **Gradishar WJ** (eds). The Breast: Comprehensive Management of Benign and Malignant Disorders, 5th Edition, Elsevier, Philadelphia, 2017.

5. **Gradishar, WJ** (ed). Optimizing Breast Cancer Management. 1st Edition, Springer International Publishing AG: Cha, Switzerland 2018.

6. Shao, Z, Cordeiro, O, Balch, C (ed), Yu, K, Kimberg, V, **Gradishar, W** (Assoc Ed). Breast Cancer, 1st Edition, AME Publishing, Hong Kong, 2017.

7. Klimberg S, Gradishar WJ, Bland K et al (eds). Bland and Copeland's The Breast: Comprenhensive Management of Benign and Malignant Diseases 6th Edition, Elsevier, Philadelphia 2023

Reviews/Commentaries

1. **Gradishar WJ,** Schilsky RL. Effects of cancer treatment on the reproductive system. CRC Critical Reviews in Oncology/Hematology, 8:153-171, 1988.

2. **Gradishar WJ,** Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Seminars in Oncology, 16:425-436, 1989.

3. **Gradishar WJ,** Majid P, Bitran JD. Supportive care of the lung cancer patient. Hematol Oncol Clin North Am, 4:1023-1025, 1990.

4. **Gradishar WJ,** Bitran JD. Optimizing the care of lung cancer patients: A multidisciplinary approach. Hematol Oncol Clin North Am, 4:1183-1199, 1990.

5. **Gradishar WJ,** Vokes EE. 5-Fluorouracil Cardiotoxicity: A Critical Review. Ann Oncol, 1:409-414, 1990.

6. Volm M, **Gradishar WJ**. How to diagnose and manage male breast cancer. Contemporary Oncology, 4:17-28, 1994.

7. Von Gunten CF, Von Roenn JH, **Gradishar WJ,** et al. A hospice/palliative medicine rotation for fellows training in hematology-oncology. J Cancer Educ, 10:200-202, 1995.

8. Volm M, **Gradishar WJ**. How to diagnose and manage male breast cancer. Internal Medicine 16:51-65, 1995.

9. **Gradishar WJ.** Inflammatory breast cancer: The evolution of multimodality treatment strategies. Sem Surg Oncol, 12:352-363, 1996.

10. **Gradishar WJ,** Tallman MS, Abrams JS. Adjuvant high-dose chemotherapy for breast cancer: A case for databases, not biases. Ann Int Med, 125:599-604, 1996.

11. Jordan VC, **Gradishar WJ.** The molecular mechanism of action and clinical potential of new antiestrogens. Med Asp Mol Med, 17:235-384, 1996.

12. Carlson RW, Goldstein LJ, **Gradishar, WJ**, et al. National Cancer Care Network, Breast Cancer Guidelines, Oncology 10:47-80, 1996 (supplement).

13. **Gradishar WJ,** Jordan VC. The clinical potential of new antiestrogens. J Clin Oncol, 15:840-852, 1997.

14. Bines J, **Gradishar, WJ**. Primary care issues in the breast cancer survivor. Cancer Ther, 23:605-611, 1997.

15. **Gradishar WJ.** An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Investig New Drugs, 15:49-59, 1997.

16. Twardowski P, **Gradishar WJ**. Clinical trials of antiangiogenic agents. Curr Opin Oncol, 9:584-589, 1997.

17. Bines J, **Gradishar, WJ**. Medical issues facing the breast cancer survivor. Int Med 19: 14-24, 1998.

18. **Gradishar WJ**. Primary chemotherapy regimens and schedules. Semin Oncol 25:(suppl 3): 25-30, 1998.

19. Cianfrocca M, **Gradishar, WJ**. Follow-up of breast cancer survivors. Consultant, 38:1734-1745, 1998.

20. Cianfrocca M, **Gradishar, WJ**. Primary care for the breast cancer survivor. Women's Health in Primary Care, 1:371-385, 1998.

21. Carlson RW, Goldstein LJ, **Gradishar WJ**, et al. Update: National Cancer Care Network Practice Guidelines for the Treatment Breast Cancer Guidelines. Oncology, 13:41-66, 1999.

22. **Gradishar WJ**, Jordan VC. Hormonal therapy for breast cancer. Hematology/Oncology Clin North Am, 13:435-455, 1999.

23. **Gradishar WJ**. Recently initiated studies: neoadjuvant treatments in the next century. Semin Oncol 26:26-29, 1999 (supp 10).

24. **Gradishar W.** Current clinical practice: Have the recently completed phase III trials significantly impacted adjuvant treatment choices for stage II breast carcinoma? Sem Oncol 26:xix-xx, 1999.

25. **Gradishar WJ**. Formulating guidelines for chemotherapy in advanced breast cancer. Oncology 13:231-235, 1999.

26. Breast Cancer Risk Reduction Guidelines Panel Members (Carlson R, Baraket R, Bevers T, Daly MB, Edge S, Garber JE, **Gradishar W**, Mahoney M, Sellin RV, Shapiro C, Singletary E, Theriault R, Ward J, Whittemore A, Williams C, Winer E. NCCN Breast Cancer Risk-Reduction Guidelines. Oncology 13:241-254, 1999.

27. **Gradishar WJ**. High-dose chemotherapy and breast cancer. JAMA, 282:1378-1380, 1999.

28. Hensley ML, Schuchter LM, Lindley C, Meropol N, Cohen G, Broder G, **Gradishar WJ** et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. J Clin Oncol 17:3333-3355, 1999.

29. **Gradishar WJ.** Improving breast cancer outcomes: early detection is still key. Primary Care Cancer 20:9-10, 2000.

30. **Gradishar WJ.** Clinical status of capecitabine in the treatment of breast cancer. Oncology 15(suppl):S69-S72, 2001.

31. O'Regan RM, **Gradishar WJ.** Selective estrogen-receptor modulators in 2001. Oncology 15:1177-1190, 2001.

32. Antman K, Abraido-Lanza AF, Blum D, Brownfield E, Cicatelli B, Debor MD, Emmons K, Fitzgibbon M, Gapstur SM, **Gradishar W,** et al. Reducing disparities in breast cancer survival: a Columbia University and Avon Breast Cancer Research and Care Network Symposium. Breast Cancer Res Treat 75:269-280, 2002.

33. **Gradishar WJ,** Morrow M. Advances in endocrine therapy of metastatic breast cancer. Br J Surg 89:1489-1492, 2002.

34. Forbes, JF, Osborne CK, **Gradishar WJ**, Ravdin PM. Choosing between endocrine therapy and chemotherapy – or is there a role for combination therapy? Breast Cancer Res Treat 75(Suppl 1):S37-S44, 2002.

35. **Gradishar WJ.** Docetaxel and capecitabine in breast cancer: current status and future directions. Cancer Conference Highlights 6:3-5, 2002.

36. Morrow M, **Gradishar W.** Recent advances in breast cancer. Br Med J 2:282-286, 2002.

37. Kaklamani VG, **Gradishar WJ.** Advances in adjuvant chemotherapy of breast cancer: the role of taxanes. J Natl Comprehensive Cancer Network 1(Suppl 1):S107-S118, 2003.

38. **Gradishar WJ.** Adjuvant systemic therapy of early stage breast cancer. Curr Treat Options Oncol 4:141-150, 2003.

39. **Gradishar WJ.** Tamoxifen – What Next? The Oncologist; 9(4): 378-84, 2004.

40. Kaklamani VG, **Gradishar WJ.** Role of capecitabine (Xeloda®) in breast cancer. Expert Rev Anticancer Therapy; 3:137-144, 2003.

41. Kaklamani VG, **Gradishar WJ.** Epirubicin vs. doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clinical Breast Cancer 4(Supp 1):S26-S33, 2003.

42. **Gradishar WJ.** The role of aromatase inhibitors as first- and second-line therapy for hormone-sensitive metastatic breast cancer. Curr Oncol 10(Suppl 1):S14-S19, 2003.

43. 2003 EIFBCR Participants: Bartelink H, Benz C, Cleveland C, Dorn R, Gralow J, **Gradishar WJ,** Grant K, et al. Consensus statement: Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. Breast Cancer Research Treatment 80(2): 139-44, 2003.

44. **Gradishar WJ**, O'Regan R. Progress in Systemic Adjuvant Therapy of Early-Stage Breast Cancer. International Journal of Clinical Oncology; 8:230-247, 2003.

45. Sokolowicz L, **Gradishar WJ**,. Implications of First-Line Adjuvant Treatment with Aromatase Inhibitors. Clinical Breast Cancer Supplement; 5:S24-S30, 2004

46. Estevez LG, **Gradishar WJ**. Evidence-based use of Neoadjuvant taxane in Operable and Inoperable Breast Cancer. Clinical Cancer Research; 15:10(10): 3249-61, 2004.

47. **Gradishar, WJ**. Albumin-bound nanoparticle paclitaxel. Clin adv Hematol Oncol. 3: 348-9, 2005.

48. **Gradishar WJ**. Fulvestrant in the Treatment of Postmenopausal Women with Advanced Breast Cancer. Expert Rev. Anticancer Therapy. 5(3): 445-453, 2005.

49. **Gradishar WJ**. Hormone Therapy in Postmenopausal Women with Breast Cancer. Advanced Studies in Medicine, 5(9B): S817-S822, 2005.

50. **Gradishar WJ**. Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal Women. Oncology, 69: 1-9, 2005.

51. Kaklamani VG, **Gradishar WJ**. Adjuvant Hormonal Therapy in Early Breast Cancer. Oncology, 19(11): 1433-1435, 2005.

52. Kaklamani VG**, Gradishar WJ**. Adjuvant therapy of breast cancer. Minerva Ginecologica, 57(5): 521-536, 2005.

53. Manders JB, **Gradishar WJ**. The Evolving Role of Endocrine Therapy for Early Stage Breast Cancer. Breast Cancer; 12(2):62-72, 2005.

54. **Gradishar, WJ**, Cella, D. Selective estrogen receptor modulators and prevention of invasive breast cancer. JAMA, 295: 27884-6, 2006.

55. **Gradishar, WJ**. Landmark Trials in Endocrine Adjuvant Therapy for Breast Carcinoma. Cancer, 106: 975-981, 2006.

56. Kaklamani VG, **Gradishar WJ**. Gene Expression in Breast Cancer. Current Treatment Options in Oncology, 7:123-128, 2006.

57. **Gradishar WJ**. Albumin-bound paclitaxel: a next-generation taxane. Expert Opinion, 7(8): 1041-1053, 2006.

58. **Gradishar WJ.** Update on fulvestrant for hormone receptor-positive advanced breast cancer. Community Oncology, 4 (4): 1-12, 2007.

59. Hazard HW**, Gradishar, WJ.** The Effects and Treatment of Secondary Lymphedema in the Breast Cancer Survivor. Oncologistics Magazine. 36-40, First Quarter 2007.

60. Cianfrocca ME, **Gradishar WJ**. The Next Wave of Microtubule-Target Agents: Epothilones. Breast Diseases: A Yearbook Quarterly. 203-205. Vol 19 No. 3 2008.

61. Gralow, J, Rugo, H**, Gradishar, WJ**, et al. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer, 8: 33-7, 2008.

62. **Gradishar WJ**. Management of Advanced Breast Cancer with epothilone B analog, ixabepilone. Drug Design Dev Ther. 3:1-9, 2009

63. **Gradishar, W**. Skeletal issues and bone heatlh in participants with cancer. Introduction. Oncology, 23: 7-8, 2009.

64. Kaklamani V, **Gradishar WJ**, Capecitabine: treatment options in metastatic breast cancer. Expert Rev Obstet Gynecol. 4(4): 367-376, 2009.

65. Cianfrocca M, **Gradishar W.** New molecular classifications of breast cancer. CA Cancer J Clin 59(5):303-313, 2009.

66. Abdulkadir, O, Saghir, N, Sedky, L, **Gradishar, WJ** et al. MENA Breast Cancer Regional Guidelinse Committee. Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region. J Natl Compr Canc Netw, 8(suppl 3): S8-S15, 2010.

67. Albain KS, Carey L, **Gradishar WJ,** et al. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Clin Breast Cancer. 10(6):421-39, 2010.

68. **Gradishar WJ**. Adjuvant endocrine therapy for early breast cancer: the story so far. Cancer Invest. 28(4):433-42, 2010.

69. Dranitsaris G, Coleman R, **Gradishar WJ.** nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.Breast Cancer Res Treat. 119(3):717-24, 2010.

70. Hartford, JB, Otero, IV, Anderson, BO, Cazap, E**, Gradishar, WJ**, et al. Problem solving for breast health care delivery in low and middle resources countries (LMCs): consensus statement from the Breast Health Global Initiative. Breast. 20:S20-9, 2011.

71. Huyck TK, **Gradishar WJ**, Manuguid F, Kirkpatrick P. Eribulin Mesylate. Nature Reviews Drug Discovery. 10:173-174, 2011.

72. **Gradishar WJ.** The place for eribulin in the treatment of metastatic breast cancer. Curr Ocol Rep. 13(1):11-6, 2011.

73. **Gradishar WJ**. Taxanes for the Treatment of Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research. 6:1-13, 2012.

74. **Gradishar WJ**. Sorafenib in locally advanced or metastatic breast cancer. Expert Opin Investig Drugs. 21(8):1177-91, 2012.

75. Stopeck, AT, Brown-Glaberman, U, Wong, Hy, Park, BH, Barnato, SE, **Gradishar, WJ**, Hudis, CA, Rugo, HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis. 29: 807-19, 2012.

76. **Gradishar, WJ**. Barriers and Opportunities for the Use of Personalized Medicine in Patients with Breast Cancer. American Health & Drug Benef, 6: S25-S27, 2013.

77. **Gradishar WJ**. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol. 2013;24(10):2492-500. doi:10.1093/annonc/mdt217

78. Hornberger J, **Gradishar WJ**, Alvarado MD, Chien R, Yu TM, Gutierrez HR. Author's reply to Lamy. J Natl Cancer Inst. 105(2):149-50, 2013.

79. O'Shaughnessy J, **Gradishar WJ**, Bhar P, Iglesias J. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat. 138(3):829-37, 2013.

80. Perez, EA, **Gradishar, WJ**, Twelves, C, Schwartzberg, L. Individualizing treatment to optimize survival outcomes in breast cancer. Clin Adv Hematol Oncol., 11 (suppl 10): 3-21, 2013.

81. Christopher, T, **Gradishar, WJ**, O'Shaughnessy, JA, Bramsen, N, Lurie, RH. Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer. Clin Adv Hematol Oncol. 12 (suppl): 1-14, 2014.

82. **Gradishar, WJ**. Treatment of metastatic breast cancer. J Natl Compr Canc Netw. 12(5 suppl): 759-761, 2014.

83. **Gradishar, WJ**. Quality of life in patients with metastatic breast cancer. Clin Adv Hematol Oncol. 12(suppl 4): 3-4, 2014.

84. **Gradishar WJ**. Metastatic Breast Cancer: Lessons Learned and Changing Treatment Paradigms. Santa-Maria CA, JAMA. Oncol. 1:528-34, 2015.

85. **Gradishar WJ**. Optimizing Treatment of HER2-Positive Breast Cancer. JNCCN. 13: 649-651, 2015.

86. Santa-Maria, CA. and **Gradishar, WJ.** Developments in Adjuvant Therapy for Early-Stage Breast Cancer: Endocrine Therapy for Premenopausal Women and Small HER2-Positive Tumors. Am J Hematol Oncol. 11:19-23, 2015.

87. Santa-Maria, CA, Park, SJ, Jain, S, **Gradishar, WJ**. Breast cancer and immunology: biomarker and therapeutic developments. Expert Rev Anticancer Ther, 15:1215-22, 2015.

88. Kaklamani VJ and **Gradishar WJ**. Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer? JNCCN. 13:1448-52, 2015.

89. **Gradishar WJ.** Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Cancer Management and Research; 8:85-94, 2016.

90. Kaklamani VK, **Gradishar WJ**. Endocrine therapy in the current management of postmenopausal estrogen receptor-positive metastatic breast cancer. Oncologist. 22:507-517, 2017.

91. Costa R, Carneiro BA, Wainwright Da, Santa-Maria CA, Kumthekar P, Chae YK, **Gradishar WJ**, Cristofanilli M, Giles FJ. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann Oncol 28:44-46, 2016.

92. Costa R, Navroop G, Rademaker A, Carneiro BA, Chae YK, Kumthekar P, **Gradishar WJ**, Kurzrock R, Giles FJ. Systematic review of phase I/II clinical trials in breast cancer : inclusion of patients with CNS involvement. Submitted 2016.

93. Costa, R, **Gradishar, WJ**. PI3K/AkT/mTOR pathway in triple negative breast cancer: old target…new hope? Submitted 2017.

94. Costa, R, Carneiro, BA, Wainwright, DA, Santa-Maria, CA, Kumthekar, P, Chae, YK, **Gradishar, WJ**, Cristofanilli, M, & Giles, FJ. Developmental therapeutics for patients with

breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann Oncol., 28:44-56, 2017.

95. Costa, R, Costa, RB, Talamantes, SM, Helenowski, I, Carneiro, BA, Chae, YK, **Gradishar, WJ**, Kurzrock, R, Giles, FJ. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget, 2017.

96. Costa, R., Gill, N, Rademaker, A, Carneiro, B, Chae, Y, Kumthekar, P, **Gradishar, W**, Kurzrock, R, Giles, F. Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis. Cancer Treat Rev., 55:10-15, 2017.

97. Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, **Gradishar WJ**, Giles FJ, Cristofanilli M. Developmental therapeutics for inflammatory breast cancer: biology and translational directions. Oncotarget 8:12417-32, 2017.

98. Costa R, Shah NA, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, **Gradishar WJ**, Giles FJ. Targeting epidermal growth factor receptor in triple negative breast cancer: new discoveries and practical insights for drug development. Cancer Treat Rev. 53:111-119, 2017.

99. Costa, R, Costa, RB, Talamantes, S, Helenowski, I, Peterson, J, Kaplan, J, Carneiro, B, Giles, F, **Gradishar, W**. Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib. Breast. 2017.

100. Giordano, S, **Gradishar, W**. Breast cancer: Updates and advances in 2016. Curr Opin Obstet Gynecol, 29: 12-17, 2017.

101. **Gradishar, WJ**. New Approaches to Endocrine Therapy for Breast Cancer. NCCN 15:679-81, 2017.

102. **Gradishar, WJ**. Advances in the Management of Metastatic Breast Cancer. JNCCN. 21(5.5):1-5, 2023.

Editorials

1. **Gradishar WJ,** Vokes EE. 5-FU cardiotoxicity: the risk of rechallenge - reply. Ann Oncol, 2:383, 1991.

2. **Gradishar WJ**, Tallman MS. High-dose chemotherapy for breast cancer. Ann Int Med 126: 917-918, 1997.

3. **Gradishar WJ**. Management of menopausal symptoms in the cancer patient. Oncology 13:1372-1377, 1999.

4. **Gradishar WJ**. Have the recently completed phase III trials significantly impacted adjuvant treatment choices for stage II breast carcinoma? Semin Oncol 26:xix-xx, 1999.

5. **Gradishar WJ.** Expanding horizons for patients with breast cancer. Cancer Conference Highlights 6:3-4, 2002.

6. **Gradishar WJ.** Novel approaches to the treatment of metastatic breast cancer. Cancer Abstracts and Summaries 4:3-4, 2003.

7. O'Regan RM, **Gradishar WJ.** The Mortimer/Urban Article Reviewed. Oncology, 2003.

8. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, **Gradishar WJ,** et al. Editorial from Keith et al – reply. J Clin Oncol, 2003.

9. **Gradishar WJ**, Kaklamani V. Adjuvant Therapy of Breast Cancer in the Elderly: Does One Size Fit All. JAMA; 239:1118-20, 2005.

10. **Gradishar WJ**, Cella D. Selective Estrogen Receptor Modulators and Prevention of Invasive Breast Cancer. JAMA, 295, 2006.

11. **Gradishar WJ**. HER2 therapy--an abundance of riches. N Engl J Med. 366(2):176-8, 2012.

12. **Gradishar, WJ.** No Pain, No Gain: A Fallacy So Far. J Clin Oncol. 33(3): 235-237, 2015.

13. Flaum L, **Gradishar WJ**. Refining Treatment Decisions in Older Patients With Breast Cancer. JAMA Oncol. 1:166-7, 2015.

14. Woodruff, T, Smith, K, and **Gradishar, W**. It's Time for Oncologists to Engage in Fertility Care for Their Patients: A Call To Action, JAMA Oncology Viewpoint. JAMA Oncol. 2:171-2, 2016.

15. Costa, R and **Gradishar, W**. Triple-Negative Breast Cancer: Current Practice and Future Directions. Journal Oncol Pract, 13:301-307, 2017.

16. Costa, R and **Gradishar, W**. Do Genomic Assays Provide the Necessary Confidence to De-esccalate Adjuvant Therapy? Accepted J Clin Oncol 2018.

17. **Gradishar, B**. Breast Cancer Research and Treatment. Springer US, 10.1007/s10549-019-05511-6, 2020.

C. Case reports, Technical notes, Letters (designate letters)

1. **Gradishar WJ,** Shapiro C. Plasmacytoma simulating duodenal carcinoma. Am J Gastroenterology, 83:77-79,1988.

2. **Gradishar WJ,** Vokes EE, Kai N. Chemotherapy-related hemolytic-uremic syndrome following the treatment of head and neck cancer: a case report. Cancer, 66:1914-1918, 1990.

3. Volm MD, Talamonti MS, Thangavelu, M, **Gradishar WJ.** Pituitary adenoma and bilateral male breast cancer: An unusual association. J Surgical Oncol, 64:74-78, 1997.

4. Brenin CM, Talamonti MS, Small W, **Gradishar WJ**. Radiation-induced sarcoma following treatment of breast cancer: a case report and review of the literature. Cancer Control, 5:425-432, 1998.

5. Manders JB, Barke LD, Wahl A, Wolfman JA, Small W, Keeney KM, **Gradishar WJ**, Diaz LK. A case study form the Lynn Sage Comprehensive Cancer C enter. Primary sarcoma of the breast: a diagnostic dilemma. Breast Cancer Online, 8(6), 2005.

6. Nye, L, Huyck, TK, **Gradishar, WJ**. Diagnostic and treatment considerations when newly diagnosed breast cancer coincides with pregnancy: a case report and review of literature. J Natl Compr Cancer Ntw. 10: 145-8, 2012.

7. **Gradishar, W**, Brown, K, Mundt, E, Manley, S. In Reply. Oncologist, Aug. 29, 2017.

D. Proceedings and non-refereed papers

1. Morrow M, **Gradishar WJ**, Pierce L, et al. Current controversies in breast cancer management. Current problems in surgery, 1999.

2. **Gradishar WJ,** Hortobagyi GN. Emerging data on UFT + LV in the treatment of metastatic breast cancer, 2001.

3. Crown J, **Gradishar W,** Trudeau M, Valero V. Evidence-based strategies for the use of anthracyclines and taxanes in the treatment of breast cancer, 2001.

4. **Gradishar WJ** (Commentary). Exemestane in the treatment of postmenopausal women with stage IV breast cancer. Philadelphia (PA): Omega Med, 2001.

5. Cadogan AA, Ellis MJ, **Gradishar WJ,** et al. Setting a new standard in the management of advanced breast cancer. Philadelphia (PA): Institute for Continuing Healthcare Education (CoMed Communications), 2001.

6. **Gradishar WJ.** Current management of breast cancer: adjuvant therapy. A CME Audio Program (audio and booklet program). Green Brook (NJ): Sciris Corporation, 2001.

7. Conte P, **Gradishar WJ,** Mamounas TP, Pritchard KI, Winer EP. Maximizing treatment outcomes in primary and metastatic breast cancer. CME Monograph and CD-ROM. New York (NY): Clinical Insights Inc, 2002.

8. Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM, **Gradishar WJ,** et al. A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Highlights from the 2001 San Antonio Breast Cancer Symposium. Deerfield (IL): Breast Journal 9(3):213-22, 2003 May-Jun.

9. Berk GI, Campos S, Chlebowski, Elledge RM, **Gradishar WJ,** et al. In: Buzdar AU (ed.). Hormonal agents in the treatment of breast cancer: current status. Highlights from an expert opinion forum. CME monograph. Deerfield (IL): Discovery International, 2002.

10. Gradishar WJ, Goodman M, Lindley CM, et al. Management of metastatic breast cancer: evolving treatment strategies with chemotherapy [CME monograph]. Irving (TX): S.G. Madison & Associates and The Center for Biomedical Continuing Education, 2003.

11. Perez E, Rugo H, **Gradishar WJ**, Campos S, O'Shaughnessy J, et al. A roundtable discussion of treatment strategies for anthracycline and taxane-resistant metastatic breast cancer. Based on the proceedings from the 2002 San Antonio Roundtable Discussion. CME Monograph. New York (NY): Clinical Insights Inc., 2003

12. Hortobagyi G, Goss P, **Gradishar WJ**, Mortimer J, Vogel V. The Role of Anti-Aromatase Agents in New Treatment Strategies for Breast Cancer. CME Monograph. San Antonio, (TX): Clinical Insights Inc., 2003

E. Abstracts

1. **Gradishar WJ,** Larson R, Daly K, Bitran J, Golomb H. Acute nonlymphocytic leukemia in the elderly. Proc Am Soc Clin Oncol, 4:154, 1985.

2. **Gradishar WJ,** Sinkule JA, O'Rourke K, Hallihan D. Conjunction of anticancer drugs to monoclonal antibodies. Proc Ann Symposium on Monoclonal Antibody Conjugates, 1986.

3. **Gradishar WJ,** Williams S, Bitran J, Barker C. Analysis of factors influencing hematologic recovery in patients treated with high dose chemotherapy and autologous bone marrow. Proc AACR, 1987.

4. **Gradishar WJ,** DeChristopher P, Beckman E, Larson R. Chronic lymphocytic leukemia (CLL) in 3 members of one family. Blood, 72:161a, 1988.

5. **Gradishar WJ,** Vokes EE, Panje WR, Haraf DJ, Goldman ME, McEvilly JM, Kozloff M, Moran WJ, Tybor AG, Weichselbaum RR. Neoadjuvant chemotherapy (NCT) followed by surgery (s) and concomitant chemoradiotherapy (CXRT) for locally advanced head and neck cancer (HNC). Third International Conference: The Interaction of Radiation Therapy and System Therapy, Monterey, CA 1990.

6. **Gradishar WJ,** Vokes EE, Schilsky RL, Weichselbaum R, Panje W. Catastrophic vascular events in patients receiving 5-fluorouracil (5-FU) based chemotherapy. Proc AACR, 1990.

7. **Gradishar WJ,** O'Laughlin R, Le Beau M, Epstein C, Larson R. Clinical and cytogenetic (CG) responses to granulocyte-macrophage colony stimulating factor (GM-CSF) in therapy-related myelodysplatic syndrome (t-MDS). Proc AACR, 1990.

8. **Gradishar WJ,** Hoffman P, Bitran J, Golomb H, Mick R, Krishnasamy S, Ferguson M. The impact on survival by adjuvant chemotherapy (C) and radiation therapy (R) in stage II non-small cell lung cancer (NSCLC). ASCO, 1990.

9. **Gradishar WJ,** Ellis E, Vokes E, Hoffman P, English C, Ferguson M, Krishnasamy S, Haraf D, Bitran J, Golomb H. A phase II study of neoadjuvant chemotherapy (CCRT) for stage III non-small cell lung cancer (NSCLC). Proceedings ASCO, 1991.

10. Bitran JD, Vokes EE, Hoffman PC, Ellis E, **Gradishar W**, Golomb HM. Combined modality therapy for stage III non-small cell lung cancer (NSCLC). The University of Chicago Experience. Proceedings ASCO, 1991.

11. Nelson JB, Grapey D, Cheng EY, **Gradishar W,** Kozlowski JW. Primary retroperitoneal teratoma: A rare cause of secondary hyperaldosteronism and sustained hypertension. Proc Ann Mtg North Cent Soc Am Uro Assoc, 1991.

12. Kilton L, Vogelzang N, **Gradishar WJ,** et al. Phase II study of echinomycin in metastatic sarcoma. Proc Am Soc Clin Oncol, 12:474 (Abs 1658), 1993.

13. **Gradishar WJ,** Kies M, Moalli P, et al. Effects of all-trans retinoic acid (TRA) on small cell lung cancer (SCLC). Lung Cancer, 10:5331, 1994.

14. Von Gunten CF, Von Roenn JH, **Gradishar WJ,** et al. Palliative medicine rotation for hematology/oncology fellows. Proc Am Assoc Ca Edu, 1994.

15. Athanasiadis I, **Gradishar WJ,** Sheehan T, et al. A phase II study of all-trans retinoic acid and interferon-alpha in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol, 1994.

16. Athanasiadis I, **Gradishar WJ,** Miller M, et al. A phase II study of all-trans retinoic acid (TRA) and interferon-alpha (IFN-α) in patients with advanced non-small cell lung cancer (NSCLC). Proc Fifth Int Congress on Anti-Cancer Chemotherapy, 1995.

17. Vogel CL, Glusman JE, Sledge GW, Mansi JL, Kunz KR, **Gradishar WJ**, et al. Raloxifene in ER+ metastatic breast cancer. Am Assoc Cancer Res, Keystone meeting, 1997.

18. **Gradishar WJ**, Hoh K, Erban J, Vogel C, et al. Preliminary results from a phase II study of docetaxol as primary chemotherapy followed by doxorubicin and cyclophosphamide in stage III breast cancer. Proc Am Soc Clin Oncol 16:171a (#599), 1997.

19. Sparano JA, Speyer J, **Gradishar WJ**, Hochster H. Phase I trial of dexrazoxane, doxorubicin and escalating doses of paclitaxel in advanced breast cancer. Proc Am Soc Clin Oncol 16:251a (#886), 1997.

20. Bines J, Goss, B, Chmiel J, Rousson J, Yeldandi A, **Gradishar W**. C-erb B2 and p53 overexpression as predictors of survival in patients with male breast cancer. Proc Am Soc Clin Oncol 16:161a (#558), 1997.

21. **Gradishar WJ**, O'Regan RM, Liu J, Cisneros A, et al. Phase II trial of suramin in metastatic breast cancer with an assessment of angiogenesis inhibition. Proc Am Soc Clin Oncol 16:171a (#600), 1997.

22. Piro M, Knight SJ, Mytko J, Baker K, Flynn K, Sharp L, Uziel M, Waller S, **Gradishar W** Smyrniotis P. Psychological correlates of concerns about declining health and dying in newly diagnosed women with breast cancer. Soc Behav Med, 1997.

23. Mytko J, Knight SJ, Baker K, Flynn K, Piro M, Sharp L, Uziel N, Waller S, **Gradishar W**, Smyrniotis P. Reducing the burden of psychological assessments used with cancer patients: an evaluation of three brief measures of mood. Soc Behav Med, 1997.

24. **Gradishar WJ**, Loh K, Erben J, Vogel C, et al. Preliminary results from a phase II study of (Taxotere) docetaxel as primary chemotherapy followed by doxorubicin and cyclophosphamide in stage III breast cancer. Breast cancer Res Treat 46:74 (suppl 1, abs. 310) 1997.

25. **Gradishar WJ**, Glusman JE, Vogel CL, Mansi JL, et al. Raloxifene HCL, a new endocrine agent, is active in estrogen receptor metastatic breast cancer. Breast Cancer Res Treat 46:53 (suppl. 1, abs. 209), 1997.

26. Sparano JA, Speyer J, **Gradishar W**, Wasserheit C, et al. Phase I trial of Zinecard, Adriamycin and escalating doses of Taxol in advanced breast cancer. Breast Cancer Res Treat 46:56 (suppl. 1, abs. 224), 1997.

27. **Gradishar WJ**, Cobleigh, Sparano J, etc. A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer. Proc Am Soc Clin Oncol, abstract 148, 1998.

28. Noe L, Becker R, **Gradishar WJ**, Gore M, Trotter J, et al. The cost-effectiveness of tamoxifen in reducing the incidence of breast cancer. Proc Am Soc Clin Oncol 18:82a (abstr 310), 1999.

29. **Gradishar WJ**, Von Roenn J, Cobleigh M, Sparano J, DeMichele A, et al. A phase I study of marimastat (MAR) in combination with doxorubicin (A) and Cyclophosphamide (C) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 18:125a (abstr 476), 1999.

30. Miller KD, **Gradishar WJ**, Schuchter LM, et al. A randomized phase II pilot trial of adjuvant marimastat (MAR) in patients (pts) with early breast cancer. Annals of Oncology 13(8):1220-4, 2002 Aug.

31. Nicholson BP, Thor A, Goldstein LJ, **Gradishar WJ**, et al. Weekly docetaxel (D) and rhuMAb HER2 (H) combination therapy as first line therapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 19:139a (abstr 549), 2000.

32. **Gradishar WJ,** Morrow M, Oviedo M, Wiley E, Kiel K, Small W, Schilder L, Venta L, Schipma P. Multidisciplinary Network Breast Cancer management conference. Era of Hope, Department of Defense Breast Cancer Research Program Meeting, June 2000, (abstr A1).

33. O'Regan RM, Von Roenn JH, Malik U, Sparano JA, Carlson RW, **Gradishar WJ.** Phase II study of neoadjuvant taxotere, adriamycin and cyclophosphamide (TAC) in stage III breast cancer. 2nd Annual Lynn Sage Breast Cancer Symposium, Poster Presentation, September 2000.

34. **Gradishar WJ,** O'Neill A, Cobleigh M, Goldstein LJ, Davidson NE. A phase II trial with antisense oligonucleotide ISIS 3521/Cgp 64128a in patients (pts) with metastatic breast cancer (MBC): ECOG Trial 3197. Proc Am Soc Clin Oncol 20:44a (Abstract 171 and Poster Presentation), 2001.

35. Krontiras H, Huang AC, Rademaker A, **Gradishar W,** Morrow M. Factors influencing the use of chemotherapy (CTX) for breast cancer in older women. Proc Am Soc Clin Oncol 20:28b (Abstract 1859), 2001.

36. Uber KA, Nicholson BP, Thor AD, Merkel DE, Goldstein LJ, **Gradishar WJ,** Sledge GW. A phase II trial of weekly docetaxel (D) and Herceptin (H) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer. Proc Am Soc Clin Oncol 20:50b (Abstract 1949), 2001.

37. Meza LA, Amin B, Horsey M, Petralia SA, Szatrowski TP, **Gradishar WJ.** A phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20:70b (Abstract 2029), 2001.

38. Mahadevan A, Kiel KD, Small W, Morrow M, Bethke K, Talamonti M, **Gradishar W,** Newman S. Are there predictors of local failure for young women treated by breast conserving therapy? American Society for Therapeutic Radiology and Oncology (submitted), 2001.

39. O'Regan RM, Malik U, Sparano JA, Carlson RW, Staradub V, Khan S, Morrow M, Von Roenn JH, **Gradishar WJ.** Phase II study of neoadjuvant taxotere, adriamycin and cyclophosphamide (TAC) in stage III breast cancer. 3rd Annual Lynn Sage Breast Cancer Symposium, Poster Presentation, Chicago, IL, October 2001.

40. Krontiras H, Nirupama A, Huang CF, Rademaker AW, **Gradishar WJ,** Morrow M. Differences between specialties in referral and recommendations for the use of chemotherapy for breast cancer in older women. 3rd Annual Lynn Sage Breast Cancer Symposium, Poster Presentation, Chicago, IL, October 2001.

41. **Gradishar WJ,** Meza L, Hill TH, Chen Y-M, Varkey JA, Hei YJ, Amin B. Three-year results from a multicenter phase II study of capecitabine plus paclitaxel in metastatic breast cancer. 25th Annual San Antonio Breast Cancer Symposium, Abstract, San Antonio, TX, December 2002.

42. Albain K, Elledge R, **Gradishar WJ,** Hayes DF, Rowinsky E, et al. Open-label, phase II, multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. 25th Annual San Antonio Breast Cancer Symposium, Abstract, San Antonio, TX, December 2002.

43. Sparano JA, Bernardo P, **Gradishar WJ,** Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: An Eastern Cooperative Oncology Group trial (E2196). 25th Annual San Antonio Breast Cancer Symposium, Abstract, San Antonio, TX, December 2002.

44. Sparano JA, Bernardo P, **Gradishar WJ,** Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: An Eastern Cooperative Oncology Group trial (E2196). American Society of Clinical Oncology Molecular Therapeutics Symposium 2002, San Diego, CA.

45. Citron M, Berry D, Cirrincione C, Carpenter J, Hudis C, **Gradishar W,** et al. Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741). 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2002.

46. **Gradishar W,** Tjulandin S, Davidson N, et al. Phase III trial of ABI-007 vs. Taxol in patients with metastatic breast cancer. Proc Am Soc Clin Oncol, 2003.

47. Swain SM, Jahanzeb M, Erban JK, Limentani SA, Hardikar S, Tsai K-T, Olsen SR, **Gradishar WJ.** Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide for stage III breast cancer: clinical response and long-term survival. Proc Am Soc Clin Oncol, 2003.

48. Tallman MS, Gray R, LeMaistre CF, Osborne CK, Vaughan WP, **Gradishar WJ,** et al. Phase III study of conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem cell transplantation in patients with stage II and III breast cancer at high risk of recurrence (INT 0121). Proc Am Soc Clin Oncol, 2003.

49. Iacobuzio-Donahue C, Albain K, Elledge R, **Gradishar WJ,** Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S, Rubin S. Determinants of response to gefitinib (Iressa®, ZD1839) in patients with advanced breast cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 2003.

50. O'Shaughnessy J, Tjulandin S, Davidson N, Shaw H, Desai N, Hawkins MJ, **Gradishar WJ.** Phase III trial of ABRAXANE (ABI-007), a nanoparticle albumin-bound (nab) paclitaxel, demonstrated superior efficacy vs. Taxol in MBC. 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2003.

51. **Gradishar WJ**. The Role of Aromatase Inhibitors for Advanced Breast Cancer. Chemotherapy foundation Symposium XX Innovative Cancer Therapy for Tomorrow, New York, NY, November 2002.

52. **Gradishar WJ**, Wolinsky S, Hawkins M, Vishalpura T, Nightengale B, Bramley T. Cost-effectiveness of nanoparticle Aldumin-bound (nab) paclitaxel (NP) vs Standard Paclitaxel (SP) in the Treatment of metastatic Breast Cancer (MBC). Proc Am Soc Clin Oncol 2004.

53. **Gradishar WJ.** Letrozole. Cancer Investigation; Chemotherapy Foundation Symposium XXII Innovative Cancer Therapy for Tomorrow, New York, NY, p54-55, November 2004.

54. Ivanov I, Chen F, Wiley EL, Keswani A, Memmel H, Rademaker A, **Gradishar W**, Morrow M, Cryns V, Khan SA. αβ-crystallin is a Novel Predictor of Neoadjuvant Chemotherapy Resistance in Breast Cancer. Society of Surgical Oncology 59th Annual Cancer Symposium, San Diego, CA, March 2006.

55. Chia S, Piccart M, **Gradishar W**, on behalf of the EFECT writing committee. Fulvestrant vs exemestane following non-steroidal aromatase inhibitor failure: first overall survival data from the EFECT Trial. 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2007.

56. O'Shauhnessy J, Lichtinister M, Tjulandin S, Davidson N, Shaw HS, Bhar P, **Gradishar W.** Randomized Comparisons of Weekly Versus Every-3-Week *nab*-Paclitaxel in Patients With Metastatic Breast Cancer. 2008 European Breast Cancer Symposium (EBCC 6). Berlin, Germany. April 2008.

57. **Gradishar W,** Krasnojon D, Cheporov S, Makhson A, Manikhas G, Clawson A, Bhar P**.** Randomized Comparisons of *nab*-Paclitaxel Weekly or Every 3 Weeks Compared to Docetaxel Every 3 Weeks as First-line Therapy in Patients With Metastatic Breast Cancer. 2008 European Breast Cancer Symposium (EBCC 6). Berlin, Germany. April 2008.

58. Aapro M, Tjulandin S, Bhar P, **Gradishar W**. Comparison of Weekly and Every 3-Week *nab*-Paclitaxel in Elderly Patients With Metastatic Breast Cancer. 2008 European Breast Cancer Symposium (EBCC 6). Berlin, Germany. April 2008.

59. Camburn T, Tjulandin S, Davidson N, O'Shauhnessy J, Bhar P, **Gradishar W.** Retrospective Analysis of Patients With Poor Prognostic Factors and Metastatic Breast Cancer in Phase III Study Comparing *nab*-Paclitaxel to Solvent-Based Paclitaxel. 2008 European Breast Cancer Symposium (EBCC 6). Berlin, Germany. April 2008.

60. Davidson N, Tjulandin S, O'Shauhnessy J, Bhar P, **Gradishar W**. Overall Survival Analysis of a Randomized Phase III Trial Comparing *nab*-Paclitaxel With Solvent-Based Paclitaxel in Patients With Metastatic Breast Cancer Treated With Anthracycline. 2008 European Breast Cancer Symposium (EBCC 6). Berlin, Germany. April 2008.

61. Cortes J, Specht J, **Gradishar WJ,** Strauss L, Rybicki A, WU X, Vahdat X, Paz-Ares L, Somlo G. Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase 1 Study CA 180-004. NCCN 2010 Congress Series: Breast Cancer, Abstract, Chicago, IL, January 2010.

62. Trosman JR, Weldon CB, **Gradishar WJ**, Schink C. Timing of genetic testing relative to breast cancer surgery. American Society of Clinical Oncology, 46th Annual Meeting, General Poster Session and Abstract, Chicago, IL, June 2010 (Abstract 9028). J Clin Oncol 28:15s, 2010.

63. Edwards BJ, **Gradishar WJ**, Raisch W, Bunta A, Samaras AT, West DP, Mckoy JM, Singhal S, Bennett CL. Hip fractures as a complication of cancer care in perimenopausal women with

breast cancer. American Society of Clinical Oncology, 46th Annual Meeting, General Poster Session and Abstract, Chicago, IL, June 2010 (Abstract 11086). J Clin Oncol 28, 2010.

64. **Gradishar WJ**, Dalenc F, Kaklamani VG, Costa F, Sahoo TP, Segalla J, Lokanatha D, Pinczowski H, Raina V, Baselga J. Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients with HER2-negative locally advanced or metastatic breast cancer. American Society of Clinical Oncology, 46th Annual Meeting, General Poster Session and Abstract, Chicago, IL, June 2010 (Abstract 1073). J Clin Oncol 28:15s, 2010.

65. Sahoo TP, Kaklamani VG, Lokanatha D, Raina V, Bondarde S, Jain M, Schwartzberg LS, **Gradishar WJ**. A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase IIb study evaluating sorafenib (SOR) with paclitaxel (PAC) in patients with advanced breast cancer. American Society of Clinical Oncology, 46th Annual Meeting, General Poster Session and Abstract, Chicago, IL, June 2010 (Abstract 1114). J Clin Oncol 28:15s, 2010.

66. Schink, JC, Weldon, CB, Trosman, J, Benson, AB, AI, **Gradishar, WJ**. Features of an "Oncology Medical Home": Addressing challenges in cancer care delivery. Academy Health Annual Research Meeting, 2010.

67. Schink JC, Weldon CB, Trosman JR, Benson AB, Loffler AI, **Gradishar WJ**. Care delivery barriers to personalized medicine in breast cancer. American Society of Clinical Oncology, 46th Annual Meeting, General Poster Session and Abstract, Chicago, IL, June 2010 (Abstract 6146). J Clin Oncol 28:15s, 2010.

68. Bondarde S, Kaklamani V, Prasad Sahoo T, Lokanatha D, Raina V, Jain M, Schwartzberg L, **Gradishar WJ**. Cacer Res 70: (suppl 2): P2-16-23, 2010.

69. Weldon, CB, Trosman, J, Doll, KM, Gradishar, WJ, Schink, JC. BRCA testing impact on breast cancer surgical approach. Poster presentation at 4th National Conference on Genomics and Public Health, 2010.

70. Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, **Gradishar WJ**. Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). American Society of Clinical Oncology, 47th Annual Meeting, Trials in Progress Poster Session, Chicago, IL, June 2011 (Abstract TPS124). J Clin Oncol 29: 2011.

71. Doll KM, Weldon CB, Trosman JR, Wetzel HH, Fallen TJ, **Gradishar WJ**, Schink JC. BRCA+ test result impact and timing on surgical treatment decisions for patients with breast cancer. American Society of Clinical Oncology, 47th Annual Meeting, General Poster Session and Abstract, Chicago, IL, June 2011 (Abstract 626). J Clin Oncol 29: 2011.

72. Johnston SRD, Gelmon, KA, Pivot XB, **Gradishar WJ**, Conner A, Kothari D, Legenne P, Leigh M, O'Rourke L, Parikh R. Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies. American Society of Clinical Oncology, 47th Annual Meeting, Trials in Progress Poster Session, Chicago, IL, June 2011 (Abstract TPS105). J Clin Oncol 29: 2011.

73. Schink JC, Doll KM, Weldon CB, Trosman JR, Wetzel HH, Fallen TJ, **Gradishar WJ**. Prophylactic oophorectomy for patients with breast cancer with BRCA results. American

Society of Clinical Oncology, 47th Annual Meeting, General Poster Session and Abstract, Chicago, IL, June 2011 (Abstract 1533). J Clin Oncol 29: 2011.

74. Trosman JR, Weldon CB, Benson AB, **Gradishar WJ**, Schink JC. Oncology Medical Home to address challenges in breast cancer care delivery. American Society of Clinical Oncology, 47th Annual Meeting, Publication-only Abstracts, Chicago, IL, June 2011 (Abstract e16641). J Clin Oncol 29: 2011.

75. Tsongalis GJ, Weldon CB, Trosman JR, **Gradishar WJ**, Schnink JC. Barriers to implementing primary HER2 FISH testing. American Society of Clinical Oncology, 47th Annual Meeting, Publication-only Abstracts, Chicago, IL, June 2011 (Abstract e16642). J Clin Oncol 29: 2011.

76. Goss P, Smith I, O'Shaughessy J, Ejlentser B, Kautmon M, Boyle F, Buzdar A, Fumoleav P, **Gradishar W** et cl. Results of a randomized, double-blind, multi-center, placebo-controlled study of adjuvant lapatinib in women with early-stage Erb B2-overexyresin, breast cancer. San Antonio Breast Cancer Symposium, 2011.

77. Johnston S, Heigh M, Flosorce A, Wroblewski S, **Gradishar W.** Safety and Efficacy of an Aromative Inhibitor (AI) in combination with lapatinib (L), troutuzumab (T) or both for treatment of hormone receptor-positive (HR+), HER2+ Metastatic Breast Cancer. San Antonio Breast Cancer Symposium, 2011.

78. **Gradishar WJ**, Krasnojar D, Cheperov S et al. Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial. Proc Ann Mtg Am Soc Clin Oncol, 2011 (abs 275).

79. **Gradishar WJ**, Krasnojar D, Cheperov S et al. A randomized phase 2 trial of first-line metastatic breast cancer patients: subset anaylsis of nab-paclitoxel given weekly at 150 mg/m? San Antonio Breast Cancer Symposium, 2011.

80. **Gradishar WJ**, Krasnojar D, Cheperov S et al. nab-paclitoxel versus docetoxel for the first-line treatment of metastatic breast cancer: Overall survival subset analysis of a randomized phase 2 trial. Presented 2011 ESMO-ECCO, Stockholm.

81. **Gradishar WJ**, Krasnojar D, Cheperov S et al. nab-paclitoxel versus docetoxel for the first-line treatment of metastatic breast cancer: Overall survival and safety analysis at a randomized phase 2 trial. San Antonio Breast Cancer Symposium, 2011.

82. Edwards B, **Gradishar W**, Smith M et al. Elevated prevalence of fractures in women with breast cancer: a report from the Research on Adverse Drugs Events and Reporting (RADAR) project. International Conference on Cancer-Induced Bone Disease, 2011.

83. Johnston, S, Gelmon, K, Pivot, X, **Gradishar, WJ**, et al. Ongoing clinical developments of lapatinib in HER2-positive (HER2+) metstatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies. Proc Ann Mtg, ASCO, 2011 (tps 105).

84. Weldon, C, Trosman, J, Doll, K, **Gradishar, W**, Schink, J. The impact of BRCA testing on surgical treatment decision for breast cancer patients. Abstract presented as a poster at Society of Gynecologic Oncologists 2011 Annual Meeting on Women's Cancer.

85. Barnato, S, Jeruss, J, Bethke, K, Hansen, N, Khan, S, Roenn, J, Rosen, S, Gradishar, W, Siziopikou, K, Meservey, C, Kaklamani, V. Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer. Proc An Mtg, ASCO, 2012 (tsp 1134).

86. Costa F, Baselga J, Petrencive O, Shan M, **Gradishar W**. Design of RESILIENCE: a phase 3 tRial comparing capecitabinE (CAP) in combination with SorafenIb (SOR) or pLacebo (PL) for treatment of locally advanced (adv) or metastatic HER2-Negative breast CancEr (BC). AACR-NCI-EORTC 2012 Meeting.

87. Baselga J, Costa F, Gomez H, Hudis C, Repoport B, Roche H, Schwartzberg LS, Petrerciuc O, Shan M, **Gradishar W**. Design of Resilience: A phase 3 tRial comparing capecitabinE (CAP) in combination with SorafenIb (SOR) or pLacebo (PL) for treatment of locally advanced (adv) or metastatic HER2-Negative breast CancEr (BC). European Breast Cancer Congress, 2012.

88. Belknap, S, Godinez-Puig, V, Brannigan, R, Lin, S, Cashy, J, Chowdhary, R, Postelnick, M, Fotis, M, Irwig, M, Khan, S, **Gradishar, WJ**, et al. Association of breast cancer in men with exposure to 5-a reductase inhibitors: A RADAR report. Proc Ann Mtg Am Soc Clin Oncol, 2012 (abs 2532).

89. Boyle, F. Smith, I, O'Shaughnessy, J, Ejlertsen, B, Kaufmann, M, Buzdar, A, Fumoleau, P, **Gradishar, WJ**, et al. Lapatinib in HER2+ early breast cancer: Quality of life analysis. Proc Ann Mtg Am Soc Clin 2012 (abs 604).

90. Holbrook, J, Trifilio, S, McKoy, J, Singhal, S, Rademaker, A, Mehta, J, Belknap, S, Tica, S, Clari, S, Godinez-Puig, V, Nardone, B, **Gradishar, WJ**, et al. Novel risk factors for osteonecrosis of the jaw in multiple myeloma. A RADAR report. Proc Ann Mtg Am Soc Clin, Oncol 2012 (abs 6623).

91. Smith, I, Finkelstein, D, O'Shaughnessy, J, Moy, B, Ejlertsen, B, Kaufmann, M, Buzdar, A, Fumoleau, P, **Gradishar, WJ**, et al. Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormones receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial. Proc Ann Mtg Am Soc Clin Oncol, 2012 (abs 596).

92. Munshi, P, Toppmeyer, D, Wong, S, Ganesan, S, Tkaczuk, K, Cianfrocca, M, Kaklamani, K, **Gradishar, W**, et al. Randomized phase II trial of gemcitabine versus gemcitabine and imatinib mesylate in patients with previously treated metastatic breast cancer. Proc Ann Mtg, ASCO, 2013 (abs 1091).

93. Edwards BJ, **Gradishar WJ**, et al. Smith M, Pacheco JA, Holbrook JS, McKoy JM, Nardone B, GodinezPuig V, Bunta A, Rosen ST, West DP,. Bone mineral density and FRAX as predictors of fracture risk in women with breast cancer. J Clin Oncol 31, 2013 (suppl 26; abstr 121).

94. Schink, J, Weldon, C, Trosman, J, Siziopikou, K, **Gradishar, W**, Tsongalis, G, Patel, J, Benson, A, Perez, E. Biomarker testing methods in breast, gastric, and lung canceers – a benchmarking survey of NCI cancer centers. J Clin Oncol 31, 2013 (abs 22093).

95. Siziopikou, K, Weldon, C, Trosman, J**, Gradishar, W**, Schink, J. What are NCI designated cancer centers using for breast cancer HER2 testing? K Clin Oncol 31, 2013 (abs 626).

96. Weldon, C, Trosman, J, Benson, A, Tsongalis, G, Siziopikou, K, **Gradishar, W**, Schink, J. Are oncologists involved in cancer biomarker decisions at their institutions? J Clin Oncol 31, 2013.

97. Weldon, C, Trosman, J, Roggenkamp, B, Dupuy, D, **Gradishar, W**, Simon, M, Murphy, A. Do hospitals in large metropolitan areas utilize published breast cancer care practices and guidelines? J Clin Oncol 32, 2014 (abs 1093).

98. Weldon, C, Trosman, J, Simon, M, Dupuy, D, Roggenkamp, B, **Gradishar WJ**, Murphy, AM. Do breast cancer treatment and imaging providers follow hereditary breast and ovarian cancer risk screening guidelines? ASCO Annual Meeting Abstracts J Clin Oncol 32, 2014 (suppl; abstr e17626).

99. Miller K, O'Neill AM, Dang CT, Northfelt DW, **Gradishar WJ** et al, Goldstein LJ, Mayer IA, Brufsky A, HunegsBloom S, Sparano JA, Tevaarwerk A, Fox KR, BennettHendricks C, Balcueva EP, Sledge GW,. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol 32:5s, 2014 (suppl;abstr 500).

100. Trudeau ME, Winer EP, Steinberg JL, Liostatos M, Poondru S, Dydo M, Zhou Y, Westphal M, Peterson A, **Gradishar WJ**. A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER 2)-positive breast cancer. San Antonio Breast Cancer Symposium (SABCS) abstr 2014 (submitted).

101. **Gradishar WJ**, Ju Lin F, Ji X, KingKallimanis B, Whiting S, Ko A, Stergiopoulos S, Botteman M. Quality of life (QOL) impact of nanoparticle albumin-bound paclitaxel (nab-p) vs. conventional solvent-based paclitaxel (sb-P0 in metastatic breast cancer. San Antonio Breast Cancer Symposium (SABCS) abstr 2014 (submitted).

102. Farr, D, Thomas, A, Sugg, S, **Gradishar, WJ,** Khan, S, Schroeder, M. Male breast cancer as a second primary cancer (SPC): Increased risk following hematologic malignancies. 2015, Proc Ann Mtg Am Soc Clin Oncol (abs 1583).

103. Telli, M, McMillan, A, **Gradishar, W**, et al. Homologous Recombination Deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple-negative breast cancer (TNBC): A pooled analysis. San Antonio Breast Cancer Symposium, 2015.

104. Weldon, C, Trosman, J, Roggenkamp, B, Malin, E, **Gradishar**, W, Simon, M. Will breast cancer survivors receive the same content and assessment in survivorship care plans at non-COC sites? J Clin Oncol 33, 2015 (suppl; abstr e20634).

105. Royce, M, Villanueva, C, Ozguroglu, M, Bachelot, T, De Azevedo, S, Cruz, F, Hegg, R, Debled, M, **Gradishar, W**, Corinne Manlius, Antonia Ridolfi, Francois Philippe Ringeisen, Fatima Cardoso. BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC). ASCO Annual Meeting 2016.

106. Rugo, H, Pegram, M, **Gradishar, W**, Cortes, J, Curigliano, G, Wigginton, J, Lechleider, R, Cardoso, F. SOPHIA: A Phase 3, Randomized study of Margetuximab (M) Plus Chemotherapy (CTX) vs Trastuzumab (T) Plus CTX in the Treatment of Patients with HER2+ Metastatic Breast Cancer (MBC). ASCO Annual Meeting 2016.

107. Costa, R, Rossi, G, Mu, Z, Austin, L, Rademaker, A, **Gradishar, W,** Santa-Maria, C, Jain, S, Flaum, L, Giles, F, Yang, H, Cristofanilli, M. Circulating Tumor Cells (CTCs) and Circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC). ASCO Annual Meeting 2016.

108. Rossi, G, Austin, L, Nagy, R, Rademaker, A, **Gradishar, W**, Santa-Maria, C, Jain, S, Flaum, L, Platanias, L, Giles, F, Talasaz, A, Cristofanilli, M. Circulating tumor DNA (ctDNA): a *real-time* application of Precision Medicine to the management of metastatic breast cancer (MBC). ASCO Annual Meeting 2016.

109. Jain, S, Nye, L, Santa-Maria, C, Garrett, H, Dammrich, E, Williams, A, Bontemps, L, Flaum, L, Giles, F, **Gradishar, W**. Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer. ASCO Annual Meeting 2016.

110. Santa-Maria, C, Jain, S, Flaum, L, Park, JH, Nakamura, Y, Rademaker, A, **Gradishar, W**, Cristofanilli, M, Giles, F. A PHASE II STUDY OF PD-L1 AND CTLA-4 INHIBITION AND IMMUNOPHARMCOGENOMICS IN PATIENTS WITH METASTATIC BREAST CANCER. ASCO Annual Meeting 2016.

111. Mayer IA, Arteaga CL, Nanda R, Miller KD, Jhaveri K, Brufsky AM, Rugo H, Yardley DA, Vahdat LT, Sadeghi S, Audeh MW, Rolfe L, Litten J, Knox A, Raponi M, Tankersly C, Isaacson J, , Wride K, Marganstern DE, Vogel C, Connolly RM, **Gradishar WJ**, et al. A phse 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC). P6-11-03, 2016 San Antonio Breast Cancer Symposium.

112. Rugo HS, Pegram MD, **Gradishar WJ**, et al. A phase 3, randomized study of margetuximab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer. OT1-02-07, 2016 San Antonio Breast Cancer Symposium.

113. Santa-Maria CA, Jain S, Flaum L, Park JH, Kato T, Gross L, Uthe R, Tellez C, Stein R, Rademaker A, **Gradishar WJ**, et al. A phase II study of PD-L1 and CTLA-4 inhibition and immunopharmcogenomics in metastatic breast cancer. OT3-01-01, 2016 San Antonio Breast Cancer Symposium.

114. Rossi G, Costa R, Nagy RJ, Rademaker AW, **Gradishar WJ**, et al. Estrogen receptor 1(ESR1) mutations in circulating tumor DNA (tDNA): a guide to the management of advanced breast caner (ABC). P1-05-06, 2016 San Antonio Breast Cancer Symposium.

115. Rossi G, Austin LK, Nagy RJ, Rademaker AW, **Gradishar WJ**, et al. Circulating tumor DNA (ctDNA): a real-time application of precision medicine to the management of metastatic breast cancer (MBC). PD1-02, 2016 San Antonio Breast Cancer Symposium.

116. Royce M, Villanueva C, Ozguroglu M, Bachelot T, Azevedo S, Melo Cruz F, hegg R, Debled M, **Gradishar WJ**, et al. BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC). 22O. 2016 European Society for Medical Oncology, Copenhagen, Denmark.

117. Telli ML, Badve S, Vinayak S, Silver DP, Isakoff SJ, Kaklamani VG, **Gradishar WJ**, et al. Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA ½ mutation status in triple-negative breast cancer (TNBC): a pooled analysis. P6-09-09, 2016 San Antonio Breast Cancer Symposium.

118. Weldon, C, Trosman, J, Khan, S, Strauss, J, Benson, A, **Gradishar, W**. Reengineering delivery of guidelie-recommended care: The 4R Oncology Model in breast cancer care. Natl Compr Canc Netw 14:604-614, 2016.

119. Weldon, C, Trosman, J, Perez, C, Nelson, V, Kulkarni, S, Stein, J, Curry-Edwards, R, Bunce, M, **Gradishar, W**. An Innovative Intervention to Reengineer Multidisciplinary Oncology Care; 4R- Right Information, Right Care, Right Patient, Right Time. Scientific Symposium of the Institute for Healthcare Improvement 2016.

120. Cardoso, F, Villaneuva, C, Royce, M, Cruz, F, Debled, M, **Gradishar, W**, Hegg, R. Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First and second-line data from the BOLERO-4 study. Proc Ann Mtg Am Soc Clin Oncol 2017 (abs. 1010).

121. Cruz, MR, Limentani, K, Taxter, T, Santa-Maria, CA, Behdad, A, **Gradishar, WJ**, Nagy, RJ, Cristofanilli, M. Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors. Proc 2017 San Antonio Breast Cancer Symposium.

122. Davis, AA, Zhang, Y, Behdad, A, Taxter, T, Strickland, K, Santa-Maria, C, Flaum, L, Cruz, MR, Platanias, LC, **Gradishar, WJ**, Cristofanilli, M. The utility and correlation of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) base don HER2 positivity. Proc 2017 San Antonio Breast Cancer Symposium.

123. **Gradishar, W**, Hegg, R, Im, S, et al. Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMV) with HER2+, HR+ metastatic breast cancer (MBC): Alternative Annual Mtg Am Society, Clin Oncol 2017 (abs. 10040).

124. Kircher, S, Slolum, M, Garcia, S, Veneruso, A, Patel, A, Kinahan, K, **Gradishar, W**, et al. Use of a best-practice advisory to increase survivorship clinical referrals. Proc Ann Mtg Am Clin Oncol 2017 (abs 53).

125. Rossi, G., Mu Z., Rademaker A., Austin L., Strickland K., Costa R., Nagy R., Zagonel V., Taxter T., Behdad A., Wehbe F., Platanias L., **Gradishar WJ**, Cristofanilli M.. Cell-Free DNA and Circulating Tumor Cells: Comprehensive liquid biopsy analysis in Advanced Breaast Cancer. 2017 Assoc Cancer Res.

126. Santa-Maria, C, Kumthekar, P, Rademaker, A, Gross, L, Jain, S, Flaum, L, **Gradishar, W**, Cristofanilli, M. A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastases. Annual Mtg Am Soc Clin Oncology 2017 (tps 1110).

127. Shagisultanova E, Diamond, J, Stopeck, A, Pusztai, L, O'Regan, R, **Gradishar, W** et al. Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and latrozole in patients with hormone receptor positive and HER2-positve metastatic breast cancer. Proc 2017 San Antonio Breast Cancer Symposium.

128. Trosman, J, Stein, J, Nelson, V, Tepper, J, Spagnoli, C, **Gradishar, W**, Perez, C, Bunce, M, Pan, W, Mendoza, L, Sotelo, A, Kulkarni, S, Elsen, L, Weldon, C. Helping breast cancer patients manage care transitions through patient and navigator use of 4R care plans, 4R = right information / care / patient / time. 2017 AONN+ Exceptional Post Award in Category VI: Research, Quality, Performance Improvement.

129. Trosman, J, Weldon, C, Perez, C, Kulkarni, S, Khan, S, Hansen, N, Nelson, V, **Gradishar, W**. Written care plan and patient enablement: Pre-implementation data from the 4R in Oncology Project. Proc Ann Mtg ASCO Quality Care Symposium, 2017 (abs 55).

130. Weldon, C, Nelson, V, Stein, J, Strauss, J, Szmuilowicz, E, Benson, A, Friedeald, D, **Gradishar, W**, Simon, M, Trosman, J. Metastatic breast cancer quality improvement: preimplementation data from the 4R in Oncology Project. J Natl Compr Can Netw, 2017.

131. Weldon, C, Trosman, J, Perez, C, Kulkarni, S, Khan, S, Hansen, N, Nelson, V, **Gradishar, W**. How well is interdependent care managed across specialties in breast cancer? Metric and pre-implementation data from the 4R in Oncology Project. Proc Am Mtg ASCO Quality Care Symposium, 2017 (abs 71).

132. Malorni, L, Biagioni, C, McCartney, A, Schiavon, G, Bergqvist, M, Benelli, M, Migliaccio, I, Biganzoli, L, Bonechi, M, Boccalini, G, Pestrin, M, Galardi, F, De Luca, F, Piccart, M, **Gradishar, W**, Chia, S, Di Leo, A. Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial. Proc Am Soc Clin Oncol, 2018).

133. Robson, M, Flake, D, Schwartzberg, L, Sharma, P, Soliman, H, Magliocco, A, Brown, K, Wehnelt, S, Gutin, A, Kronenwett, R, Lancaster, J, **Gradishar, W**. Predicting Expected Absolute Chemotherapy Treatment Benefit in Women with Early-Stage Breast Cancer using a 12-Gene Expression Assay. Proc Am Soc Clin Oncol, 2018.

134. Robson, M, Wagner, S, Flake, Darl III, SOliman, H, Schwartzberg, L, Sharma, P, Magliocco, A, Kronenwett, R, Lancaster, J, Lanchbury, J, Gutin, A, **Gradishar, W.** In Silico Evaluation of the 12-gene molecular score (EndoPredict) and the Recurrence Score (Oncotype DX) as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) Breast Cancer. Proc Am Soc Clin Oncol, 2018.

135. Zhang, Q., Flaum, L., Gerratana, L., Zhang, Y., Helfand, B., **Gradishar, W.**, Platanias, L., Cristofanilli, M. Increased Circulating Tumor Cell (CTC) Clusters Are Associated with Significantly Higher Level of HER2 Expression and Metastasis in Stage III/IV Breast Cancer (Abstract #5195). 2018 AACR/ASCO Meeting.

136. Zhang, Q., Flaum, L., Gerratana, L., Zhang, Y., Helfand, B., **Gradishar, W.**, Platanias, L., Cristofanilli, M. Increased Circulating Tumor Cell (CTC) After Systempic Therapy is Associated with Younger Age in Stage III/IV Breast Cancer (BCa) Abstract #1597). 2018 AACR/ASCO Meeting.

137. Zhang, Q., Helfand, B., Kuzel, T., Yang, X., Lee, C., Carneiro, B., Giles, F., **Gradishar, W**., Platanias, L., Cristofanilli, M. PSMA-Specific, TGF-β-Insensitive CD8+ T cells Derived from Metastatic Castration Resistance Prostate Cancer (mCRPC) Apoptosis of PSMA Positive Prostate Cancer (Abstract #2553). 2018 AACR/ASCO Meeting.

138. Zhang, Q., Zhang, Y., Flaum, L., Gerratana, L., Helfand, B., **Gradishar, W**., Platanias, L., Cristofanilli, M. A novel ex vivo culture workflow to enrich and expand circulating tumor cells (CTCs) from patients with Stage III/IV Breast Cancer (BCa) (LB-370). 2018 AACR/ASCO Meeting.

139. Welch, W., Gavin, K., Siddique, J., Fanning, J., Solk, P., Santa Maria, C. A., **Gradishar, W.,** Khan, S., Khulkarni, S., Phillips, S.Objectively-measured physical activity in breast cancer patients undergoing chemotherapy, 2018.

140. Robson, M., Wagner, S., Flake II, D.D., Soliman, H., Schwartzverg, L., Sharma, P., Magliocco, A., Kronenwett, R., Lancaster, J., Lanchbury, J., Gutin, A., **Gradishar W.** Evalutation of the 12-gene Molecular Score and the 21-gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogren Receptor Positive, HER2 Negative Breast Cancer. 2018, ASCO Meeting.

141. Soliman, H., Flake II, D.D., Magliocco, A., Robson, M., Schwartzverg, L., Sharma, P., Brown, K., Wehnelt, S., Kronenwett, R., Gutin, A., Lancaster, J., Lanchbury, J., Cuzick, Jack., **Gradishar, W.** Predicting Expected Absolute Chemotherapy Treatment Benefit in Women with Early-Stage Breast Cancer using EndoPredict, an integrated 12-gene clinic-molecular assay. 2018, ASCO Meeting.

142. Zhang, Q., Gerratana, L., Shah, A., Davis., A.A., Flaum, L., Zhang, Y., Backman, V., **Gradishar, W.J.,** Platanias, L., Cristofanilli, M. Increased chromatin heterogeneity in circulating tumor cells (CTCs) is associated with high levels of HER2 expression in metastatic breast cancer (MBC). 2019. AACR Meeting.

143. Zhang, Q., Gerratana, L., Shah, A., Davis., A.A., Flaum, L., Zhang, Y., Pestell, R.G., Wehbe, F., Behdad, A., **Gradishar, W.J.,** Platanias, L., Cristofanilli, M. Expression of CCR5 associated with HER2 in circulating tumor cells (CTCs) is a novel biomarker for patients with metastatic breast cancer (MBC). 2019. AACR Meeting.

144. Zhang, Q., Gerratana, L., Shah, A., Davis., A.A., Flaum, L., Zhang, Y., Pestell, R.G., Wehbe, F., Behdad, A., **Gradishar, W.J.,** Platanias, L., Cristofanilli, M. A novel application of DEPArrayTM NxT System to isolate circulating tumor cell (CTC)-clusters from patients with metastatic breast cancer (MBC) 2019. AACR Meeting.

145. Oukseub, L., Sullivan, M., Xu, J., Muzzio., Helenowski, I., Shidfar, A., Zeng, Z., Singhal, H., Jovanovic, B., Hansen, N., Bethke, K., Gann, Pt., **Gradishar, W.J.,** Kim, J.J., Clare, S., Khan, S.A., Selective progesterone receptor modulators in early stage breast cancer: a randomized, placebo-controlled Phase II window of opportunity trial using telapristone acetate. 2019.

146. Rugo, H., Im, S-A., Wright, G. S., Santiago, Escriva-de-Romani, S., De Laurentiis, M., Cortes, J., Bahadur, S.W., Haley, B.B., Oyola, R.H., Riseberg, D.A., Musolino, A., Cardoso, F., Giuseppe, C., Kaufman, P., Pegram, M., Edlich, S., Hong, S., Rock, E., Wigginton, J., **Gradishar, W.J.**, on behalf of the SOPHIA Study Group. SOPHIA primary analysis: a phase 3 study of margetuximab (M) + chemotherapy (C) vs trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). 2019. Submitted to ASCO.

147. Shah, A., Flaum, L.E., Rademaker, A., Santa-Maria, C.A., Jain, S., Helenowski, I., Kindy, K., Uthe, R., Dedic, T., Nelson, V., Tsarwhas, D., Cristofanilli, C., **Gradishar, W.J.,** Phase II Study of Pembrolizumab (P) and Capecitabine (C) for Triple Negative (TN) and Hormone-Receptor-Positive, HER2-Negative Endocrine-Refractory Metastatic Breast Cancer (MBC). 2019. Submitted to ASCO.

148. Shagisultanova, E., Chalasani, U, Brown-Glaberman, A., **Gradishar, W.J.,** Brenner, A.J., Stopeck, A., Gao, D., McSpadden, T., Kabos, P., Borges, V.F., on behalf of Academic Breast Cancer Research Consortium. Tucatinib, palbociclib and letrozole in HR+/HER2+ metastatic breast cancer: report of phase IB safety cohort. (Abstract #257879). 2019. Submitted to ASCO.

149. McCartney, A., Biagioni, C., Schiavon, G., Bergqvist, M., Mattsson, K., Migliaccio, I., Benelli, M., Romagnoli, D., Bonechi, M., Voccalini, G., PEstrin, M., Galardi, F., De Luca, F., Viganzoli, L., Piccart, M., **Gradishar, W.J**., Di Leo, A., Malorni, L. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor positive metastatic breast cancer: analysis of the randomized phase III EFECT rial. 2019. Submitted to European Journal of Cancer.

150. Rugo, H.S., Seock-Ah, I., Cardoso, F., Cortes, J., Curigliano, G., Musolino, A., Pegram, M.D., Wright, G.L.S., Manich, C.S., Escriva-de-Romani, S., De Laurentiis, M., Levy, C., Brown-Glaberman, U., Ferrero, J., de Boer, M., Kim, S-B., Petrakova, K., Yardley, D.A., Freedman, O., Jakobsen, E., Kaufman, B., Yerushalmi, R., Fasching, P., Nordstrom, J.L., Bovini, E., Koenig, S., Edlich, S., Hong, S., Rock, E.P., **Gradishar, W.J.** Margetuximab in retreated HER2-Positive Metastatic Breast Cancer. 2019. Submitted to New England Journal of Medicine.

151. Trosman JR, Weldon CB, Makower DF, Rapkin BD, Bozier M, Knightly E, Schaeffer CM, Hoskins K, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Vanderwalde L, Krueger EA, Van Horn J, Schapira L, Santa-Maria CA, Ravelo A, Benson AB, **Gradishar WJ**. Does the innovative 4R Cancer Care Delivery Model improve patient self-management in safety net and non-safety net centers? J Clin Oncol 37, 2019 (suppl; abstr 6601), DOI: 10.1200/JCO.2019.37.15_suppl.6601
152. Weldon CB, Trosman JR, Makower DF, Rapkin BD, Bozier M, Knightly E, Schaeffer CM, Hoskins K, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Vanderwalde L, Krueger EA, Van Horn J, Schapira L, Santa-Maria CA, Ravelo A, Benson AB, **Gradishar WJ**. Does the innovative 4R Care Delivery Model improve timing and sequencing of guideline recommended breast cancer care in safety net and non-safety net centers? J Clin Oncol 37, 2019 (suppl; abstr 562). DOI: 10.1200/JCO.2019.37.15_suppl.562
153. Trosman JR, **Gradishar WJ**, Makower DF, Rapkin BD, Bozier M, Knightly E, Schaeffer CM, Hoskins K, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Vanderwalde L, Krueger EA, Van Horn J, Ravelo A, Schapira L, Santa-Maria CS, Benson AB, Weldon CB; Does the innovative 4R Cancer Care Delivery Model improve patient self-management in safety net and non-safety net centers? J Clin Oncol 37, 2019 (suppl 27; abstr 172) DOI: 10.1200/JCO.2019.37.27_suppl.172
154. Weldon CB, Trosman JR, Makower DF, Rapkin DR, Bozier M, Knightly E, Schaeffer CM, Hodskins K, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Vanderwalde L, Krueger EA, Van Horn J, Schapira L, Santa-Maria CA, Ravelo A, Benson AB, **Gradishar WJ**. Does the innovative 4R Care Delivery Model improve timing and sequencing of guideline recommended breast cancer care in safety net and non-safety net centers? J Clin Oncol 37, 2019 (suppl 27; abstr 36). DOI: 10.1200/JCO.2019.37.27_suppl.36
155. Zhang, Q., Gerratana, G., Zhang, Y., Flaum, L., Shah, A., Davis, A., Behdad, A., **Gradishar, W**., Platanias, L., Zhou, X., Backman, V., Cristofanilli, M. HER2 alterations and ESR1 mutations in cell free DNA (cfDNA) associate with increased circulating tumor cells (CTCs) and predicts the multiple metastasis and worst prognosis in Stage III/IV breast cancer (BCa). American Society of Clinical Oncology (ASCO) Annual Meeting, 2019. AB-1036.
156. Zhang, Q., Gerratana, L., Zhang, Y., Flaum, L., Shah, A., Davis, A., Behdad, A., **Gradishar, W**., Platanias, L., Pestell, R.G., Wehbe, F., Cristofanilli, M. Increased Expression of CCR5 associated with HER2 in circulating tumor cells (CTCs) is a novel biomarker for patients with metastatic breast cancer (MBC) 110th American Association for Cancer Research (AACR) Annual Meeting. Cancer Research, 2019. AB-1953.
157. Zhang, Q., Gerratana, L., Shah, A., Davis, A.A., Flaum, L., Zhang, Y., Wehbe, F., Behdad, A., Platanias, L., **Gradishar, W**., Cristofanilli, M. Anatomical staging and value of CTCs in Locally Advanced Breast Cancer (LABC) and metastatic breast cancer (MBC). SABCS, 2019. AB#848. P4-01-08
158. Zhang, Q., Gerratana, L., Zhang, Y., Flaum, L., Shah, A., Davis, A., Behdad, A., **Gradishar, W**., Platanias, L., Wehbe, F., Cristofanilli, M. Epithelial-Mesenchymal Transition Expression of PD-L1 is associated with increased circulating tumor cells (CTCs) in Triple-Negative breast cancer (TNBC)**.** 4th Advances in Criculating Tumor Cells (ACTC) Annual Meeting. Corfu, Greece. 2019. (Poster Session 2)
159. Trapani, D., Douillard, J.Y., Winer, E., Burstein, H., Carey, L., Cortes, J., Lopes, G., Gralow, J., **Gradishar, W.J.**, Magrini, N., Curigliano, G., Ilbawi, M.A. A ststematic review of clinical guidelines for the management of breast cancer: building the concept for a

resource-appropriate development of clinical guidelines to enhance consistent, coherent and comprehensive national cancer control planning. 2020. Submitted to Lancet Oncology.

160. Solk, P.,Welch, W., Fanning, J., Maria, C.S., Gavin, K.L., Auster-Gussman, L.A., Lu, M., Cullather, E., Khan, S., Kulkarni, S., **Gradishar, W.J**., Siddique, J., Phillips, S.M. Effect of Daily Physical Activity on Symptom Ratings during Chemotherapy for Breast Cancer: A Longitudinal Examination. 2020. Submitted to 2021 Society of Behavioral Medicine Annual Meeting.
161. Weiser, R., Polychronopoulou, E., Haque, W., Hatch, S., He, J., Qiu, S., Aziz, N., Markowitz, A., **Gradishar, W.J**., Kuo, Y., Klimberg, V. Not all Micrometastatic Lymph Nodes are Created the Same: A Proposal for New Staging from an NCDB Analysis. 2020. Elsevier.
162. Gerratana, L., Davis, A., Polano, M., Zhang, Q., Shah, A., Lin, C., Basile, D., Toffoli, G., Wehbe, F., Puglisi, F., Behdad, A., Platanias, L., Gradishar, W.J., Cristofanilli, M. Understanding the Organ Tropism of Metastatic Breast Cancer Through the Combination of Liquid Biopsy Tools. 2020.
163. Shah, A., Lin, C., Carroll, K., Gerratana, L., D'Amico, P., Bell, K., Davis, A., Zhang, Q., Zhang, Y., Kocherginsky, M., Behdad, A., **Gradishar, W.J**., Cristofanilli, M. HER2-Positive Circulating Tumor Cells in Her2-Negative Metastatic Breast Cancer: Prevalence, Associated Features and their Potential Role as a Therapeutic Target. 2020.
164. Weldon CB, Trosman JR, Berardi R, Benson AB, Roggenkamp B, Hand ME, Stamp M, Bao JJ, Feldman LE, Pasquinelli M, **Gradishar WJ**, Shah AN, Kircher SM, Foster KD, Nelson V, Wiebe LA, Baer RP, England GM, Dalal N, Perez CB. Promoting patient health maintenance with cancer care planning at diagnosis and during treatment: baseline data of the Coleman Supportive Oncology Collaborative (CSOC). J Clin Oncol 38: 2020 (suppl; abstr e24051). DOI: 10.1200/JCO.2020.38.15_suppl.e24051.
165. Weldon CB, Trosman JR, Makower DF, Rapkin BD, Perez CB, Kulkarni S, Schaeffer SM, Hoskins K, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Krueger E, Van Horn J, Reaves BC, Ravelo A, Yu E, Benson AB, Schapira L, **Gradishar WJ**. 4R Program results in breast cancer: the impact of 4R Care Delivery Model on timing and sequence of guideline recommended care. J Clin Oncol 38: 2020 (suppl; abstr 573). DOI: 10.1200/JCO.2020.38.15_suppl.573
166. Trosman JR, Weldon CB, Makower DF, Rapkin BD, Perez CB, Kulkarni S, Schaeffer CM, Hoskins K, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Krueger E, Van Horn J, Reaves BC, Ravelo A, Yu E, Schapira L, Benson AB, **Gradishar WJ**. 4R Care Delivery Program results: impact of implementation metrics on patient self-management and 4R usefulness. J Clin Oncol 38: 2020 (suppl; abstr e14039). DOI: 10.1200/JCO.2020.38.15_suppl.e14039.
167. Weldon CB, Trosman JR, Makower DF, Rapkin BD, Perez CB, Kulkarni S, Schaeffer CM, Hoskins K, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Krueger EA, Van Horn J, Reaves BC, Ravelo A, Yu E, Benson AB, Schapira L, **Gradishar WJ**. 4R program results in breast cancer: the impact of 4R Care Delivery Model on timing and sequence of guideline recommended care. J Clin Oncol 38, 2020 (suppl 29; abstr 15). DOI: 10.1200/JCO.2020.38.29_suppl.15
168. Trosman JR, Weldon CB, Makower DF, Rapkin BD, Bozier M, Perez CB, Kulkarni S, Schaeffer CM, Hoskins k, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Krueger EA, Van Horn J, Ravelo A, Yu E, Schapira L, Benson AB, **Gradishar WJ**. 4R program results: What is the impact of 4R care delivery model on patient self-management and which patients benefited? J Clin Oncol 38, 2020 (suppl 29; abstr 139). DOI: 10.1200/JCO.2020.38.29_suppl.139.
169. Trosman JR, Weldon CB, Makower DF, Rapkin DF, Perez CB, Kulkarni S, Schaeffer CM, Hoskins K, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Krueger EA, Van Horn J, Reaves BC, Ravelo A, Yu E, Schapira L, Benson AB, **Gradishar WJ**. 4R Care Delivery Program results: Impact of implementation metrics on patient self-management and

4R usefulness. J Clin Oncol 38, 2020 (suppl 29; abstr 225). DOI: 10.1200/JCO.2020.38.29_suppl.225.

170. Weldon CB, Trosman JR, Makower DM, Rapkin BD, Perez CB, Kulkarni S, Schaeffer CM, Hoskins K, Gallagher C, Lo SS, Grace-Louthen C, Throckmorton A, Krueger EA, Van Horn J, Reaves BC, Ravelo A, Yu E, Benson AB, Schapira L, **Gradishar WJ**. 4R program results in breast cancer: the impact of 4R Care Delivery Model on timing and sequence of guideline recommended care. J Clin Oncol 38, 2020 (suppl 29; abstr 15) DOI: 10.1200/JCO.2020.38.29_suppl.15.
171. Zhang, Q., Gerratana, L., Davis, A., Zhang, Y., Flaum, L., Shah, A., Behdad, A., **Gradishar, W**., Platanias, L., Cristofanilli, Mdep. Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome. American Society of Clinical Oncology (ASCO) Annual Meeting, 2020. AB-1028
172. Zhang, Q., Gerratana, L., Davis, A., Zhang, Y., Flaum, L., Shah, A., Behdad, A., **Gradishar, W**., Platanias, L., Cristofanilli, M. Genetic heterogeneity profiling for HER2 positive single circulating tumor cell (CTC) in metastatic breast cancer (MBC) by application of DEPArrayTM System and single cell DNA sequencing for HER2 positive single circulating tumor cell (CTC) in metastatic breast cancer (MBC) by application DEPArrayTM system and single cell DNA sequencing. 111th American Association for Cancer Research (AACR) Annual Meeting, 2020. AB-3120.
173. Zhang, Q., Gerratana, L., D'Amico, P., Davis, A.A., Jacob, S.L., Wang, X., Ji, Z., Cai, Z., Vagia, E., Qiang, W., Shah, A., Zhang, Y., Flaum, L., Wehbe, F., Behdad, A., **Gradishar, W.,** Platanias, L., Cristofanilli, M. Genetic profiling for circulating tumor cell clusters to unveil molecular drivers of metastasis. SABCS, 2020. #1295 (PS2-05)
174. Zhang, Q., D'Amico, P., Donahue, J., Gerratana, L., Davis, A.A., Jacob, S.L., Cai, Z., Vagia, E., Qiang, W., Shah, A.N., Kerby, K., Flaum, L., Zhang, Y., Wehbe, F., Behdad, A., **Gradishar, W**., Platanias, L., Cristofanilli, M. The detection and enumeration of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in metastatic breast cancer. SABCS, 2020. #1327 (PS2-06).
175. Zhang, Q., Cai, Z., Gerratana, L., D'Amico, P., Davis, A.A., Jacob, S.L., Vagia, E., Shah, A.N., Flaum, L., Zhang, Y., Qiang, W., Wehbe, F., Behdad, A., **Gradishar, W**., Platanias, L., Cristofanilli, M. Prognostic value of baseline circulating tumor cells (CTCs) enumerations is for stage III and Stage IV breast cancer. SABCS, 2020. #1357 (PS2-20).
176. Musolino, A., **Gradishar, W.J**., Rugo, H.S., Nordstrom, J.L., Rock, E.P., Arnaldez, F., Pegram, M.D. Role of Fc Gamma Receptors in HER2-Targeted Breast Cancer Therapy. Submitted to Journal of ImmunoTherapy of Cancer. 2021.
177. Zhang, Q., Cai, Z., Gerratana, L., Davis, A.A., D'Amico, P., Jacob, S.,Vagia, E., Kerby, K.L., Zhang, Y., Qiang, W., Donahue, J., Shah, A., Behdad, A., Flaum, L., **Gradishar, W.J**., Platanias, L., Cristofanilli, M. Baseline Level of Circulating Tumor Cells and Circulating Tumor DNA to Early Evaluate Tumor Heterogeneity and Clinical Outcome in Locally Advanced Breast Cancer and Metastatic Breast Cancer. (submitted), 2021.
178. Zhang, Q., Gerratana, L., Shah, A., Davis, A., Behdad, A., Flaum, L., Zhang, Y., **Gradishar, W**., Platanias, L.,Cristofanilli, M. ESR1 Mutations and HER2 Alterations in Circulating Tumor DNA Contribute to Increased Circulating Tumor Cells Clusters Associated with Metastasis in Stage III/IV Breast Cancer. (ready for submission), 2021
179. Moy, B., Oliveira, M., Saura, C., **Gradishar, W**., Kim, S., Brufsky, A., Hurvitz, SA., Ryvo, L., Fagnani, D., Kalmadi, S., Silverman, P., Delaloge1, S., Alarcon, J., Kwong, A., Seok, K., Siang Ang, P.C., WeiOw, S., Chu, S., Bryce, R., Keyvanjah, K., Bebchuk, J., Zhang, B., Oestreicher, N., Bose, R., Chan, N. Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥2 prior HER2-directed regimens. Submitted to Breast Cancer Research and Treatment. (In Press). 2021.
180. Howell, S., Krebs, M.G., Lord, S., Kenny, L., Bahl, A., Clack, G., Ainscow, E., Dickinson, P.A., Barrett, AGM., Arkenau, T., Mansi, J., Palmieri, C., Bertelli, G., Chap, L.,

Richards, P., Jeselsohn, R., Mitri, Z., **Gradishar, W**., Sardesai, S., Melear, J., O'Shaughnessy, J., Ward, P., Chalasani, P., Lehnert, M., Ali, S., McIntosh, S., Coombes, R.C. Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced Hormone Receptor positive HER2 negative breast cancer (HR+BC). Submitted to ESMO. 2021.

181. Weiser, R., Polychronopoulou, Hatch, S.S., Haque, W., Ghani, H.A., He, J., Kuo, Y., **Gradishar, W.J**., Klimberg, V.S. Adjuvant Chemotherapy in Invasive Lobular Carcinoma Patients and the Use of the 21-gene. Submitted 2021.

182. Shagisultanova, E., **Gradishar, W.J.**, Brown-Glaberman, U., Chalasani, P., Brenner, A., Stopeck, A., Mayordomo, J., Diamond, J., Kabos, P., Borges, V. Intracranial Efficacy of Tucatinib, Palbociclib and Letrozole Combination in Patients with HR+/HER2+ Breast Cancer and Brain Metastases. Submitted to SABCS. 2021

183. Self, K.J., Sommer, R.K., Penedo, F.J., Horner, F.S., Torzewski, J.B., Thomas, J.L., **Gradishar, W.**, Victorson, D., Moreno, P.I. ACT and CBSM for Women with Metastatic Breast Cancer: Participant Characteristics and Acceptability. Submitted to APA 2022.

184. Agnew, M., Tevaryweek, A., Spencer, R., Barber, E., Gangnon, R., Solk, P., Freeman, H., Muller, L., Mishory, A., **Gradishar, W.J.,** Spring, B., Phillips, S., Cadmus-Bertram, L. Physical activity beliefs and practices among oncology providers at MyActivity trial sites. Submitted to Society og Behavioral Medicine. 2022.

185. Moreno, P. I., Noriega Esquives, B., Thomas, J. L., Horner, F. S., Torzewski, J. B., **Gradishar, W.**, Victorson, D., & Penedo, F. J. (in press). Characterizing unique supportive care needs among women living with metastatic breast cancer: A qualitative study. Journal of Psychosocial Oncology Research and Practice. Submitted 2022.

186. Gerratana, L., Davis, A.A., Medford, A.J., Reduzzi, C., Clifton, K., Podany, E.L., Hensing, W.L., Velimirovic, M., Shah, A.N., Foffano, L., Munoz-Arcos, L., Dai, C.S., Keenan, J., Behdad, A., Wander, S., **Gradishar, W.J.**, Ma, C.X., Puglisi, F., Bardia, A., Cristofanilli, M. Differential genomic profiling of progesterone receptor (PR) negative, estrogen receptor (ER) positive HER2 negative metastatic breast cancer (MBC) through circulating tumor DNA for an in-depth definition of endocrine sensitivity. Submitted to SABCS. 2023.

187. Nicolo, E., Gerratana, L., Foffano, L., Munoz-Arcos, L., Serafini, M. S., Manai, M., Pontolillo, L., Bayou, N., Molteni, E., Strickland, K., Zhang, Y., D'Amico, P., Davis, A.A., Donahue, J., Liu, H., **Gradishar, W.J.**, Shah, A., Curigliano, G., Reduzzi, C., Cristofanilli, M. Association of tumor-derived extracellular vesicles with circulating tumor DNA alterations in metastatic breast cancer patients: exploring differences in inflammatory breast cancer. Submitted to SABCS. 2023.

188. Molteni, E., Reduzzi, C., Davis, A.A., Foffano, L., Medford, A.J., Clifton, K., Hensing, W.L., Velimirovic, M., Shah, A.N., Munoz-Arcos, L., Dai, C.S., Keenan, J., Denault, E.N., **Gradishar, W.J.**, Damante, G., Behdad, A., Gerratana, L., Puglisi, F., Ma, C.X., Bardia, A., Cristofanilli, M. Integration of synonymous mutations (SYN) and variants of unknown significance (VUS) for basal and longitudinal characterization of metastatic breast cancer (MBC) by circulating tumor DNA (ctDNA). Submitted to SABCS. 2023.

189. Nicolo, E., Munoz-Arcos, L., D'Amico, P., Zhang, Y., Gerratana, L., Serafini, M.S., Pontolillo, L., Strickland, K., Manai, M., Davis, A.A., Donahue, J., Liu, H., **Gradishar, W.J.**, Shah, A.N., Curigliano, G., Reduzzi, C., Cristofanilli, M. Distribution and prognostic role of

HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2-metastatic breast cancer (MBC) patients (pts). Submitted to ESMO. 2023.

190. Phillips, S.M., Solk, P., Freeman, H., Starikovisky, J., Carden, L.B., Agnew, M., Schmidt, C., Reading, J.M., Wang, S., Hasanaj, K., Tevaarwerk, A.J., Spring, B., Barber, E., Sesto, M.E., **Gradishar, W.J.**, Hodgson, V., Muller, L., Naxi, S., Spencer, R., Gangnon, R., Nahum-Shani, I., Cadmus-Bertram, L., Pickett, K. A 6-month, Multi-site Electronic Health Record-Integrated Physical Activity Intervention (MyActivity) Significantly Increases Physical Activity in Breast & Endometrial Cancer Survivors. Accepted for oral presentation. Annual Meeting of the American Society of Preventive Oncology, Chicago, IL 2024.

17. PRESENTATIONS – (Select Invited **CME** Presentations at International & National Symposiums and Grand Rounds)

6/10/94	Lecture: Meeting:	Controversies in the Management of Breast Cancer Medical Grand Rounds, Department of Medicine, Northwestern University
1/22/95	Lecture: Moderator: Meeting: Chicago, IL	Controversies in Breast Cancer Treatment from the NSABP Cancer Screening and Prevention, American Cancer Society 1995 Midwest Clinical Conference, Chicago Medical Society,
1/25/95	Lecture: Meeting:	Diagnosis and Treatment of Breast Cancer The Year in Internal Medicine, The Department of Medicine, Northwestern University Medical School
4/20/96	Lecture: Meeting:	An Overview of Angiogenesis as a Prognostic Tool and Therapeutic Target University of Pennsylvania Cancer Center Grand Rounds
9/17/96	Lecture: Meeting:	Optimizing Clinical Trial Design for Cytostatic Agents The Extracellular Matrix as a Target for Anticancer Agents, National Institutes of Health, Bethesda
10/16/96	Lecture: Meeting:	Advances in the Treatment of Breast Cancer Department of Medicine Grand Rounds New York University Medical Center
11/17/96	Lecture: Course:	Update in Oncology Update in Internal Medicine Using the MKSAP 10 Program, American College of Physicians Chicago, IL
1/28/97*	Lecture: Meeting:	Anti-angiogenesis Therapy as a Treatment Strategy for Cancer Santa Monica Cancer Forum, Santa Monica/UCLA Medical Center Santa Monica, CA
1/29/97*	Lecture: Meeting:	Controversies in Breast Cancer Management San Diego Cancer Conference, Sharp Memorial Hospital San Diego, CA
1/31/97*	Lecture:	Controversies in Breast Cancer Management

	Meeting:	OB/Gyne Grand Rounds, Loma Linda University Medical Center, Loma Linda, CA
2/10/97	Lecture:	Surrogate Endpoints as a Measure of Efficacy in Clinical Trials of Angiogenesis Inhibitors
	Meeting:	3rd Annual Meeting, Angiogenesis: Novel Therapeutic Development, Boston, MA
3/20/97	Lecture:	Systemic Treatment of Breast Cancer
	Meeting:	Spring Cancer Symposium, Hoag Cancer Center, Newport Beach, CA
3/23-24/97	Lectures:	(1) Meet the Professor - New Breast Cancer Treatments (2) Meet the Professor - Primary Care Issues for the Breast Cancer Survivor
	Meeting:	American College of Physicians Annual Meeting, Philadelphia, PA
5/30/97	Lecture:	Anthracycline-Resistant Breast Cancer
	Meeting:	Hematology/Oncology Grand Rounds, University of Alabama, Birmingham, AL
7/12/97	Lecture:	Update on Chemotherapy for Breast Cancer
	Meeting:	Treatment of Solid Tumors in Women, University of Chicago, Chicago, IL
7/16/97	Lecture:	Advances in the Treatment of Breast Cancer
	Meeting:	Cancer Center Grand Rounds, University of Wisconsin Comprehensive, Cancer Center, Madison, WI

** American Cancer Society Traveling Oncology Consultant Program*

7/17/97	Lecture:	New Approaches for the Treatment of Breast Cancer
	Meeting:	Medical Oncology Grand Rounds, University of Illinois, Chicago, IL
7/25/97	Lecture:	Advances in the Treatment of Metastatic Breast Cancer
	Meeting:	Cancer Center Grand Rounds, Cardinal Bernadin Cancer Center, Loyola University Medical Center, Maywood, IL
8/15/97	Lecture:	Clinical Development of Antiangiogenesis Agents for Cancer Therapy
	Meeting:	Drug Discovery Team Seminar, Cancer Research, Abbott Laboratories
11/1/97	Lecture:	Management of Locally Advanced and Inflammatory Breast Cancer
	Meeting:	14th Allen Zieger Memorial Lecture Series, Breast Cancer into the 21st Century, Botsford Hospital, Novi, MI
11/17/97	Lecture:	Taxotere Effective in the Treatment of Breast Cancer
	Meeting:	Chairperson, 14th Asia-Pacific Cancer Conference, 4th Hong Kong International Cancer Conference, Hong Kong
12/15/97	Lecture:	Advances in the Treatment of Breast Cancer

	Meeting:	Medical Grand Rounds, Gunderson Clinic, University of Wisconsin, LaCross, WI
2/25/98	Lecture:	New Adjuvant Treatments in the Next Century
	Meeting:	6th International Conference on Adjuvant Therapy for Primary Breast Cancer, St. Gallen, Switzerland
4/3/98	Lecture:	Meet the Professor: Primary Care Issues for the Breast Cancer Survivor
	Meeting:	American College of Physicians San Diego, CA
4/18/98	Lecture:	Advances in the Treatment of Breast Cancer: Taxanes
	Meeting:	Chinese Cancer Association Conference Tapei, Taiwan
4/24/98	Lecture:	Update on Chemotherapy for Breast Cancer - 1998
	Meeting:	Innovative Therapies for Cancer Management, University of Missouri, Columbia, MO
5/6/98	Lecture:	Therapy for Locally Advanced Breast Cancer
	Meeting:	Medical Oncology Grand Rounds, University of Iowa Iowa City, IA
5/19/98	Lecture:	Discussant/Topics in Breast Cancer
	Meeting:	American Society of Clinical Oncology Los Angeles, CA
5/27/98	Lecture:	Advances in Breast Cancer Treatment
	Meeting:	Twin Cities Oncology Society and University of Minnesota Minneapolis, MN
6/26/98	Lectures:	(1)Raloxifene in Breast Cancer Prevention (2)Strategies in Hormone Therapy
	Meeting:	Breast Cancer International Research Group. New Concepts in Breast Cancer Research Edmonton, Alberta, Canada
7/16/98	Lecture:	Review of Breast Cancer
	Meeting:	Subspecialty Review in Internal Medicine, National Center for Advanced Medical Education Chicago, IL
8/11/98	Lecture:	Advances in Endocrine Treatment of Breast Cancer
	Meeting:	Baton Rouge Oncology Society, Mary Perkins Cancer Center Baton Rouge, LA
8/24/98	Lecture:	Management of Early Stage Breast Cancer
	Meeting:	17th International Cancer Congress, UICC, American College of Surgeons Rio de Janeiro, Brazil

8/24/98	Lecture:	Treatment Strategies for Locally Advanced Breast Cancer
	Meeting:	17th International Cancer Congress, UICC Rio de Janeiro, Brazil
9/19/98	Lecture:	Treatment of Metastatic Breast Cancer
	Meeting:	Turkish Oncology Society Lake Abant, Turkey
9/30/98	Lecture:	Advances in the Treatment of Metastatic Breast Cancer
	Meeting:	Grand Rapids Clinical Cancer Oncology Program Grand Rapids, MI
10/2/98	Lecture:	Raloxifene – A New Antiestrogen
	Meeting:	Iowa Oncology Society Annual Meeting Des Moines, IA
10/16/98	Lecture:	Locally Advanced and Metastatic Treatment
	Meeting:	Future Directions in Breast Cancer Symposium, Medical College of Toledo Toledo, OH
10/27/98	Lecture:	Update on Adjuvant Therapy of Breast Cancer
	Meeting:	St. Louis Oncology Society and Washington University St. Louis, MO
2/12/99	Lecture:	Advances in Breast Cancer Management
	Meeting:	University of Colorado Cancer Center, Grand Rounds Denver, CO
2/28/99	Lecture:	Issues in Formulating Guidelines for Chemotherapy of Advanced Breast Cancer
	Meeting:	4th Annual Conference of the National Comprehensive Cancer Network, Ft. Lauderdale, FL
2/26/99	Lecture:	Advances in Breast Cancer Management
	Meeting:	Denali Oncology Group Anchorage, AK
3/5/99	Lecture:	New Agents in the Treatment of Metastatic Breast Cancer
	Meeting:	International Bone Marrow Transplant/American Stem Cell – BMT Tandem Meeting Keystone, CO
3/12/99	Lecture:	Advances in Breast Cancer Management
	Meeting:	Grand Rounds, Mt. Sinai Hospital/Albert Einstein Cancer Center New York, NY
3/25/99	Lecture:	Advances in Breast Cancer Management
	Meeting:	Grand Rounds, Scott & White Clinic, Texas A&M Medical Center Temple, TX
4/9/99	Lecture:	Advances in Adjuvant Therapy for Breast Cancer
	Meeting:	Grand Rounds, George Washington University Medical Center Washington, DC

4/9/99	Lecture:	Advances in Breast Cancer Management
	Meeting:	Grand Rounds, Washington Hospital Center Washington, DC
5/17/99	Lecture:	Future Directions for the Use of Liposomal Chemotherapy
	Meeting:	American Society of Clinical Oncology Atlanta, GA
5/27/99	Lecture:	High-Dose Chemotherapy for Breast Cancer – 1999
	Meeting:	University of Chicago Chicago, IL
6/25/99	Lecture:	Breast Cancer – ASCO 1999
	Meeting:	ASCO Review Course Atlanta, GA
7/29/99	Lecture:	Adjuvant Therapy of Breast Cancer
	Meeting:	MD Anderson National Medical Oncology Fellows Course in Breast Cancer Houston, TX
8/5/99	Lectures:	(1)Adjuvant Therapy of Breast Cancer (2)High-Dose Chemotherapy for Breast Cancer
	Meeting:	Southern Oncology Society Hamilton, Bermuda
9/25/99	Lecture:	Update on Breast Cancer Therapeutics
	Meeting:	Y-ME National Breast Cancer Conference Chicago, IL
10/15/99	Lecture:	Non-Transplant Approaches for the Treatment of Breast Cancer
	Meeting:	Controversies in Stem Cell Transplantation Oregon Health Sciences University/Northwest Marrow Transplant Program Portland, OR
10/22/99	Lecture:	Metastatic Breast Cancer: Treatment Update
	Meeting:	Plenary Session, 13th Annual Scientific Convention/Philippine Society of Medical Oncology Manila, Philippines
10/30/99	Lecture:	Endocrine Therapy of Breast Cancer
	Meeting:	ICA (International Cancer Alliance)/National Institutes of Health Bethesda, MD
11/5/99	Lecture:	Increasing Access to Modern Multidisciplinary Breast Cancer Care
	Meeting:	American College of Surgeons, Commission on Cancer Chicago, IL
12/7/99	Lecture:	Anthracyclines for Adjuvant Therapy of Breast Cancer
	Meeting:	Annual San Antonio Breast Symposium San Antonio, TX

12/8/99	Lecture:	Future Directions in Treatment of Advanced Breast Cancer
	Meeting:	Annual San Antonio Breast Symposium
	San Antonio, TX	
2/11/00	Lecture:	Rationale for a New Generation of Trials in Adjuvant Therapy of Breast Cancer
	Meeting:	First Genolier-MSKCC Geneva Cancer Conference Geneva, Switzerland
3/14/00	Lecture:	UFT as Treatment for Metastatic Breast Cancer
	Meeting:	Fox Chase Cancer Center Workshop Lanai, Hawaii
3/17/00	Lecture:	Advances in the Adjuvant Therapy of Breast Cancer
	Meeting:	5th Annual NCCN Conference Ft. Lauderdale, FL
6/27/00	Lecture:	Chemoprevention of Breast Cancer – Raloxifene Trials
	Meeting:	Second International Breast Cancer International Research Group Conference Edmonton, Alberta, Canada
8/18/00	Lecture:	Endocrine Therapy of Breast Cancer
	Meeting:	Henry Ford Hospital Medical Grand Rounds Wayne State University Detroit, MI
10/7/00	Lecture:	NCCN Breast Cancer Treatment Guidelines
	Meeting:	6th Annual Perspectives in Breast Cancer Symposium Washington, DC
10/13/00	Lecture:	Primary Chemotherapy for Breast Cancer
	Meeting:	Annual Meeting of European Society of Medical Oncology Hamburg, Germany
10/24/00	Lecture:	Primary Chemotherapy in Operable Breast Cancer
	Meeting:	American College of Surgeons Clinical Congress Chicago, IL
10/27/00	Lecture:	Novel Schedules and Combinations with Docetaxel in Breast Cancer
	Meeting:	4th Annual Fall Oncology Conference, "Advances in Solid Tumors," Baylor University Amelia Island, FL
2/20/01	Lecture:	Taxanes Plus Xeloda for Metastatic Breast Cancer
	Meeting:	7th International Conference on Adjuvant Therapy of Primary Breast Cancer Zurich, Switzerland
2/21/01	Lecture:	Epirubicin in Combination with Taxanes
	Meeting:	7th International Conference on Adjuvant Therapy of Primary Breast Cancer

St. Gallen, Switzerland

2/22/01	Lecture:	Taxane-Based Neoadjuvant Therapies for Breast Cancer
	Meeting:	7th International Conference on Adjuvant Therapy of Primary Breast Cancer St. Gallen, Switzerland
3/1/01	Lecture:	Overview of Breast Cancer Management
	Meeting:	Surgical Society of Ethiopia Addis Ababa, Ethiopia
4/12/01	Lecture:	Advances in Adjuvant Therapy of Breast Cancer
	Meeting:	Grand Rounds, Simmons Cancer Center University of Texas Southwestern, Dallas, TX
4/29/01	Lecture:	Current Management of Metastatic Breast Cancer: Chemotherapy
	Meeting:	American Society of Breast Disease New York, NY
5/3/01	Lecture:	Advances in Endocrine Therapy of Breast Cancer
	Meeting:	Centre Hospitalier Universitaire de Québec Quebec City, Canada
6/14/01	Lecture:	Advances in the Management of Locally Advanced Breast Cancer
	Meeting:	Grand Rounds, University of Pittsburgh Pittsburgh, PA
6/20/01	Lecture:	Endocrine Therapy of Breast Cancer
	Meeting:	Grand Rounds, Hospital of the University of Pennsylvania Thomas Jefferson Medical Center Philadelphia, PA
6/22/01	Lecture:	Breast Cancer
	Meeting:	American Society of Clinical Oncology 2001 Review Chicago, IL
7/15/01	Lectures:	(1) Use of Aromatase Inhibitors as First-Line Therapy of Metastatic Breast Cancer (2) Current Standards for Adjuvant Systemic Therapy of Breast Cancer
	Meeting:	Breast Cancer Hormonal Therapies: Current Practices, Emerging Concepts, University of Miami Miami, FL
8/15/01	Lecture:	Advances in Endocrine Therapy of Breast Cancer
	Meeting:	Association of Northern California Oncologists Breast Cancer Tumor Board San Francisco, CA
8/16/01	Lecture:	Advances in Endocrine Therapy of Breast Cancer
	Meeting:	Association of Northern California Oncologists Breast Cancer Tumor Board

		Sacramento, CA
8/18/01	Lecture: Meeting:	Estrogen Receptor Downregulators and Novel SERMs Current Perspectives in Breast Cancer 2001 Harvard University Boston, MA
9/7/01	Lecture: Meeting:	The Evolution of Aromatase Inhibitors in the Treatment of Breast Cancer Changing Concepts in Breast Cancer 2001 University of Pennsylvania Philadelphia, PA
9/22/01	Lecture: Meeting:	Therapy of Adjuvant Breast Cancer: Current Status and Future Prospects Sarah Cannon Cancer Center Fifth Annual Minnie Pearl Research Network Conference New Orleans, LA
10/05/01	Lecture: Meeting:	Breast Cancer Treatment Using Hormonal Therapy University of Washington School of Medicine Breast Cancer Summit 2001 Seattle, WA
10/12/01	Lecture: Meeting:	Breast Cancer Research Advances in Cancer Prevention, Diagnosis, and Treatment Cosponsored by the St. John's Hospital Cancer Institute and Southern Illinois University School of Medicine Springfield, IL
11/8/01	Lecture: Meeting:	Increasing Participation of Underserved Minority Populations in Clinical Research Related to Breast Cancer Screening and Prevention Avon Products Foundation Breast Cancer Research and Care Network Working Conference: "Reversing Disparities in Breast Cancer Care for Medically Underserved Women" New York, NY
11/9/01	Lecture: Meeting:	Hormone Therapies for Treatment and Prevention of Breast Cancer Froedtert Hospital/Medical College of Wisconsin Breast Cancer Symposium 2001: "Progress in the Management of Breast Cancer" Milwaukee, WI
1/8/02	Lecture: Meeting:	The Evolving Role of Endocrine Therapy in Breast Cancer London Regional Cancer Centre London, Ontario, Canada
1/30/02	Lecture: Meeting:	Highlights of San Antonio Breast Cancer Symposium Greater Baltimore Oncology Society Baltimore, MD

2/1/02	Lecture:	Adjuvant/Neoadjuvant Breast Cancer Trial
	Meeting:	Sixth Annual Joint Cancer Conference of the Florida Universities sponsored by the University of Florida College of Medicine Orlando, FL
2/15/02	Lecture:	New Endocrine Therapies for Breast Cancer
	Meeting:	Cancer 2002: Advances in Research, Prevention, Diagnosis & Treatment, sponsored by the Southern Illinois University School of Medicine Springfield, IL
2/24/02	Lecture:	Applying Predictive Factors in Clinical Practice
	Meeting:	Annual Scientific Meeting of the International Society of Breast Pathology Chicago, IL
3/1/02	Lecture:	Early Stage Breast Cancer
	Meeting:	National Comprehensive Cancer Network 7th Annual NCCN Conference: Practice Guidelines and Outcomes Data in Oncology Hollywood, FL
3/07/02	Lecture:	Highlights from the 2001 San Antonio Breast Cancer Symposium
	Meeting:	Aultman Cancer Center Breast Cancer Mini-Symposium University of Akron Canton, OH
3/27/02	Lecture:	Update on the Use of Aromatase Inhibitors
	Meeting:	Breast Cancer Conference Notre Dame Hospital Montreal, Quebec, Canada
4/5/02	Lecture:	Advances in Hormone Therapy for the Treatment of Breast Cancer
	Meeting:	Semiannual Michigan State University Cancer Treatment Consortium East Lansing, MI
4/9/02	Lecture:	Novel Options in Hormonal Therapy
	Meeting:	Nashville Oncology Society Nashville, TN
4/12/02	Lecture:	Hormone Receptor-Positive Metastatic Breast Cancer: The Role of Aromatase Inhibitors as First- and Second-Line Therapy
	Meeting:	National Cancer Institute of Canada Clinical Trials Group Spring Meeting 2002: "The Emerging Role of Aromatase Inhibitors for the Treatment of Patients with Hormone Receptor-Positive Breast Cancer" Montreal, Quebec, Canada
6/21/02	Lecture:	State of the Art: Endocrine Therapy (Session Chair)
	Meeting:	3rd International Breast Cancer International Research Group Conference

		Los Angeles, CA
7/24/02	Lecture: Meeting:	Use of Adjuvant Chemotherapy in Breast Cancer Ireland Cancer Center Clinical Seminars University Hospitals of Cleveland Cleveland, OH
7/31/02	Lecture: Meeting:	Epirubicin: Beyond Doxorubicin The Future of Breast Cancer: First International Breast Cancer Congress, Paradise Island, Bahamas
9/10/02	Lecture: Meeting:	Clinical Issues Related to the Use of Herceptin in Breast Cancer Washington University School of Medicine St. Louis Society of Medical Oncology Lecture Series St. Louis, MO
9/12/02	Lectures: Meeting:	(1)Targeted Therapy in Breast Cancer (2)Advances in Adjuvant Therapy of Breast Cancer Cancer Center Grand Rounds, Wake Forest University Charlotte, NC
9/27/02	Lecture: Meeting:	Breast Cancer: Advances in Adjuvant Treatment Grand Rounds, Albert Einstein Cancer Center Philadelphia, PA
10/18/02	Lecture: Meeting:	Breast Cancer – Update 40th Annual Meeting of Japanese Society of Clinical Oncology, Tokyo, Japan
10/19/02	Lecture: Meeting:	Advances in Endocrine Therapy of Breast Cancer Breast Cancer Workshop IV, Annual Meeting of Japanese Society of Clinical Oncology Osaka, Japan
11/14/02	Lecture: Meeting:	The Role of Aromatase Inhibitors for Advanced Breast Cancer Chemotherapy Foundation Symposium XX New York, NY
11/22/02	Lecture: Meeting:	Advances in Endocrine Therapy of Breast Cancer Grand Rounds, Taussig Cancer Center, Cleveland Clinic Cleveland, OH
12/5/02	Lectures:	(1)Visiting Professor, University of Pittsburgh Breast Cancer: Adjuvant Therapy, University of Pittsburgh Cancer Center Grand Rounds (2)Challenging Cases, Women's Hospital
12/11/02	Lecture: Meeting:	Sequencing of Anti-Aromatase Agents: Does It Make A Difference? "The Role of Anti-Aromatase Agents in New Treatment Strategies for Breast Cancer" Annual San Antonio Breast Cancer Symposium San Antonio, TX
1/25/03	Lectures:	(1)Dose Dense Adjuvant Chemotherapy

		(2)Optimizing Adjuvant Anthracycline Use
	Meeting:	Current Trends in Breast Cancer: Updates from the 2002 San Antonio Breast Cancer Symposium Baylor University Medical Center Charles A. Sammons Cancer Center Washington, DC
2/7/03	Lecture:	Treatment of Metastatic Breast Cancer
	Meeting:	Cancer 2003: Advances in Research, Prevention, Diagnosis and Treatment, Southern Illinois University Cancer Institute Springfield, IL
2/14/03	Lecture:	Update on Adjuvant Therapy of Breast Cancer
	Meeting:	University of Virginia Health Sciences Center, Department of Hematology/Oncology Grand Rounds Charlottesville, VA
2/20/03	Lecture:	Breast Cancer – Risk Reduction
	Meeting:	The Expedition Inspiration Fund for Breast Cancer Research 7th Annual Laura Evans Memorial Breast Cancer Symposium: "Metastases: Mechanism of Formation; Identification of Characterization; Therapeutic Opportunities" Sun Valley, ID
3/12/03	Lecture:	Life after Arimidex: What Should Be the New Sequence of Treatments in Advanced Breast Cancer Following Adjuvant Treatment with Arimidex?
	Meeting:	Putting Progress into Practice: Life after Tamoxifen St. Gallen, Switzerland
3/13/03	Lecture:	Clinician's Perspective, including Panel Discussion
	Meeting:	Oncology Day: Breast Cancer Sponsored by Deutsche Bank London, England
3/19/03	Lecture:	Controversies in Adjuvant Therapy of Breast Cancer
	Meeting:	Grand Rounds, Beth Israel Deaconess Medical Center Harvard University Boston, MA
4/26/03	Lecture:	A State of the Art Review of Adjuvant Chemotherapy
	Meeting:	International Oncology Network (ION) Breast Cancer Symposium Las Vegas, NV
7/10/03	Lecture:	Taxanes in Adjuvant Therapy
	Meeting:	Breast Cancer: Current Controversies and New Horizons Harvard Medical School/Dana-Farber/Partners Cancer Care Cambridge, Massachusetts
7/12/03	Lecture:	Breast Cancer (Moderator) Supportive Care (Moderator)
	Meeting:	Emerging Trends in Oncology 2003 University of Washington

Seattle, WA

7/12/03	Lecture:	New Developments in Management of Advanced Disease
	Meeting:	Emerging Trends in Oncology 2003, University of Washington Seattle, WA
7/23/03	Lecture:	New Advances in the Treatment of Breast Cancer
	Meeting:	University of Virginia Grand Rounds Charlottesville, VA
7/31/03	Lecture:	Novel Models of Hormonal Therapy Resistance: The Utility of Fulvestrant and Estrogen Therapy
	Meeting:	The Future of Breast Cancer: An International Breast Cancer Congress, Banff, Alberta, Canada
7/31/03	Lecture:	Doxil in Breast Cancer
	Meeting:	The Future of Breast Cancer: An International Breast Cancer Congress, Banff, Alberta, Canada Banff, Alberta, Canada
8/2/03	Lecture:	Single-Agent Gemcitabine in Breast Cancer
	Meeting:	The Future of Breast Cancer: An International Breast Cancer Congress Banff, Alberta, Canada
8/2/03	Lecture:	ABI-007 Update
	Meeting:	The Future of Breast Cancer: An International Breast Cancer Congress Banff, Alberta, Canada
9/5/03	Lecture:	Clinical Applications of Aromatase Inhibitor Therapy for Hormone Receptor-Positive Breast Cancer: A Case Study Approach
	Meeting:	Grand Rounds, H. Lee Moffitt Comprehensive Cancer Center University of Florida Tampa, FL
10/08/03	Lecture:	Advances in Endocrine Therapy
	Meeting:	Grand Rounds, Sunnybrook Women's Hospital University of Toronto Toronto, Canada
10/08/03	Lecture:	Advances in Endocrine Therapy
	Meeting:	Grand Rounds, Hamilton Regional Cancer Center McMaster University Ontario, Canada
10/08/03	Lecture:	Meet the Professor, Clinical Cases
	Meeting:	Princess Margaret Hospital University of Toronto Toronto, Canada
10/10/03	Lecture:	Treatment for Advanced Breast Cancer: Chemotherapy, Immunotherapy, Hormonal Therapy, Bisphosphates
	Meeting:	NCCN Clinical Practice Guidelines in Oncology Symposium

		New York, NY
10/17/03	Lecture: Meeting:	Hormonal Therapy in Breast Cancer Challenges & Controversies in Breast Cancer University of Washington Seattle, Washington
10/28/03	Lecture: Meeting:	Advances in Endocrine Therapeutics of Breast Cancer 22nd National Oncology Congress, Mexico Society of Oncology Queretaro, Mexico
10/30/03	Lecture: Meeting:	Treatment for Advanced Breast Cancer: Chemotherapy, Immunotherapy, Hormonal Therapy, Bisphosphonates NCCN Clinical Practice Guidelines in Oncology Symposium Atlanta, GA
11/3/03	Lecture: Meeting:	Therapeutic Prodrug Strategy Exploring Thymidylate Synthase Overexpression in Chemo Resistant Cancers Grand Rounds, Rush Presbyterian St. Luke Medical Center Chicago, IL
11/5/03	Lecture: Meeting:	Treatment for Advanced Breast Cancer: Chemotherapy, Immunotherapy, Hormonal Therapy, Bisphosphonates NCCN Breast Cancer Symposium San Francisco, CA
11/13/03	Lecture: Meeting:	Adjuvant Hormonal Therapy for Low-and High-Risk Breast Cancer School of Breast Oncology, Emory University Atlanta, GA
12/13/03	Lecture: Meeting:	Controversies in Early Stage Breast Cancer Grand Rounds, David Geffen School of Medicine at UCLA Santa Monica, CA
1/21/04	Lecture: Meeting:	Novel Treatment Strategies for Breast Cancer Grand Rounds, Emory University Atlanta, GA
2/6/04	Lecture: Meeting:	The Advances of Endocrine Therapy in Breast Cancer University of Iowa San Antonio Breast Cancer Symposium Review Iowa City, Iowa
2/7/04	Lectures: Meeting:	(1) Breast Cancer Prevention: 2004 (2) Adjuvant Chemotherapy for Early Breast Cancer (3) Hormonal Therapy for Breast Cancer (4) Management of Advanced Breast Cancer Annual Meeting of the Society of Gynecologic Oncology Post Graduate Course: Breast Cancer in 2004 San Diego, CA
2/13/04	Lectures:	(1) Endocrine and Bisphosphonate Therapy

		(2) Adjuvant Hormone Therapy (3) When Chemotherapy/Hormone Therapy Can Be Avoided
	Meeting:	The 9th Annual Multidisciplinary Symposium of Breast Cancer University of Florida Amelia Island, FL
2/16/04	Lecture:	Current Hormonal Options: Sequences and Integration with Chemotherapy
	Meeting:	Clinical Hematology & Oncology 2004 Scripps Cancer Center La Jolla, CA
2/28/04	Lecture:	(1) Overview of Adjuvant Therapy of Breast Cancer (2) Role of Capecitabine in Breast Cancer
	Meeting:	2004 Asian Breast Cancer Conference Taipei, Taiwan
3/13/04	Lectures:	(1) 2nd Line Metastatic Chemotherapy & Beyond (2) Hormonal Therapy for the Postmenopausal Metastatic Patient
	Meeting:	International Oncology Network Breast Cancer Symposium Atlanta, GA
3/27/04	Lectures:	(1) Adjuvant Endocrine Therapy: ER Positive, Postmenopausal (2) Extended Adjuvant Hormonal Therapy & Molecular Diagnostic Testing
	Meeting:	NOCR - Challenging Cases in Breast Cancer Las Vegas, NV
5/22/04	Lectures:	(1) Extended Adjuvant Therapy in Early Breast Cancer (2) Relapse Following Adjuvant Tamoxifen
	Meeting:	NOCR – Challenging Cases in Oncology and Hematology New York, NY
6/7/04	Lecture:	Endocrine Therapy for Breast Cancer
	Meeting:	American Society of Clinical Oncology New Orleans, LA
6/11/04	Plenary Lecture:	The Evolving Paradigm for the use of Endocrine Therapy in Breast Cancer
	Meeting:	Annual Meeting of Japanese Breast Cancer Society Fukuoka, Japan
6/19/04	Lectures:	(1) Molecular Diagnostic Testing (2) First-Line Metastatic Chemotherapy: Relapse at 1-Year
	Meeting:	NOCR – Challenging Cases in Breast Cancer New York, NY
6/25/04	Lecture:	Breast Cancer Update
	Meeting:	International Oncology Network ASCO Review Meeting Chicago, IL
7/10/04	Lecture:	Nonprotocol Decision-Making in the Adjuvant and Metastatic Settings

	Meeting:	Breast Cancer Update Chicago, IL
7/16/04	Lecture: Meeting:	Abraxane: Preclinical and Clinical Overview Abraxane Advisory Board San Francisco, CA
7/17/04	Lecture: Meeting:	Breast Cancer: Treatment of Choice NOCR - Challenging Cases in Breast Cancer San Francisco, CA
7/23/04	Lecture: Meeting:	Novel Adjuvant Chemotherapy Schedules: Preclinical and Clinical Rationale 3rd Annual International Breast Cancer Congress Bermuda
7/24/04	Lecture: Meeting:	Breast Cancer Highlights NOCR – 2004 ASCO Review Chicago, IL
7/29/04	Lecture: Meeting:	Advances in Adjuvant Therapy of Breast Cancer Medical Grand Rounds, Saint Francis Hospital Evanston, IL
7/30/04	Lecture: Meeting:	Breast Cancer Highlights from ASCO 2004 Northwestern University ASCO Review
8/10/04	Lecture: Meeting:	Clinical Overview of Abraxane NCCN Taxane Scientific Advisory Board Chicago, IL
9/2/04	Lecture: Meeting:	Advances in Treatment of Early Stage of Breast Cancer Grand Rounds, Columbia University New York, NY
9/11/04	Lecture: Meeting:	Overview of Letrozole Clinical Data Novartis Regional Advisory Board Chicago, IL
9/12/04	Lecture: Meeting:	Expert Perspectives in the Latest Breast Cancer Treatments and Research Lynn Sage Town Hall Meeting 2004 Chicago, IL
9/13/04	Lecture: Meeting:	NCCN Guidelines for Metastatic Breast Cancer NCCN Breast Cancer Guidelines, Roswell Park Cancer Institute Buffalo, NY
10/2/04	Lecture: Meeting:	Update on Aromatase Inhibitors 2004 Breast Cancer Update, Ohio State University Columbus, Ohio
10/7/04	Lecture: Meeting:	Advances in Breast Cancer Grand Rounds - Hinsdale Hospital

		Hinsdale, IL
10/15/04	Lecture:	Understanding Breast Cancer
	Meeting:	ASCO Webcast
10/17/04	Lecture:	Metastatic Breast Cancer: Overview and Management Update
	Meeting:	ION National Meeting Amelia Island, FL
10/22/04	Lecture:	Abraxane: Overview of Clinical and Preclinical Data
	Meeting:	Abraxane Advisory Board Boston, MA
10/23/04	Lectures:	(1) Extended Adjuvant Hormonal Therapy and Molecular Diagnostic Testing (2) Chemotherapy Options in Metastatic Breast Cancer
	Meeting:	NOCR – Challenging Cases in Breast Cancer Boston, MA
10/30/04	Lecture:	Emerging Novel Agents in the Treatment of Metastatic Breast Cancer
	Meeting:	6th Annual Lynn Sage Satellite Symposium Chicago, IL
10/30/04	Lecture:	Update on Dose Dense Chemotherapy
	Meeting:	6th Annual Lynn Sage Symposium Chicago, IL
10/31/04	Lecture:	Aspects of Anemia in the Breast Cancer Patient
	Meeting:	6th Annual Lynn Sage Satellite Symposium Chicago, IL
11/4/04	Lecture:	Management of Metastatic Breast Cancer
	Meeting:	Perception vs Practice Chicago, IL
11/11/04	Lecture:	Letrozole – Clinical Update
	Meeting:	Chemotherapy Foundation Symposium XXII New York, NY
11/12/04	Lecture:	Adjuvant Hormonal Therapy for Low and High Risk Breast Cancer
	Meeting:	School of Breast Oncology, Emory Universiy Atlantic, GA
11/17/04	Lecture:	Advances in Adjuvant Endocrine Therapy
	Meeting:	University of North Texas Fort Worth, TX
12/8/04	Lecture:	Advances in Adjuvant Breast Cancer Therapy
	Meeting:	Merck Symposium – San Antonio Breast Cancer Symposium San Antonio, TX
12/10/04	Lecture:	Advances in Taxane Therapy

	Meeting:	Meet the Professor – San Antonio Breast Cancer Symposium San Antonio, TX
1/3/05	Lecture: Meeting:	Overview of Abraxane: Preclinical and Clinical Data Abraxane Launch Meeting Palm Springs, CA
1/15/05	Lecture: Meeting:	Single Agent versus Combination Therapy for Metastatic Breast Cancer 4th Annual UCSF Clinical Cancer Update Squaw Valley, CA
1/21/04	Lecture: Meeting:	Adjuvant/Neoadjuvant Abstracts NOCR - 2004 San Antonio Breast Cancer Symposium Highlights New York, NY
1/28/04	Lecture: Meeting:	Managing Recurrence and Progression: The Case for Fulvestrant (Faslodex) Primary Therapy of Early Breast Cancer – An International Consensus Meeting St. Gallen, Switzerland
2/5/05	Lecture: Meeting:	Novel Preoperative Therapy Strategies Current Trends in Breast Cancer – Post San Antonio Breast Cancer Symposium Update Boston, MA
2/11/05	Lecture: Meeting:	NCCN Guidelines for Metastatic Breast Cancer NCCN Clinical Practice Guidelines in Oncology Symposium and San Antonio Breast Cancer Symposium Review, Northwestern University Chicago, IL
2/12/05	Lecture: Meeting:	Taxanes: Where Are We Now? ION Breast Cancer Symposium San Diego, CA
2/25/05	Lecture: Meeting:	Clinical Genomics in Early Breast Cancer Breast Cancer Multi-Specialty Treatment Planning Conference St. John's Mercy Medical Center Saint Louis, MO
03/1/05	Lecture: Meeting:	New Prognostic Tools in Early Stage Breast Cancer Grand Rounds, Medical University of South Carolina Charleston, SC
03/4/05	Lecture: Meeting:	The Role of Abraxane – Therapy in Metastatic Breast Cancer: A Clinical Focus Dartmouth Hitchcock Medical Center Lebanon, New Hampshire
03/5/05	Lecture: Meeting:	Update on Adjuvant Therapy of Breast Cancer Karmanos Cancer Center Breast Cancer Symposium Wayne State University

Detroit, MI

03/18/05	Lecture:	Treatments of Metastatic Breast Cancer
	Meeting:	Grand Rounds, University of Indiana Indianapolis, IN
03/19/05	Lecture:	Adjuvant Hormonal Therapy – Changing Paradigms and the Role Molecular Profiling
	Meeting:	NOCR – Reality Oncology: Your Challenging Cases in Breast Cancer Faculty Training San Francisco, CA
3/24/05	Lecture:	Recent Updates In the Treatment of Metastatic Breast Cancer
	Meeting:	Grand Rounds, Good Samaritan Medical Center West Palm Beach, FL
3/31/05	Lectures:	(1) The Role of Herceptin in HER2 Positive Breast Cancer (2) Define the Role of Xeloda in Early Breast Cancer
	Meeting:	Xian Roche Oncology Forum Xian, China
4/4/05	Lecture:	Combination of Sequential Single Agent Chemotherapy for Metastatic Breast Cancer
	Meeting:	Hong Kong College of Radiologists, Hong Kong Society of Clinical Oncology Hong Kong, China
4/22/05	Lecture:	Advances in the Treatment of Metastatic Breast Cancer
	Meeting:	Grand Rounds, Medical College of Wisconsin Milwaukee, Wisconsin
4/27/05	Lecture:	Advances in Metastatic Breast Cancer
	Meeting:	St. Agnes Hospital Baltimore, Maryland
4/28/05	Lecture:	Advances in Metastatic Breast Cancer
	Meeting:	St. Mary's Hospital Baltimore, Maryland
05/1/05	Lecture:	Role of Anthracyclines in Adjuvant Therapy of Early Breast Cancer
	Meeting:	NCCN Breast Adjuvant Task Force Meeting Chicago, IL
6/17/05	Lecture:	Phase III AT (doxorubicin/docetaxel) vs. AC doxorubicin/cyclophosphamide) in the Adjuvant Treatment of Node Positive and High Risk Node Negative Breast Cancer
	Meeting:	Best of ASCO San Francisco, CA
6/18/05	Lectures:	Breast Cancer Highlights from ASCO 2005
	Meeting:	Updates in Oncology 2005 Chicago, IL
9/17/05	Lecture:	Metastatic Breast Cancer – Novel Taxanes

	Meeting:	NOCR Challenging Cases in Breast Cancer Las Vegas, NV
9/24/05	Lecture:	Update in Adjuvant Hormonal Therapy
	Meeting:	Aultman Cancer Center Fifth Annual Cancer Conference Canton, OH
10/9/05	Lecture:	Chemotherapy: Teaching an Old Dog New Tricks
	Meeting:	7th Annual Lynn Sage Breast Cancer Symposium Chicago, IL
10/15/05	Lecture:	Adjuvant Chemotherapy – Recurrence Score Testing
	Meeting:	NOCR Challenging Cases in Breast Cancer Vancouver, British Columbia
10/18/05	Lecture:	Current Status of Trastuzumab (Herceptin) in Adjuvant Therapy
	Meeting:	Annual Meeting of American College of Surgeons San Francisco, CA
10/24/05	Lecture:	Treatment for Advanced Breast Cancer: Chemotherapy, Biologic Therapy, Hormonal Therapy
	Meeting:	NCCN Clinical Practice Guidelines in Oncology Symposium Omaha, Nebraska
10/28/05	Lecture:	Adjuvant Chemotherapy Treatment of Metastatic Disease
	Meeting:	The American School of Oncology Great Debates in Breast Cancer Lake Tahoe, CA
11/10/05	Lecture:	New Treatments for Breast Cancer
	Meeting:	Ingalls Comprehensive Cancer Program Harvey, IL
11/11/05	Lecture:	Adjuvant Hormonal Therapy
	Meeting:	School of Breast Oncology Atlanta, GA
11/12/05	Lecture:	Metastatic Breast Cancer – Novel Taxanes
	Meeting:	NOCR Challenging Cases in Breast Cancer Miami, FL
1/14/06	Lecture:	Metastatic Breast Cancer: Different Standards for Different Patients?
	Meeting:	SABCS Review – University of Cincinnati Cincinnati, OH
1/27/06	Lecture:	Treatment for Advanced Breast Cancer: Chemotherapy, Biologic Therapy, Hormonal Therapy
	Meeting:	Northwestern University SABCS Review and NCCN Guidelines
2/1/06	Lecture:	Update on Hormonal Therapy
	Meeting:	Aultman Cancer Center Breast Cancer Update Canton, OH

2/11/06	Lecture:	Emerging Nano-taxane Technology
	Meeting:	ION SABCS Review Las Vegas, NV
2/25/06	Lecture:	Adjuvant Chemotherapy
	Meeting:	NMCR Challenging Cases in Breast Cancer Chicago, IL
3/04/06	Lectures:	(1)Adjuvant Therapy of Breast Cancer (2)Neoadjuvant Therapy and Biology of Breast Cancer
	Meeting:	Review and Interpretation of SABCS St. Louis, MO
3/10/06	Lecture:	Chemotherapy in Metastatic Breast Cancer
	Meeting:	NCCN 11th Annual Conference Hollywood, FL
3/18/06	Lectures:	(1)Adjuvant Therapy of Breast Cancer: Gaining Insight into Who Benefits (2)An Overview of Adjuvant Therapy of Breast Cancer
	Meeting:	4th Annual Meeting of the Japanese Society of Medical Oncology Osaka, Japan
3/21/06	Lecture:	Phase I/II Data and Pivotal Phase III Trial of Novel Taxanes
	Meeting:	European Breast Cancer Congress Nice, France
3/23/06	Lecture:	Integrating Recent Landmark Systemic Therapy Data in Clinical Practice: What the Surgeon needs to know
	Meeting:	Annual Meeting of the Society of Surgical Oncology San Diego, CA
4/14/06	Lecture:	Metastatic Breast Cancer
	Meeting:	Grand Rounds – University of Wisconsin Madison, WI
4/22/06	Lecture:	New Paradigms in Adjuvant Therapy
	Meeting:	20th Annual Midwest Cancer Symposium Oak Brook, IL
4/24/06	Lecture:	Adjuvant Therapy in Early Breast Cancer
	Meeting:	Grand Rounds – Christ Hospital Oak Lawn, IL
5/20/06	Lecture:	Extending Adjuvant Therapy beyond 5 years
	Meeting:	European Breast Cancer Meeting Stockholm, Sweden
7/21/06	Lecture:	Cytotoxic Chemotherapy
	Meeting:	NCCN Adjuvant Therapy in Breast Cancer Symposium Duarte, CA
8/03/06	Lecture:	Adjuvant Therapy: Role of Taxanes
	Meeting:	NCCN Breast Cancer Guidelines Panel Salt Lake City, UT

8/26/06	Lecture:	Breast Cancer – Lapatanib
	Meeting:	NOCR - Regional Oncology Highlights Washington, DC
9/15/06	Lecture:	Optimal Adjuvant Chemotherapy
	Meeting:	8th Annual Lynn Sage Breast Cancer Symposium Chicago, IL
9/29/06	Lecture:	Extending the Span of Disease Free Survival
	Meeting:	Satellite - Extending the span of Patient Care in Breast Cancer Symposium: European Society Medical Oncology (ESMO) Annual Meeting Istanbul, Turkey
9/29/06	Lecture:	The Role of Extended Adjuvant Endocrine Therapy
	Meeting:	European Society Medical Oncology (ESMO) Annual Meeting Istanbul, Turkey
9/30/06	Lecture:	Novel Taxanes for Treatment of Advanced Breast Cancer
	Meeting:	European Society Medical Oncology (ESMO) Istanbul, Turkey
10/05/06	Lecture:	Advances in Treatment of Metastatic Breast Cancer
	Meeting:	Roche Memorial Lecture Cancer Institute of New Jersey Robert Wood Johnson School of Medicine, NJ
10/21/06	Lecture:	Metastatic Breast Cancer – Soft Tissue Mets
	Meeting:	NMCR - Challenging Cases in Breast Cancer Miami, FL
10/23/06	Lecture:	Treatment for Advanced Breast Cancer: Chemotherapy, Biologic Therapy, Hormonal Therapy
	Meeting:	NCCN Clinical Practice Guidelines in Oncology Symposium Breast Cancer Columbus, OH
10/27/06	Lecture:	Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer
	Meeting:	School of Breast Oncology Atlanta, GA
11/09/06	Lectures:	(1)Ixabepilone (2)Novel Antibodies Inhibitory Signed Transduction as a Treatment Strategy to Treat Breast Cancer
	Meeting:	Chemotherapy Foundation Symposium XXIV Mt. Sinai School of Medicine, NYC
11/16/06	Lecture:	Advances in Treatment of Metastatic Breast Cancer
	Meeting:	Mayo Clinic Fellow Conference Rochester, MN
12/02/06	Lecture:	Overview of Taxane Therapy as Treatment of Metastatic Breast Cancer
	Meeting:	Abraxis Western Breast Cancer Advisory Board

		Vancouver, Canada
12/08/06	Lecture: Meeting:	Metastatic Breast Cancer Missouri Baptist Medical Center – Tumor Board St. Louis, MO
2/08/07	Lecture: Meeting:	Update on Breast Cancer 2007 2nd Annual Community Oncology Conference Washington, DC
2/22/07	Lecture: Meeting:	Management of Medullary Carcinoma Annual Miami Breast Cancer Conference, Miami
2/22/07	Lecture: Meeting:	SPARC in Tumorigenesis Annual Miami Breast Cancer Conference, Miami
2/23/07	Lecture: Microtubules Meeting:	Innovations in Breast Cancer: Novel Strategies for Targeting Annual Miami Breast Cancer Conference, Miami
2/24/07	Lecture: Meeting:	Which Patients Benefit from Taxanes? Are all Taxanes the same? Annual Miami Breast Cancer Conference, Miami
3/3/07	Lecture: Meeting:	Advances in Adjuvant Therapy 3rd Annual Helene Madeira Breast Cancer Symposium, Lankenau Hospital, Philadelphia, PA
3/14/07	Lecture: Meeting:	Development of Abraxane® in Breast Cancer: Phase II Data and The Pivotal Trial 10th International Conference – Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland
3/15/07	Lecture: Meeting:	New directions in cytotoxic therapy – focus on new taxanes 10th International Conference – Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland
3/27/07	Lecture: Meeting:	Update on Chemotherapy in Breast Cancer Oncology Best Practices 2007 Evanston, IL
3/31/07	Lecture: Meeting:	Role of Taxanes in Metastatic Breast Cancer Advances in Breast Cancer Tokyo, Japan
3/31/07	Lecture: Meeting:	Abraxane in Breast Cancer Advances in Breast Cancer Tokyo, Japan
4/21/07	Lecture: Meeting:	New Paradigms in Adjuvant Therapy of Breast Cancer 21st Annual Midwest Cancer Symposium – Cancer In Women Oakbrook, IL
5/5/07	Lecture: Meeting:	Chemotherapy Management of Adjuvant Breast Cancer ION Woman's Cancer Care Meeting

		St. Louis, MO
5/5/07	Lecture: Meeting:	Chemotherapy Management of Metastatic Breast Cancer ION Woman's Cancer Care Meeting St. Louis, MO
5/11/07	Lecture: Meeting:	Issues in Breast Cancer Management Medical College of Wisconsin Milwaukee, WI
5/11/07	Lecture: Meeting:	Overview of Sorafenib in Breast Cancer Nexavar® Investigators Meeting Chicago, IL
6/01/07	Lecture: Meeting:	Harnessing SPARC Protein for Enhanced Selective Uptake of Chemotherapy Agents in Tumors Translating the Complexities of Cancer Development onto Novel Therapeutics, ASCO Chicago
6/02/07	Lecture: Meeting:	Overview of Adjuvant Endocrine Therapy ASCO, Japanese Investigator Meeting, Chicago
6/03/07	Lecture: Meeting:	Overview of Abraxane in Metastatic Breast Cancer ASCO, Abraxane Investigator Meeting, Chicago
6/03.07	Lecture: Meeting	Poster Discussion Adjuvant/NeoAdjuvant Therapy ASCO 2007, Chicago
6/29/07	Lecture: Meeting:	Northwestern University ASCO Review – Course Director Breast Cancer ASCO 2007, Chicago
7/12/07	Lecture: Meeting:	Advances in Endocrine Therapy Breast Cancer: Current Controversies & New Horizons Harvard Medical School Boston, MA
7/12/07	Lecture: Meeting:	CPC-New England Journal of Medicine Breast Cancer: Current Controversies & New Horizons Harvard Medical School Boston, MA
7/25/07	Lecture: Meeting:	Novel Taxanes Formulations for Breast Cancer Congress on the Future of Breast Cancer Kona, Hawaii
7/26/07	Lecture: Meeting:	Sorafenib as Treatment for Breast Cancer Congress on the Future of Breast Cancer Kona, Hawaii
8/25/07	Lecture: Meeting:	Breast Cancer Clinical Research: An Appraisal of Recent Progress Asia International Breast Cancer Beijing, China
8/26/07	Lectures:	(1)Optimal Taxane Therapy: Choice of agent, dose and schedule

		(2)Optimal Application of Trastuzumab in clinical practice
	Meeting:	Asia International Breast Cancer Beijing, China
8/30/07	Lecture:	Breast Cancer 101
	Meeting:	GE Health Care Diagnostic Division Milwaukee, WI
9/6/07	Lecture:	Overview of Sorafenib (Nexavar) Phase II Clinical Program in Metastatic Breast Cancer
	Meeting:	Onyx Investigator Meeting, ASCO Breast San Francisco, CA
9/7/07	Lecture:	Epothilones and other Novel Microtubule – Targeting Agents in Clinical Development
	Meeting:	Beyond Taxanes: New Chemotherapeutic Options for Patients with Refractory Breast Cancer - Chair ASCO Breast, San Francisco, CA
9/9/07	Lecture:	Pro: *All Patients with Metastatic Breast Cancer Should be Treated with Combination Therapy*
	Meeting:	Third Annual Oncology Congress San Francisco, CA
9/11/07	Lecture:	Treatment of Metastatic Breast Cancer in the Older Adult
	Meeting:	NCCN Breast Cancer in the Older Women Task Force Meeting Philadelphia, PA
9/23/07	Lectures:	(1)The Nab Technology Platform and Nab-paclitaxel (2)Metastatic Breast Cancer: Data Supporting the role of Nab-paclitaxel
	Meeting:	ECCO 14 – Barcelona, Spain
9/23/07	Lecture:	Chair, Fulvestrant: An emerging story providing an increasing role
	Meeting:	ECCO 14 – Barcelona, Spain
10/13/07	Lecture:	State of the Art: Breast Cancer
	Meeting:	ION National Meeting Atlanta, GA
10/16/07	Lecture:	Advances in Treatment of Metastatic HER2+ Breast Cancer
	Meeting:	Cancer Center Research Grand Rounds Kansas University Medial Center, Kansas City, KS
11/07/07	Lecture:	Practical Implication of Innovative Cancer Therapies: Novel Treatment Advances and Performance Improvement in Metastatic Breast Cancer
	Meeting:	Illinois State Oncology Hematology Administrators 2007 Fall Meeting Rosemont, IL
11/08/07	Lecture:	Clinical Activity of Capecitabine Plus Bevacizumab in Metastatic Disease
	Meeting:	Chemotherapy Foundation Symposium XXV New York, New York

11/09/07	Lecture:	Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer
	Meeting:	School of Breast Oncology Atlanta, GA
11/16/07	Lecture:	Therapeutic Strategies in Advanced Breast Cancer Hormone Therapy
	Meeting:	Esteve Symposium of Advances in Hormone Receptor Positive Breast Cancer Barcelona, Spain
11/29/07	Lectures:	(1)Treatment Options in Metastatic Breast Cancer
	Meeting:	Juravinski Cancer Center – McMaster University Medical Center Hamilton, Ontario
		(2)Treatment Options in Metastatic Breast Cancer
	Meeting:	University of Toronto, Toronto, Ontario
12/14/07	Lecture:	Overview of Metastatic Breast Cancer Lecture (Chair) Responsive, Node Negative Breast Cancer
	Meeting:	Optimizing Chemotherapy Outcomes in early and advanced Breast Cancer: A Case-based Discussion, 2007 San Antonio Breast Cancer Symposium
12/15/07	Lecture:	The Role of Gene Array Profiles in the Care of Endocrine Responsive, Node Negative Breast Cancer
	Meeting:	European and US Perspectives on Current Clinical Trials, Clinical Practice and Treatment Guidelines, 2007 San Antonio Breast Cancer Symposium
1/25/08	Lecture:	Advances in Metastatic Breast Cancer
	Meeting:	Saitama Medical University International Medical Center Tokyo, Japan
1/26-27/08	Lectures:	(1)Assessment of recurrence risk (2)Treatment of metastatic breast cancer: chemotherapy and targeted therapy
	Meeting:	NCCN – Japanese Comprehensive Cancer Network International Seminar Tokyo, Japan
2/21/08	Lectures:	(1)Overview of NCCN Breast Cancer Guidelines (2)Targeting Breast Cancer with Small Molecules (3)Evolving Strategies for the Management of Breast Cancer
	Meeting:	1st Annual Asia and Middle East NCCN Guidelines in Oncology Symposium Al Ain, United Arab Emirates
03/1/08	Lecture:	Genomics in Breast Cancer
	Meeting:	Challenging Cases in Breast Cancer New York, NY
03/6/08	Lecture:	Evaluation and Management of Cardiac Toxicity in the Treatment of

		Breast Cancer
	Meeting:	13th Annual NCCN Conference Clinical Practice Guidelines & Quality Cancer Care Hollywood, FL
3/15/08	Lecture:	Advances in Adjuvant Endocrine Therapy
	Meeting:	3rd Annual Georgetown Breast Cancer Update Washington, DC
03/16/08	Lecture:	Indications for Postoperative Trastuzumab and Novel Targeted Therapies
	Meeting:	The Society of Surgical Oncology 61st Annual Cancer Symposium Chicago, IL
4/15/08	Lecture:	Clinical Choices Making a Difference (discussant and Chair)
	Meeting:	2008 European Breast Cancer Center (EBCC 6) Berlin, Germany.
4/16/08	Lecture:	Breast Cancer in 2008: Debating the Important Issues
	Meeting:	2008 European Breast Cancer Center (EBCC 6) Berlin, Germany.
4/17/08	Lecture:	Current and Novel Chemotherapeutic Options in Breast Cancer
	Meeting:	2008 European Breast Cancer Center (EBCC 6) Berlin, Germany.
5/01/08	Lecture:	Panel speaker
	Meeting:	The Second Annual National Many Faces of Breast Cancer Event New York , NY
5/30/08	Lecture 1:	
	Meeting:	ASCO Annual Meeting 2008, Chicago, IL
7/12/08	Lectures:	(1)Anthracyclines: redefining their role in adjuvant setting (2)Adjuvant hormonal therapy: refining the end-point (3)Overview of Erb B-2 targeted treatment in breast cancer
	Meeting:	2nd Asia International Breast Cancer Summit, Hangzhou, China
9/04/08	Lecture:	New Options in the Management of HER2-Positive Disease
	Meeting:	NCCN 1st Annual Forum: Innovative Diagnostics and Therapeutics in Cancer Care New York, NY
9/18/08	Lectures:	(1)Introduction to Hormonal Therapy (2)Historical view of hormonal therapy in the adjuvant setting
	Meeting:	Breast Cancer Learning Days Chicago, IL
9/19/08	Lecture:	Breaking Down Barriers to Clinical Trial Enrollment
	Meeting:	Bridging Gaps & Expanding Outreach for metastatic Breast Cancer New York, NY
10/3/08	Lectures:	(1)Advances in Adjuvant Therapy of Breast Cancer (2)New Treatment Options for Breast Cancer
	Meeting:	2008 North Coast Breast Cancer Conference Sandusky, OH
10/9/08	Lectures:	(1)Debate Con: Bisphosphonates therapy should not be used routinely in

		Early Stage Breast Cancer (2)Case Presentation: Early Stage Breast Cancer
	Meeting:	ZENITH Meeting Madrid, Spain
11/07/08	Lecture:	Adjuvant Endocrine Therapy for Postmenopausal Hormone Receptor-Positive Breast Cancer
	Meeting:	School of Breast Oncology Atlanta, GA
11/15/08	Lectures:	(1)Local Control: Advances in Surgical Radiation Strategies Case Discussion (2)Advances in Hormonal Therapies and Bone-Targeted Agents Case Discussion
	Meeting:	New Developments in Breast Cancer Minneapolis, MN
12/12/08	Lectures:	(1)Sequencing Endocrine Therapies in Metastatic Disease (2)Management of early Endocrine Responsive Postmenopausal Breast Cancer
	Meeting:	2008 San Antonio Breast Cancer Symposium San Antonio, TX
12/13/08	Lectures:	(1)Optimal Management of Early Breast Cancer (2)Using Tumor Markers and Imaging for Asymptomatic Patients after Adjuvant Systemic Therapy
	Meeting:	2008 San Antonio Breast Cancer Symposium San Antonio, TX
12/19/09	Lecture:	New Strategies in Anti- HER2 treatments
	Meeting:	Rush University Hospital – Chicago IL
1/29/09	Lecture:	Update on New Data on the Use of Hormone Therapy
	Meeting:	Post San Antonio –North Shore - Long Island Jewish Health System Great Neck, NY
1/30/09	Lecture:	Treatment for Advanced Breast Cancer: Chemotherapy, Biologic Therapy, Immunotherapy, and Hormonal Therapy
	Meeting:	NCCN Clinical Practice Guidelines in Oncology Symposium™ Breast Cancer and 2008 San Antonio Breast Cancer Symposium Review Chicago, IL
2/08/09	Lecture:	Highlights of the 2008 San Antonio Breast Cancer Review
	Meeting:	Fourth Annual Community Oncology Conference Scottsdale, FL
2/08/09	Lecture:	Chemotherapy in Metastatic Breast Cancer
	Meeting:	Orlando Breast Cancer Conference Orlando, FL
3/06/09	Lectures:	(1)Estado de Arte: Tratamiento Neoadjuvante (2)Estado de Arte: Adjuvancia hormonal no Cancer de Mama (3)Estado de Arte: Arsenal terapeutico para doenca metastatica (4)Estado de Arte: Acaliacao criteriosa do uso de bisfosfonatos em

		adjuvancia no Cancer de Mama
	Meeting:	3 Conferencia Brasileira de Cancer de Mama Sao Paolo, Brazil
3/12/09	Lecture:	New Advances in Risk Reduction for Recurrence of Breast Cancer in Premenopausal Women
	Meeting:	14th Annual NCCN Conference Hollywood, FL
3/27/09	Lecture:	Optimizing the outcome of patients receiving adjuvant therapy
	Meeting:	Brustkrebstherapie in Wandel. Neus aus San Antonio und St. Gallen Munich, Germany
4/23-26/09	Lecture:	Treatment of HER2+ MBC: Current Treatment Options
	Meeting:	2nd Annual MENA NCCN Clinical Practice Guidelines in Oncology™ Congress Abu Dhabi, UAE
5/29/09	Lecture:	Targeting the Microtubules: A Key Mediator of Cell Division
	Meeting:	Advances in Treatment Options for Metastatic Breast Cancer: New Horizons for Cytotoxic and Targeted Agents Orlando, FL
6/18/09	Lecture:	Post ASCO Update – Breast Cancer
	Meeting:	North Shore LIJ Monter Cancer Center Lake Success, NY
6/19-20/09	Lecture:	Debate: 68 year old with Stage II, ER +, lymph node (+) breast cancer with recent history of osteoporotic spine fractures now on calcium, Vitamin D, and a bisphosphonate. What adjuvant hormone therapy is most appropriate?
	Meeting:	Great Debates & Updates in Breast Cancer, Chairperson San Francisco, CA
6/26/09	Lecture:	Breast Cancer
	Meeting:	2009 ASCO Review, Chair Chicago, IL
7/1/09	Lectures:	(1)Progress on Taxane Chemotherapies for Metastatic Breast Cancer (2)Genomic Profiling in Breast Cancer
	Meeting:	Annual Meeting of the Japanese Breast Cancer Society Tokyo, Japan
1/23/10	Lecture:	Emerging Data and Implications for Bone Health in Early and Advanced Disease
	Meeting:	Current Trends in Breast Cancer, Chair Minneapolis, MN
01/28/10	Lecture:	Treatment of Locoregional Disease
	Meeting:	NCCN 2010 Congress Series: Breast Cancer (Moderator) Chicago, IL
02/6/10	Lecture:	Seamlessly Integrating All Treatment Modalities
	Meeting:	2nd Asian Breast Cancer Congress (ABCC)

		Bangalore, India
02/7/10	Lectures:	(1)Adjuvant Hormonal Therapy: Do We have a Clear Sky Ahead? (2)Novel Taxane Therapy for Breast Cancer and Other Malignancies
	Meeting:	2nd Asian Breast Cancer Congress (ABCC) Bangalore, India
03/24/10	Lecture:	Metastatic Breast Cancer: Clinical Trials Update
	Meeting:	5th Annual Georgetown Breast Cancer Update Washington, DC
04/16/10	Lecture:	Advances in Breast Cancer Therapeutics
	Meeting:	Cancer Centers of Excellence (CCE) Philadelphia, PA
04/24/10	Lectures:	(1)Clinical Update on TK1 for Treatment of HER2 Positive Breast Cancer (2)Meet the Professor
	Meeting:	16th Hellenic Congress on Clinical Oncology Athens, Greece (via videoconference)
05/7-8/10	Lectures:	(1)Chair, Trastuzumab for Stage I Breast Cancer (2)Chair, Ovarian Suppression for Premenopausal Women with High Risk Early Stage Breast Cancer
	Meeting:	Great Debates in Breast Cancer San Francisco, CA
05/21/10	Lecture:	Moderator and Member, RIBBON-1 and E2100 Overview, Discussion, and Case Discussion
	Meeting:	Avastin Breast RIBBON 1 GENIC Steering Committee Advisory Board Meeting New York, NY
06/03/10	Lecture:	Emerging Science: Precision Medicine
	Meeting:	ASCO Chicago Chicago, IL
06/05/10	Lecture:	Sorafenib plus Paclitaxel in locally recurrent or metastatic breast cancer (NU07B1)
	Meeting:	Meet the Breast Cancer Experts Breakfast, ASCO Chicago, IL
06/09/10	Lecture:	Breast Cancer
	Meeting:	IPEA Awardees, ASCO Chicago, IL
06/25/10	Lecture:	Breast Cancer Update
	Meeting:	2010 Northwestern Univeristy ASCO Oncology Review Chicago, IL
06/26/10	Lecture:	Current Debates in the Treatment of HER2+ Metastatic Breast Cancer – A Case Based Discussion
	Meeting:	2010 Northwestern Univeristy ASCO Oncology Review

		Chicago, IL
07/15/10	Lecture:	Picking the Optimal Adjuvant Endocrine Therapy for Post-Menopausal Women
	Meeting:	Breast Cancer New Horizons Current Controversies Boston, MA
07/24/10	Lecture:	Highlights of 2010 ASCO Meeting
	Meeting:	Postgraduate Institute for Medicine/ University of Wisconsin Milwaukee, WI
07/27/10	Lecture:	Rapid Reviews in Oncology – ASCO 2010
	Meeting:	Dallas, TX
08/06/10	Lecture:	ABI-007 Developmental Strategies
	Meeting:	Cancer Institute Hospital of JFCR Tokyo, Japan
08/19/10	Lecture:	Treatment of HER 2+ Breast Cancer
	Meeting:	Biblioteca Hospital Oncologic Isaac Gonzalez Martinez San Juan, Puerto Rico
9/17/10	Lecture:	Biological targeted therapy in Breast Cancer
	Meeting:	Chinese Society of Clinical Oncology (CSCO) Beijing, China
9/18/10	Lecture:	Update Anti-HER2 Therapy
	Meeting:	Chinese Society of Clinical Oncology (CSCO) Beijing, China
9/23/10	Lecture:	Novel Agents in Breast Cancer
	Meeting:	Univ. of Miami/Miller School of Medicine Visiting Professor Braman Family Breast Cancer Institute Miami, FL
9/24/10	Lecture:	Advances in the Treatment for Metastatic Breast Cancer
	Meeting:	Univ. of Miami/Miller School of Medicine Visiting Professor Braman Family Breast Cancer Institute Miami, FL
11/12/10	Lecture:	Adjuvant Endocrine Therapy for Breast Cancer
	Meeting:	Emory School of Breast Oncology Atlanta, GA
11/19/10	Lecture:	Fulvestrant Clinical Development
	Meeting:	Advanced Breast Cancer Treatment Algorithm Meeting University of Nottingham Nottingham, UK
1/15/11	Lecture:	San Antonio Review
	Meeting:	Northwestern University Chicago, IL

1/29/11	Lecture:	San Antonio Review
	Meeting:	University of Kansas Kansas City, KS
2/05/11	Lecture:	Metastatic Disease Management of ER-PR negative Disease
	Meeting:	NCCN 2011 Congress Series: Breast Cancer ASCO Review Chicago, IL
2/09/11	Lecture:	Aultman Cancer Center ASCO Review
	Meeting:	Canton, OH
3/03/11	Lecture:	San Antonio Review
	Meeting:	Clinical Care Options Las Vegas, NV
3/26/11	Lecture:	Current Strategies in Treatment of Breast Cancer Adjuvant Endocrine Therapy
	Meeting:	Philadelphia, PA
4/02/11	Lecture:	Optimizing Management of Metastatic Breast Cancer
	Meeting:	Chicago, IL
4/04/11	Lecture:	Breast Cancer Update
	Meeting:	Christ Hospital
4/15/11	Lecture:	Guidelines for Adjuvant Therapy
	Meeting:	Advancing Multidisciplinary Breast Care, ASBD Course Santo Domingo, Dominican Republic
4/15/11	Lecture:	Treating Advanced/Inflammatory Breast Cancers
	Meeting:	Advancing Multidisciplinary Breast Cancer, ASBD Course Santo Domingo, Dominican Republic
5/05/11	Lecture:	Highlights from 2010 San Antonio Breast Cancer
	Meeting:	Breast Cancer Symposium, South Shore Hospital Chicago, IL
5/06/11	Lecture:	Overview of Abraxane for Breast Cancer
	Meeting:	Speaker Training Chicago, IL
5/07/11	Lecture:	Improving Survival in Metastatic Breast Cancer
	Meeting:	Controversies in Management of Advanced and Metastatic Breast Cancer Boston, MA (Chair)
5/14/11	Lecture:	Novel Approaches to Treating HER2+ Breast Cancer
	Meeting:	4th International Symposium on Cancer Metastasis and The Lymphovascular System New York, NY
5/14/11	Lecture:	Advances in MBC: Update in Clinical Practice
	Meeting:	New York, NY

5/21/11	Lecture: Meeting;	Advances in MBC-IMNE New York, NY
6/17/11	Lecture: Meeting:	Breast Cancer Update Northwestern University ASCO Review Chicago, IL
6/18/11	Lecture: Meeting:	Advances in MBC: Update in Clinical Practice Metastatic Breast Cancer: Updates in Clinical Treatments Boston, MA
7/8/11	Lecture: Meeting:	Advances in Treatment Metastatic Breast Cancer Glico, Latin America Oncology Conference Rio de Janeiro
7/21/11	Lecture: Meeting:	ASCO Review Stroger Hospital, Chicago, IL
7/30/11	Lecture: Meeting:	ASCO Highlights Milwaukee, WI
9/9/11	Lecture: Meeting:	Discuss at Ord Abstracts ASCO Breast San Francisco, CA
9/15/11	Lecture: Meeting:	Treatment of Bone Metastases Annual APAQ Conference Chicago, IL
9/16/11	Lectures: Meeting:	(1) New Strategies for Bone Metastases (2) Novel treatments for Refractory Metastatic Breast Cancer Annual Lynn Sage Breast Cancer Symposium Chicago, IL
10/14/11	Lecture: Meeting:	Neoadjuvant therapy for Breast Cancer Annual Meeting of the American Roentgen Ray Society Chicago, IL
10/27/11	Lecture: Meeting:	Advances in HER2 Therapy Annual Japanese Society of Clinical Oncology Nagano, Japan
10/29/11	Lecture: Meeting:	Treatment of Metastatic Breast Cancer Y-ME Chicago, IL
11/5/11	Lecture: Meeting:	Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer School of Breast Oncology Atlanta, GA
11/11/11	Lecture: Meeting:	Overview of ECOG Endocrine Trials ECOG Retreat Ft. Lauderdale, FL

1/7/12	Lecture:	Advances in HER2 Therapy
	Meeting:	Fourth Harbin Breast Cancer Forum Harbin, China
1/8/12	Lecture:	Advances in Treatment of Metastatic Breast Cancer
	Meeting:	Tianjin Cancer Hospital Tianjin, China
2/11/12	Lecture:	The Appropriate Use of Preoperative Neoadjuvant Therapy
	Meeting:	17th Annual Multidisciplinary Symposium on Breast Disease University of Florida, Amelia Island, Florida
3/24/12	Lecture:	(1) Screening Strategies for Breast Cancer (2) Prevention & Treatment of Breast Cancer
	Meeting:	Diagnosis, Screening, Prevention & Treatment of Primary Breast Cancer Fondazione Biblioteca Biomedica Biellese Biella, Italy
5/16/12	Lectures:	(1) Advances in neoadjuvant therapy of Locally Advanced Breast Cancer (2) Management of Hormone Receptor-Positive Breast Cancer (3) Advances in Decision Making for Early Stage Breast Cancer (4) Management of Metastatic Breast Cancer
	Meeting:	Visiting Professor Sun Yat-Sen Cancer Center Taipai, Taiwan
6/1/12	Lecture:	Chemotherapy Induced Peripheral Neuropathy Current & Emerging Strategies Using Novel Chemotherapy & Targeted Therapy for Metastatic Breast Cancer
	Meeting:	American Society of Clinical Oncology Chicago, IL
6/15/12	Lecture:	Update on Breast Cancer
	Meeting:	Northwestern University ASCO Review Chicago, IL
6/22/12	Lecture:	Breast Cancer Update
	Meeting:	2012 Northwestern University ASCO Review Chicago, IL
7/30/12	Lecture:	Disparities in Breast Cancer
	Meeting:	Bridging Racial Disparities in Cancer Incidence and Outcomes. National Medical Association Annual Meeting New Orleans, LA
8/4/12	Lecture:	Breast Cancer Update
	Meeting:	2012 ASCO Review Medical College of Wisconsin, Milwaukee
9/12/12	Lecture:	The Role of mTOR inhibitor in Metastatic Disease
	Meeting:	ASCO Breast Symposium San Francisco, CA

9/21/12	Lecture:	Barriers and Opportunities to the Use of Personalized Medicine in Breast Cancer
	Meeting:	Genomic Testing and the Quality of Care: Exploring the Impact of Healthcare Reform Philadelphia, PA
10/1/12	Lecture:	Managing the Axilla in Breast Cancer-the Medical Oncologist Perspective
10/2/12	Panel Discussion: New Trial Evidence and Emerging Controversies in Cancer Care	
	Meeting:	American College of Surgeons Clinical Conference Chicago, IL
10/6/12	Lectures:	(1) Selecting and Applying Genomic Assays (2) Overcoming Resistance to Endocrine Agents
	Meeting:	14th Annual Lynn Sage Breast Cancer Symposium Chicago, IL
11/3/12	Lectures:	(1) Adjuvant Endocrine Therapy for Postmenopausal ER+ breast cancer (2) Management of HER2-Positive Metastatic Breast cancer
	Meeting:	School of Breast Oncology (SOBO) Emory University Conference Center Atlanta, GA
1/18/13	Lecture:	Breast Cancer Roundtable
	Meeting:	Miami, FL
2/9/13	Lectures:	San Antonio Symposium Review
	Meeting:	University of Kansa, Kansas City, KS
2/19/13	Lecture:	Advances in Therapeutic Options for HER2-Negative Breast Cancer
	Meeting:	Southend University Hospital/Marygreen Manor Hotel, Essex, UK
2/20/13	Lecture:	Advances in Therapeutic Options for HER2-Negative Breast Cancer
	Meetings:	(1) Velindre Cancer Centre, Cardiff, UK (2) Royal United Hospital, Bristol, UK
2/21/13	Lectures:	Advances in Therapeutic Options for HER2-Negative Breast Cancer
	Meetings:	(1) York Hospital, York, UK (2) Newcastle Cancer Centre, Newcastle, UK
3/7/13-3/10/13	Lectures:	(1) Non-Anthracycline Adjuvant Therapy: When to Use? (2) Chemotherapy Choices in Later Lines of Therapy (3) Adjuvant Bisphosonates: Has The Time Come? (4) Managing Patients with Taxane and Anthracycline Pretreated, HER2-Negative, Metastatic Breast Cancer
	Meeting:	30th Miami Breast Cancer Conference Miami, Florida
4/12/13	Lecture:	Novel Directions in Breast Cancer Therapy
	Meeting:	18th Annual Phase II Symposium University of Chicago, Gleicher Center
5/16/13	Lecture:	Advances in HER2 Therapy

	Meeting:	Ochsner Medical Center, New Orleans, LA
6/1/13	Lecture:	Visiting Professor: Advances in Treatment of Metastatic Breast Cancer
	Meeting:	Radiosurgery Symposium, Northwestern University, Chicago, IL
6/7/13	Lecture:	Advances in Treatment for Early Stage Breast Cancer
	Meeting:	Joan W. Gibson Memorial Lecture, University of Virginia, Charlottesville, VA
6/27/13	Lecture:	ASCO Review- Breast Cancer
	Meeting:	Northwestern University, Chicago, IL
7/13/13	Lecture:	ASCO Update Breast Cancer
	Meeting:	Second Annual Cancer Treatment Center of America Review Chicago, IL
7/15/13	Lecture:	Prevention of Skeletal-Related Events in Patients with Breast Cancer To Bone
	Meeting:	Chicago, IL
8/9/13	Lecture:	Breast Cancer Update
	Meeting:	Best of ASCO Meeting Chicago, IL
8/16/13	Lecture:	Visiting Professor: Evolving Treatment Strategies for Early Stage Breast Cancer
	Meeting:	Moffit Cancer Center, Tampa, FL
9/9/13	Lecture:	New Data in Estrogen Receptor- Positive Disease and Treatment Sequence
	Meeting:	ASCO Breast Cancer Symposium San Francisco, CA
9/26/13	Lectures:	(1) Incorporating Genomic Assays into Clinical Reactions (2) Refining Theory for HER2-Positive Breast Cancer (3) Optimizing Treatment for Patient with TNBC
	Meeting:	Lynn Sage Breast Cancer Symposium Chicago, IL
10/2/13	Lecture:	Controversies in Management of Metastatic Breast Cancer
	Meeting:	Central DuPage Hospital Cancer Center Warrenville, IL
10/5/13	Lecture:	Assessing Current Treatment Modalities for Metastatic Breast Cancer
	Meeting:	Evolving Therapeutic Paradigms for Individualizing Treatment Options In Breast Cancer Hilton, Chicago, IL
10/5/13	Lecture:	Landscape Update: Metastatic Breast Cancer
	Meeting:	Individualizing Treatment Options for MBC Chicago, IL
10/15/13	Lecture:	The Evolution of Treatment for Early Stage Breast Cancer
	Meeting:	Department of Medicine Grad Rounds, Northwestern University Chicago, IL

10/18/13	Lecture:	Advanced Care Discussion of ER + Breast Cancer
	Meeting:	NCCN Webinar Chicago, IL
10/26/13	Lecture:	Landscape Update: Metastatic Breast Cancer
	Meeting:	Individualizing Treatment Options for MBC Houston, TX
11/8/13	Lecture:	Triple-Negative Breast Cancer: Are we any closer to finding real targets?
	Meeting:	Overcoming Disparities in Oncology Chemotherapy Foundation Symposium New York, NY
11/9/13	Lectures:	(1) Adjuvant Endocrine Therapy for Postmenopausal Hormone-Receptor Positive Breast Cancer (2) Management of HERZ-Positive Metastatic Breast Cancer and Novel Investigational Strategies
	Meeting:	11th Annual School of Breast Oncology Atlanta, GA
11/15/13	Lecture:	Nanoparticle Albumin-bound Taxanes: Where are we?
	Meeting:	3rd International Meetings on New Drugs in Breast Cancer Rome, Italy
01/11/14	Lecture:	Review of Endocrine Therapy SABCS 2013 Atlanta, Georgia
01/11/14	Lecture:	Revolutionizing the treatment strategy for recurrent breast Cancer
	Meeting:	PCME Science Atlanta, Georgia
02/01/14	Lecture:	Management of ER-positive Disease
	Meeting:	Review & Interpretation of the 2013 San Antonio Breast Symposium Orlando, FL
02/28/2014	Lecture:	Advances in Endocrine Therapy
	Meeting:	Annual NOCR Meeting Las Vegas, NV
03/07-08/14	Lectures:	(1) Individualized decision making for adjuvant therapy (2) Selecting Neo adjuvant therapy/rationale and therapeutic options (3) Systemic therapy in the elderly-making the right decision (4) Tumor Board (5) Therapeutic algorithm for endocrine manipulation
	Meeting:	Annual Meeting of the Breast Cancer Foundation of India Kochi, India
03/15/14	Lectures:	(1) Update on metastatic breast cancer (2) Meet the expert
	Meeting:	Annual NCCN Meeting Hollywood, FL
03/21/14	Lecture:	Advances in Treatment of Advanced Breast Cancer
	Meeting:	Hot Topics in Breast Cancer for Visiting Spanish Oncologists

03/22/14	Lecture:	Therapeutic Horizons: Maximizing the Benefit of Cytotoxice Agents
	Meeting:	Metastatic Breast Cancer, Emerging Paradigms in Care Dallas, TX
03/28-29/14	Lecture:	Challenges in the Management of ER-positive disease
	Meetings:	Master Classes in Breast Cancer (1) Thessaloniki, Greece (2) Athens, Greece (3) Athens, Greece
04/24/14	Lecture:	Balancing Efficacy with Tolerability in the Management of Metastatic Breast Cancer
	Meeting:	Mount Sinai Medical Center Grand Rounds Chicago, IL
05/16/14	Lecture:	Metastatic Breast Cancer
	Meeting:	Annual International Meeting of Lithuanian Senological Society Vilnius, Lithuania
05/31/14	Lecture:	Overview of treatment options, hormone-Insensitive Metastatic Breast Cancer
	Meeting:	ASCO 2014 Chicago, IL
06/02/14	Lecture:	New Therapeutic Targets for Prevention of SRE in Solid Tumors
	Meeting:	Indian Cooperative Oncology Network (ICON) ASCO 2014 Chicago, IL
06/21/14	Lecture:	Update from ASCO 2014 Breast Cancer
	Meeting:	NCCN/Japanese Comprehensive Cancer Network Tokyo, Japan
9/6/14	Lecture:	Evolving Standards in the Treatment of Breast Cancer
	Meeting:	ASCO Breast Cancer Symposium San Francisco, CA
09/08/14	Lecture:	The Evolution of Adjuvant Therapy for Breast Cancer
	Meeting:	MUSC Medical Ground Rounds Charleston, South Carolina
10/03/14	Lecture:	New Approaches to Systemic Therapy: Challenges to conventional Treatment
	Meeting:	Medical Grand Rounds, Melodie Wilson Oldenburg Breast Cancer Symposium Milwaukee, WI
10/23/14	Lecture:	The Evolution of Adjuvant Therapy for Early Stage Breast Cancer
	Meeting:	Hematology/Oncology Grand Rounds, Advocate Lutheran General Hospital Park Ridge, IL
11/7-8/14	Lectures:	1) Metastatic HER2-positive breast cancer

		2) Postmenopausal adjuvant endocrine therapy
	Meeting:	12th Annual School of Breast Oncology Atlanta, GA
11/10-11/14	Lecture:	Guideline Development: the NCCN experience
	Meeting:	Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer National Cancer Policy Forum Workshop, Institute of Medicine Washington, DC
12/13/14	Lecture:	Update in Metastatic Disease
	Meeting:	Year In Review San Antonio Breast Cancer Symposium San Antonio, TX
1/17/15	Lecture:	Personalized Therapy in Breast Cancer: Are We There Yet?
	Meeting:	2nd Annual USC Multidisciplinary Breast Cancer Symposium Keck School of Medicine of USC Los Angeles, CA
1/31/15	Lecture:	Management of ER-Positive Breast Cancer
	Meeting:	Review and Interpretation of the 2014 San Antonio Breast Cancer Symposium Orlando, FL
2/13/15	Lecture:	Management of Patients with Metastatic Disease, Including SABCS Updates
	Meeting:	NCCN 2015 Congress Series™: Breast Cancer with Updates from The 2014 San Antonio Breast Cancer Symposium Chicago, IL
2/19/15	Lecture:	The Promise of Personalized Medicine in Breast Cancer
	Meeting:	Special Seminar, Wake Forest University School of Medicine Winston-Salem, NC
2/27/15	Lecture:	1) When is Neoadjuvant Endocrine Therapy Appropriate? 2) Optimizing Adjuvant Therapy in Patients with Very Small HER2-positive Breast Cancer 3) How to Decide upon Optimal Duration of Adjuvant Hormonal Therapy
	Meeting:	Miami Breast Cancer Symposium Miami, FL
3/12/15	Lecture:	Optimizing Treatment of HER2-Positive Breast Cancer
	Meeting:	NCCN 20th Annual Conference: Advancing the Standard of Care Hollywood, FL
3/13/15	Lectures:	1) Moderator, "Breast Cancer: Highlights from Oncology Society Meetings (ASCO, ESMO, and SABCS) 2) Advanced hormone receptor-positive breast cancer
	Meeting:	20th Annual NOCR Meeting Las Vegas, NV

3/27/15	Lecture:	Moderator for entire meeting
	Meeting:	Breast Cancer National Advisory Board New York, NY
4/24-25/15	Lectures:	1) Advances in Treatment of Advanced ER+ Breast Cancer 2) Challenging Cases in Metastatic Breast Cancer
	Meeting:	Global Breast Cancer Summit 2015 Paris, France
5/1/15	Lecture:	Management of Disease/Advances in Treatments and Issues
	Meeting:	NCCN Peer Review of Proposals Committee In-Person Meeting Philadelphia, PA
5/13/15	Lecture:	Breast Cancer Landscape: 2015
	Meeting:	CVS/Caremark National Pharmacy and Therapeutics Committee Chicago, IL
5/28/15	Lecture:	Overview of HER2 Directed Therapy
	Meeting:	Australian Roundtable, ASCO Annual Meeting Chicago, IL
5/30/15	Lecture:	Differentiating Taxane Therapy
	Meeting:	ASCO Annual Meeting Chicago, IL
6/1/15	Lecture:	Discussant – Endocrine Therapy
	Meeting:	ASCO Annual Meeting Chicago, IL
6/1/15	Lecture:	ER-Positive, HER2-Negative Breast Cancer
	Meeting:	ASCO Breast Cancer Panel with Dr. Neil Love Chicago, IL
6/25-26/15	Lectures:	1) Treating Patients with Luminal A and B Breast Cancer 2) Interactive Case Presentations
	Meeting:	Milan Cancer Conference/European Institute of Oncology Milan, Italy
6/28/15	Lecture:	New Perspectives and Future Directions in Breast Cancer
	Meeting:	Best of ASCO Hyderabad, India
6/28/15	Lecture:	New Perspectives and Future Directions in Breast Cancer
	Meeting:	Best of ASCO Mumbai, India
6/29/15	Lecture:	Challenging Case Presentations
	Meeting:	Tate Memorial Hospital Mumbai, India
6/29/15	Lecture:	New Perspectives and Future Directions in Breast Cancer
	Meeting:	Best of ASCO Chennai, India

6/29/15	Lecture:	Challenging Case Presentations
	Meeting:	Adigar Cancer Institute Chennai, India
6/30/15	Lecture:	New Perspectives and Future Directions in Breast Cancer
	Meeting:	Best of ASCO Delhi, India
6/30/15	Lecture:	Debates in Breast Cancer
	Meeting:	Fortis Cancer Center Delhi, India
7/2-3/15	Lectures:	1) Update of NCCN Breast Cancer Guidelines 2) Consensus Panel on Clinical Practice Guidelines 3) Recent Advances in Systemic Therapy of Breast Cancer
	Meeting:	23rd Annual Meeting of Japanese Breast Cancer Society Tokyo, Japan
7/10/15	Lecture:	Breast Cancer Update
	Meeting:	Northwestern Medicine 2015 Oncology Review Chicago, IL
8/28/15	Lecture:	Triple Negative Breast Cancer and Local Therapy
	Meeting:	Best of ASCO 2015 Chicago, IL
9/12-13/15	Lecture:	1) Dual Blockade Target Therapy for HER2+ Early Breast Cancer 2) Co-Chair: International Consensus Panel on Breast Cancer Management 3) Consideration of Medical Treatment for Brain Metastasis 4) Role of Eribulin in Metastatic Breast Cancer
	Meeting:	2015 Taipei International Breast Cancer Symposium Taipei, Taiwan
9/25/15	Lecture:	Abstract Discussant
	Meeting:	ASCO Breast 2015 San Francisco, CA
10/1/15	Lecture:	Therapeutic Advances in Breast Cancer
	Meeting:	Steppin' Out for Women's Health Northwestern Lake Forest Hospital, IL
10/3/15	Lecture:	Novel Agents & Treatment Strategies for HER2-Positive and ER-Positive Breast Cancers
	Meeting:	Year in Review, Research to Practice New York City, NY
10/5/15	Lecture:	The Landscape of ER-Positive Breast Cancer
	Meeting:	Genentech/Roche Breast Cancer Summit San Francisco, CA
10/6/15	Lecture:	Choosing the Right Neoadjuvant Regimen
	Meeting:	American College of Surgeons Annual Meeting Chicago, IL

10/17/15	Lecture:	Advances in Breast Care Management
	Meeting:	Medical College of Wisconsin's Fourth Annual Advances in Hematology and Oncology Fall Symposium Green Bay, WI
10/29-31/15	Lecture:	1) Moderator: Sesssion 3, "Challenging Clinical Cases" 2) Session Chair, Session 6, "Employing Molecular Medicine in the Clinic" 3) New Approaches to ER Positive Metastatic Cancer
	Meeting:	Lynn Sage Breast Cancer Symposium Chicago, IL
11/6-7/15	Lecture:	1) Postmenopausal Adjuvant Endocrine Therapy 2) Metastatic HER2-Positive Breast Cancer 3) Moderator, "Treatment of HER2-Positive Disease"
	Meeting:	13th Annual School of Breast Oncology Atlanta, GA
1/20/16	Lecture:	Fundamentals of Neoadjuvant Therapy
	Meeting:	Webinar, Society of Surgical Oncology
1/29/16	Lecture:	Update on HER2 Therapy
	Meeting:	University of Wisconsin San Antonio Breast Cancer Symposium Review Milwaukee, WI
2/6/16	Lecture:	Plenary Lecture, Promise of Precision Medicine in Breast Cancer
	Meeting:	Washington University San Antonio Breast Cancer Symposium Review St. Louis, MO
2/12/16	Lecture:	Advances in Management of Advanced Disease
	Meeting:	NCCN 2016 Breast Cancer Congress & SABCS Updates Northwestern University Chicago, IL
2/20/16	Lecture:	Role of Taxanes in Metastatic Breast Cancer
	Meeting:	Innovation in Breast Cancer Symposium Madrid, Spain
3/5-6/16	Lectures:	1) Advances in Adjuvant Endocrine Therapy in Pre and Post-Menopausal Patients 2) Trends in Management of Metastatic Breast Cancer
	Meeting:	Best of SABCS India Mumbai, India
3/11/16	Lecture:	Advances in Systemic Therapy for Advanced Breast Cancer
	Meeting:	NCCN Webinar
3/15-17/16	Lectures:	1) Breast Cancer Management in Low and Middle Income Countries 2) Applying Resource Stratified Practice Guidelines 3) Adjuvant Endocrine Therapy for Pre- and Post-Menopausal Women
	Meeting:	Center for Global Health

Northwestern University & University of Jos, Nigeria

3/15/16	Lecture:	Systemic Neoadjuvant Approaches for Operable Breast Cancer
	Meeting:	Grand Rounds, Stroger Hospital Chicago, IL
3/30/16	Panel:	NCCN Guideline Panel Expert
	Meeting:	NCCN Academy for Excellence and Leadership in Oncology 21st NCCN National Meeting Hollywood, FL
4/1/16	Lecture:	NCCN Breast Guideline Update
	Meeting:	21st NCCN National Meeting Hollywood, FL
4/28-30/16	Lecture:	1)The Role of Adjuvant Chemotherapy in HER2-ve Luminal Breast Cancers 2) Case Discussion in Locally Advanced Breast Cancer 3) Targeting CDC4/6 and PI3K/ m-TOR pathways in HR+/HER2-: insights and outcome 4) Choosing the Right Anti HER2 Treatment for mBC Patients
	Meeting:	Pan Arab Oncology Congress Cairo, Egypt
6/5/16	Lecture:	Taxanes in TNBC
	Meeting:	ASCO – Meet the Expert Chicago, IL
6/7/16	Lecture:	EPIC – Expert Roundtable Review of ASCO – Breast Cancer
	Meeting:	ASCO Annual Meeting Chicago, IL
6/15-19/16	Lecture:	1) Obamacare & The Affordable Care Act of 2010 2) When is Pre-Operative Endocrine Therapy Appropriate? 3) ASCO Highlights: Endocrine Therapy
	Meeting:	Guangzhou Breast Cancer Symposium Guangzhou, China
7/15/16	Lecture:	Advances in Breast Cancer – Oncology Year in Review
	Meeting:	ASCO Review Northwestern University Chicago, IL
7/15/16	Lecture:	Update in Breast Cancer
	Meeting:	Oncology Year in Review, Northwestern University Chicago, IL
7/27/16	Lecture:	Update in Breast Cancer
	Meeting:	CVS National Pharmacy & Therapuetic Communications Chicago, IL
8/19/16	Lecture:	Metastatic Breast Cancer- Current Clinical Standards of Care in 2016
	Meeting:	Metastatic Breast Cancer in 2016 and Beyond: Insight from the Experts Las Vegas, Nevada

9/1/16 Lecture: Experience and challenges in the development of better cooperation between patients' organizations, scientific societies and authorities.
Meeting: 19th Congree of the Polish Society of Clinical Oncology
Gdansk, Poland

10/13/16 Lecture: Endocrine Therapies in Management of Hormone Receptor-Positive Breast Cancer: State of the Art
Meeting: State of the Science Breast Cancer Summit
Chicago, IL

10/16/16 Lecture: Medical Oncology Considerations for Young Breast Cancer Patients and Patients at High Risk
Meeting: American College of Surgeons Clinical Congress
Washington D.C.

10/24/16 Lecture: Breast Cancer
Meeting: Year in Review Florida Cancer Specialists/ Research to Practice
Orlando, FL

11/10/16 Lecture: Medical Crossfire- Role of HER2- Directed Therapy
Meeting: 34th Annual Chemotherapy Foundation Symposium
New York, New York

11/10/16 Lecture: Extended Adjuvant Endocrine Therapy
Meeting: 34th Annual Chemotherapy Foundation Symposium
New York, New York

11/10/16 Lecture: Medical Crossfire: Anthracycline: Here to Stay or Go
Meeting: 34th Annual Chemotherapy Foundation Symposium
New York, New York

12/7/16 Lecture: Novel strategies for overcoming resistance in ER+, Early and Late Stage Breast Cancer
Meeting: 2016 San Antonio Breast Cancer Symposium
San Antonio, Texas

12/9/16 Lecture: Role of Extended Adjuvant Endocrine Therapy.
Meeting: 2016 San Antonio Breast Cancer Symposium
San Antonio, Texas

12/15/16 Lecture: Novel Targets in TNBC
Meeting: Astellas Oncology Grand Rounds Series
Northbrook, IL

1/21/17 Lecture: Systemic therapy: Early Therapies
Meeting: Best of San Antonio Breast Cancer Symposium Chair and Speaker
Boston, MA

1/28/17 Lecture: Review of HER2 Directed Therapy
Meeting: Wisconsin Association of Hematology/Oncology San Antonio Breast Cancer Review
Milwaukee, WI

2/2/17	Lecture:	Breast Cancer as a Group of Diseases: Challenges and Opportunities
	Meeting:	University of Illinois/Chicago Breast Cancer Research Symposium Chicago, IL
2/4/17	Lecture:	New and Emerging Endocrine Therapies for Metastatic Breast Cancer Patients
	Lecture:	Systemic Therapy Considerations for DCIS
	Meeting:	The New York Metropolitan Breast Cancer Group 44th Annual Symposium New York, NY
2/10/17	Lecture:	Stage Breast Cancer including SABCS Highlights
	Meeting:	NCCN 2017 Breast Cancer Congress w/ SABCS Updates Meeting Chair Chicago, IL
2/25/17	Lecture:	HER2 Positive Breast Cancer: SABCS Highlights
	Meeting:	Georgia Society of Clinical Oncology Atlanta, GA
3/24/17	Lecture:	NCCN Guideline Updates: Breast Cancer and New Approaches to Endocrine Therapy
	Meeting:	NCCN Annual Conference Orlando, FL
4/10/17	Lecture:	Metastatic breast cancer guidelines: process for review and adaptation
	Meeting:	Workshop on Harmonization of Cancer treatment guidelines for Sub-Saharan Africa, African Cancer Coalition Nairobi, Kenya
5/6/17	Lecture:	The estrogen receptor-new drugs, sequencing pathways and duration
	Meeting:	Wendy and Emery Reves International Breast Cancer Symposium, UT Southwestern, Dallas TX
6/17/17	Lecture 1:	2017 NCCN Guidelines for Treatment of Advance Breast Cancer
	Lecture 2:	Advances in neoadjuvant therapy in HER2-positive disease
	Lecture 3:	Is neoadjuvant endocrine therapy suitable for HR positive breast cancer?
	Meeting:	2nd China-America Summit Forum on Breast Cancer, Guangzhou, China
6/24/17	Lecture:	Breast Cancer 2017
	Meeting:	George Washington University Review Course/Update, Washington, DC
8/5/17	Lecture:	Breast Cancer Update
	Meeting:	Best of ASCO, Philadelphia, PA
8/17/17	Lecture:	Precision Medicine in Breast Cancer
	Meeting:	Mid-year SOBO (School of Breast Oncology) Update Live webcast, Cranbury, NJ
8/22/17	Meeting:	NCCN/African Cancer Coalition Guideline Adaptation/Harmonization Workshop, Kampala, Uganda

9/8/17	Lecture 1:	Global Patient Advocacy
	Lecture 2:	Biosimilars in Breast Cancer
	Meeting:	European Society of Medical Oncology, Madrid, Spain
9/14/17-	Lecture 1:	Challenging Cases
9/17/17	Lecture 2:	Multidisciplinary Tumor Board
Chair	Lecture 3:	Optimal Direction of Endocrine Therapy
	Meeting:	19th Annual Lynn Sage Breast Cancer Symposium, Chicago, IL
10/1/17	Lecture 1:	Role of Neoadjuvant Chemotherapy
	Lecture 2:	Personalized Strategy in Management HER2+ Metastatic Breast Cancer
	Lecture 3:	Developmental Therapeutics for Breast Cacner and Brain Metasases
	Meeting:	Taipei International Breast Cancer Symposium, Taipei, Taiwan
10/3/17	Lecture:	Breast Cancer Screening and Risk Assessment
	Meeting:	Northwestern Univ. Dept. of Medicine Grand Rounds, Chicago, IL
10/20/17	Lecture:	Precision Medicine in Breast Cancer
	Meeting:	Japanese Society of Clinical Oncology (JSCO), Yokahana, Japan
11/3/17	Lecture:	Precision Medicine in Breast Cancer
	Meeting:	Rush University, Chicago, IL
11/4/17	Lecture 1:	Adjuvant Endocrine Therapy for Postmenopausal Women
	Lecture 2:	Management of HER2+ Metastatic Breast Cancer
	Meeting:	School of Breast Oncology, Emory, Atlanta, GA
11/5/17	Lecture:	Molecular Tumor Testing for Breast Cancer
	Meeting:	Henry Ford Hospital Breast Cancer Symposium, 1st Annual Detroit, MI
1/6/18	Lecture:	HER2 Targeted Therapy of Breast Cancer
	Meeting:	Best of SABCS, Georgia Oncology Society Atlanta, GA
1/27/18	Lecture:	HER2-Positive Breast Cancer
	Meeting:	Third Annual Wisconsin Review of the San Antonio Breast Cancer Symposium Milwaukee, WI
1/31/18	Lecture:	Future Targets for the Treatment of Breast Cancer
	Meeting:	Practical Recommendations in Immuno & Molecular Oncology (PRIMO) Maui, HI
2/8/18	Lecture:	Update of Breast Cancer
	Meeting:	Amity Health Grand Rounds, Oak Brook, IL
2/9/18	Lecture:	Metastatic Breast Cancer
	Meeting:	NCCN 2018 Breast Cancer with Updates from SABCS Chicago, IL
3/8/18-	Lecture 1:	What Ever Happened to Chemoprevention? Is it Dead?

3/10/18	Lecture 2:	When to Use Platinum-Based Chemotherapy in Daily Practice
	Lecture 3:	Modifying Extended HER2-Positive Breast Cancer
	Lecture 4:	Medical Crossfire: Everyone Should Receive >5 Years of Extended Adjuvant Endocrine Therapy
	Meeting:	35th Annual Miami Breast Cancer Conference – Mini-Symposium 360-Degree Patient Care
6/16-17/18	Lecture 1:	NCCN Guidline Update
	Lecture 2:	HER2+ Breast Cancer
	Meeting:	China-America Summit on Breast Cancer Guangzhou, China
6/30/18	Lecture:	Oncology Review: Breast Cancer
	Meeting:	George Washington Oncology Review Washington, DC
7/13/18	Lecture:	Breast Cancer Update
	Meeting:	2018 Oncology Review at Northwestern University Chicago, Il
8/10/18	Lecture:	HER 2+ Disease
	Meeting:	Best of ASCO Chicago, IL
8/31/18	Lecture 1:	Shaping the treatment paradigm for HR+/HER2- Metastatic Breast Cancer
	Lecture 2:	Changing the Face of Metastatic Breast Cancer
	Meeting:	Hong Kong Oncology Society Hong Kong
8/10/18	Lecture:	Breast Cancer Update
	Meeting:	2018 Oncology Review, Northwestern University Chicago, IL
9/28/18- 9/29/18	Lecture 1:	Molecular Assays for Early Stage Breast Cancer
	Lecture 2:	Adjuvant Endocrine Therapy for Premenopausal Women
	Meeting:	VII Multidisciplincary International Symposium on Breast Cancer San Paulo, Brazil
10/6/18	Lecture 1:	Triple-Negative Breast Cancer
	Lecture 2:	Management of Locally Advanced Breast Cancer
	Meeting:	2nd Annual Indian Breast Cancer Conference Jaipur, India
10/13/18	Lecture:	Lynn Sage Memorial Lecture: Looking Back 20 Years
	Meeting:	Lynn Sage Foundation Breast Cancer Symposium Chicago, IL
11/2-3/18	Lecture 1:	Management of HER2+ Metastatic Breast Cancer
	Lecture 2:	Advances in Adjuvant Endocrine Therapy
	Meeting:	School of Breast Oncology (SOBO) Emory, Atlanta
11/11/18	Lecture:	Triple-Negative Breast Cancer

	Meeting:	Oncology Nursing Society Minneapolis, MS
11/30/18	Lecture: Meeting:	Triple-Negative Breast Cancer Oncology Nursing Society Philadelphia, PA
12/4/18	Lecture: Meeting:	HER2+ Breast Cancer Research to Practice, SABCS 2018 San Antonio, TX
1/25/19	Lecture: Meeting:	KATHERINE and Breast Cancer Landscape Genentech/Roche Advisory Board Houston, TX
12/14/18	Lecture: Meeting:	Precision Medicine in Breast Cancer Oncology Grand Rounds, Rush University Chicago, IL
1/25/19	Lecture: Meeting:	KATHERINE and Breast Cancer Landscape Genentech/ Roche Advisory Board Houston, TX
1/26/19	Lecture: Meeting:	Advances in HER2+ Breast Cancer Wisconsin Association of Hematology/Oncology Milkwaukee, WI
2/2/19	Lecture 1: Lecture 2: Meeting:	Precision Medicine meets Breast Oncology: Molecular testing to direct treatment decisions New Treatment Options for Metastatic HER2+ Breast Cancer PRIMO 2019 Wailea, Maui, HI
2/9/19	Lecture 1: Meeting:	Utility of Multigene Assays in Management of Early Stage Breast Cancer NCCN 2019 Breast Cancer Congress Chicago, IL
3/7/19	Lecture 1: Lecture 2: Lecture 3: Meeting:	Early Stage TNBC Management HER2 Testing New Agents for Advanced ER+ Breast Cancer Miami Breast Cancer Symposium, Miami, FL
3/21/19	Lecture 1: Meeting:	Treatment of HR+/-, HER2- Advanced Breast Cancer Annual Conference of NCCN Hollywood, FL
4/24/19	Lecture 1: Meeting:	Harmonization of NCCN Guidelines in South America NCCN - Bolivia La Paz, Bolivia
6/28/19	Lecture 1:	TAILOR X – Interpretation and Implications for Clinical Practice

	Meeting:	9th Annual Asia Pacific Genomic Forum Yokahama, Japan
6/21-22/19	Lecture 1:	NCCN Guidelines Update
	Lecture 2:	ASCO Update 2019
	Meeting:	2019 China-America Summit Forum on Breast Cancer Guangzhou, China
7/11-12/19	Lecture 1:	Management of TNBC
	Lecture 2:	CDK 4/6 Inhibitor in ER+ Breast Cancer
	Meeting:	Annual Meeting Japonese Breast Cancer Society Tokyo, Japan
7/26/19	Lecture 1:	Breast Cancer Update
	Meeting:	Annual Oncology Review Northwestern University, Chicago, IL
8/6-7/19	Lecture 1:	Screening & Diagnosis
	Lecture 2:	Early & Local Advanced Breast Cancer
	Meeting:	ASCO Advantage ASCO Headquarters, Alexandira, VA
8/14/19	Lecture 1:	Breast Cancer Update
	Meeting:	CVS National Pharmacy and Therapeutics Committee Chicago, IL
8/22-23/19	Lecture 1:	Lobular Breast Cancer Panel
	Lecture 2:	Update from 2019 NCCN Guidelines
	Meeting:	5th Annual Cleveland Breast Cancer Summit Cleveland Clinic, Cleveland, OH
8/24/19	Lecture 1:	Standard of Care Neoadjuvant/Adjuvant Therapies for TNBC: NCCN recommendations
	Meeting:	Emerging Treatment Options in the Management of Early Stage TNBC Rush University, Chicago, IL
10/5/19	Lecture 1:	Optimal Approach to Residual Disease After Neoadjuvant Therapy
	Meeting:	Lynn Sage Breast Cancer Symposium Chicago, Il
10/23/19	Lecture 1:	Genetics of Breast Cancer
	Meeting:	ASCO Advantage Bethesda, MD
10/25/19	Lecture 1:	Role of Biosimilar
	Meeting:	Fall Foliage Conference at the University of North Carolina Asheville, NC
11/1-11/2/19	Lecture 1:	Adjuvant Endocrine Therapy in Postmenopausal Women
	Lecture 2:	Management of HER2+ Metastatic Breast Cancer
	Meeting:	School of Breast Oncology Atlanta, GA

11/15/19	Lecture 1:	Combination of HER2 Directed Therapy plus Novel Agents
	Meeting:	Sixth International Meeting in New Drugs in Breast Cancer Rome, Italy
12/11/19	Lecture 1:	Promise of Precision Medicine in Breast Cancer
	Meeting:	POA Breast Tumor Group San Antonio Breast Cancer Symposium San Antonio, TX
1/11/20	Lecture 1:	Adjuvant Endocrine Research
	Meeting:	Georgia Association of Clinical Oncology Atlanta, GA
1/25/20	Lecture 1:	Updates in HER2 Disease SABCS Review
	Meeting:	Wisconsin Association of Hematology-Oncology Milwaukee, WI
2/1/20	Lecture 1:	Plenary Lecture: Systemic Management of Breast Cancer
	Meeting:	Ohio State University Review of SABCS Columbus, OH
2/7/20	Lecture 1:	Updates on HER2 Metastatic Breast Cancer and SABCS Updates
	Meeting:	NCCN Breast Cancer Congress Chicago, IL
2/15/20	Lecture 1:	Updates on HER2 Disease Management
	Meeting:	Kansas University Medical Center SABCS Review Kansas City, KS
2/15/20	Lecture 1:	Molecular Testing in Early Breast Cancer
	Meeting:	PRIMO Honolulu, HI
2/22/20	Lecture 1:	HER2+ New MBC and New Agents
	Meeting:	Strategic Insights and Opinions on breast Cancer Scottsdale, AZ
4/6/20	Lecture 1:	COVID-19 and Cancer Care: What Oncologists Need to Know Today- Breast Cancer
	Meeting:	PER National Webcast on COVID-19 and Breast Cancer Virtual
4/8/20	Lecture 1:	HER2 Strategies in Breast Cancer
	Meeting:	Webcast Shanghai, China
4/14/20	Lecture 1:	NCCN Guidelines, Recommendations and CDK4/6 Inhibitors
	Meeting:	Webcast Shanghai, China
5/18/20	Lecture 1:	Hot Topics in Breast Cancer

	Meeting:	EPICS Breast Cancer in 2020 and Beyond Virtual
5/20/20	Lecture 1: Meeting:	COVID-19 and Breast Cancer American Society of Breast Surgeons Webcast
5/22/20	Lecture 1: Meeting:	Management of Metastatic Breast Cancer Annual Meeting of NCCN Virtual
6/1/20	Lecture 1: Meeting:	COVID-19 and Cancer Care: What Oncologists Need to Know Today- Breast Cancer PER National Webcast on COVID-19 and Breast Cancer Virtual
6/4/20	Lecture 1: Meeting:	COVID-19 Pandemic and Breast Cancer Consortium Reccomendations Breast Cancer Chakravyuh- Breaking Barriers Virtual Conference India-Virtual
6/19/20	Lecture 1: Meeting:	Changing Paradigm of the Management of Advanced ER+/HER2- Breast Cancer China America Summit Forum on Breast Cancer (Virtual) Guangzhou, China
6/20/20	Lecture 1: Meeting:	How to Use Biomarkers in the Clinical Management of Breast Cancer China America Summit Forum on Breast Cancer (Virtual) Guangzhou, China
6/21/20	Lecture 1: Lecture 2: Meeting:	Fam-Trastuzumab deruxtecan in HER2+ Metastatic Breast Cancer Advances in Systemic Therapy for HR+ MBC Patients China America Summit Forum on Breast Cancer (Virtual) Guangzhou, China
6/26/20	Lecture 1: Meeting:	Implementing Evidence-Based Recommendations for Treatment of Hormone Positive Metastatic Breast Cancer 2020 Egyptian Oncology Congress (Virtual) Cairo, Egypt
6/29/20	Lecture 1: Meeting:	COVID-19 and Cancer Care: What Oncologists Need to Know Today- Breast Cancer PER National Webcast on COVID-19 and Breast Cancer Virtual
7/18/20	Lecture 1: Meeting:	Breast Cancer Update NU Oncology Year in Review Virtual
8/7/20	Lecture 1: Meeting:	CDK 4/6 Inhibitor: From Bench to Bedside Fronteir Oncology Symposium- Cell Cycle and Breast Cancer China (Virtual)

8/14/20	Lecture 1:	CDK 4/6 Inhibitors in Metastatic Breast Cancer
	Meeting:	Wuhan China Oncology Society China (Virtual)
8/21/20	Lecture 1:	Advances in the Treatment of ER+ / HER2- Advanced Breast Cancer
	Meeting:	China Oncology (CISCO) China (Virtual)
9/10/20	Lecture 1:	Novel Endocrine Agents
	Meeting:	22nd Annual Lynn Sage Breast Cancer Symposium (Virtual)
10/1/20	Lecture 1:	Applying NCCN Guidelines in Resource Restricted Regions of the World
	Meeting:	7th Ain Shams University International Clinical Oncology Conference (Virtual) Cairo, Egypt
10/8/20	Lecture 1:	Treatment Options for Patients with Early Stage HER2+ Metastatic Breast Cancer
	Meeting:	Opinions in Breast Cancer: An Interactive Forum (Virtual)
10/10/20	Lecture 1:	Advances in Management of HER2+, Metastatic Breast Cancer
	Meeting:	Opinions in Breast Cancer (Virtual) Phoenix, AZ
10/21/20	Lecture 1:	Update on Managing ER+ Metastatic Breast Cancer
	Meeting:	University of Florida Cancer Center Grand Rounds (Virtual) Gainesville, FL
10/24/20	Lecture 1:	Update on HER2+ Metastatic Breast Cancer
	Meeting:	Annual Meeting of the Oregon Society of Medical Oncology (OSMO) (Virtual) Vancouver, WA
10/24/20	Lecture 1:	The Priorities for Breast Cancer Over the Next Decade
	Meeting:	Breast Cancer Odyssey (Virtual) New Delhi, India
10/28/20	Lecture 1:	Developments in Management of Breast Cancer
	Meeting:	CVS National P+T Committee Meeting (Virtual)
10/30/20	Lecture 1:	Update on Management of Metastatic TNBC
	Meeting:	John Wayne Cancer Center Grand Rounds (Virtual)
10/30/20	Lecture 1:	Metastatic Breast Cancer: To 2021 and Beyond
	Meeting:	Multidisciplinary Care Discussions in Oncology (Virtual) Athens, Greece
11/6-7/20	Lecture 1:	Treatments of HER2 Metastatic Breast Cancer
	Lecture 2:	Adjuvant Endocrine Therapy
	Meeting:	School of Breast Oncology (SOBO)

Atlanta, GA (Virtual)

11/20/20	Lecture 1:	Clinical Applications of ADC's
	Meeting:	PRIMO ADC Summit Virtual
12/11/20	Lecture 1:	View from the Tranches: What Will you do Monday?
	Meeting:	Annual San Antonio Breast Cancer Symposium Virtual
12/14/20	Lecture 1:	Retiring Treatment Approaches to HER2+ Breast Cancer
	Meeting:	OncLive PEER Exchange Virtual
12/17/20	Lecture 1:	Data Review from SABCS 2020
	Meeting:	OncLive Virtual
1/8/21	Lecture 1:	Adjuvant CDK 4/6 in Early Breast Cancer
	Meeting:	2021 International Symposium of Neoadjuvant Therapy for Early Breast Cancer Taipei, Taiwan (Virtual)
1/12/21	Lecture 1:	Gauging When Enough is Enough for Early Stage Disease
	Meeting:	Onc Live Summitt- UCLA (Virtual)
1/23/21	Lecture 1:	Metastatic HER2 Trials
	Meeting:	8th Annual USC Multi-Disciplinary Breast Cancer Symposium Los Angeles (Virtual)
1/23/21	Lecture 1:	Update: HER2+ Breast Cancer
	Meeting:	6th Annual Wisconsin Association of Hematology/Oncology (Virtual)
1/27/21	Lecture 1:	HER2+ Metastatic Breast Cancer
	Meeting:	Curio Science Interactive Workshop (Virtual)
2/3/21	Lecture 1:	Clinical Applications of Anti-Drug Conjugates
	Meeting:	PRIMO ADC Summitt 2021 (Virtual)
2/6/21	Lecture 1:	Updated in HER2+ Breast Cancer
	Meeting:	Advances in Hematology/Oncology Virtual Symposium Medical College of Wisconsin (Virtual)
2/12/21	Lecture 1:	Genomics to Guide Therapy in Early and Late Stage Breast Cancer
	Meeting:	PRIMO 2021 Hawaii (Virtual)
2/13/21	Lecture 1:	Update on Treatment of Metastatic Breast Cancer
	Meeting:	2021 NCCN Virtual Breast Cancer Congress (Virtual)

2/20/21	Lecture 1:	Advances in HER2+ Metastatic Breast Cancer
	Meeting:	Best of SABCS: India- Dehli (Virtual)
3/18/21	Lecture 1:	Update on Triple Negative Breast Cancer
	Meeting:	Annual Meeting of the National Comprehensive Cancer Network (NCCN) (Virtual)
3/17-21/21	Lecture 1:	Optimizing Adjuvant Endocrine Therapy
	Lecture 2:	Management of Lobular Cancer: Is it Different
	Meeting:	International Breast Cancer Consensus Panel 17th Annual St. Gallen International Breast Cancer Conference Vienna, Austria (Virtual)
3/21/21	Lecture 1:	The Phoenix of Breast Cancer Care- Emerging from Crisis
	Lecture 2:	Sequencing of Endocrine Therapy in Metastatic Breast Cancer
	Meeting:	30th Annual NCBC International Breast Conference Las Vegas (Virtual)
3/21/21	Lecture 1:	St. Gallen Consensus (Panel Member)
	Meeting:	17th Annual St. Gallen International Breast Cancer Consortium Virtual
3/24/21	Lecture 1:	Treatment of HER2+ Brain Met.
	Meeting:	PER Workshop Virtual
3/26/21	Lecture 1:	Updates in the Management of HER2+ Breast Cancer
	Meeting:	OncLive Scientific Workshop China, (Virtual)
3/27/21	Lecture 1:	Hotspots of Systemic Therapy for Breast Cancer from St. Gallen
	Meeting:	Breast Cancer Summitt China, (Virtual)
3/31/21	Lecture 1:	PARP Inhibitors in the Clinic
	Meeting:	AACR PARP Inhibitor Symposium Virtual
4/28/21	Lecture 1:	Evolving Paradigmes in HER2+ MBC
	Meeting:	EPICS Breast Cancer in 2021 and Beyond Virtual
5/14/21	Lecture 1:	Clinical Guidelines in Breast Cancer
	Meeting:	Polish NCCN Virtual Education Workshop Virtual
5/26/21	Lecture 1:	Optimizing Therapy in HER2+ Breast Cancer
	Meeting:	Peerview Virtual
6/5/21	Lecture 1:	Discussant: Leveraging Oral Therapy in Advanced Breast Cancer
	Meeting:	Annual ASCP Meeting

Virtual

6/14/21	Lecture 1:	HER2+ Breast Cancer Tumor Board
	Meeting:	PER Crossfire Virtual
6/28/21	Lecture 1:	CDA 4/6 Inhibitors in BC
	Meeting:	Current + Future Trends in ER+HER2- BC Virtual
7/16/21	Lecture 1:	Breast Cancer Update
	Meeting:	NU Oncology Year in Review Virtual
7/24/21	Lecture 1:	BRCA Testing and Treatment Decisions in BC
	Meeting:	Opinions in Breast Cancer Virtual
9/27/21	Lecture 1:	Current and Emerging Approaches in TNBC
	Meeting:	EPICS Global Perspectives: Current + Future Management of BC Virtual
10/1/21	Lecture 1:	CDA 4/6 Inhibitors in BC
	Meeting:	8th AIN SHAMS International Clinical Oncology Consortium Virtual
9/30-10/2/21	Lecture 1:	HER2+ Metastatic Breast Cancer
	Meeting:	Annual Lynn Sage Breast Cancer Symposium Virtual
10/16/21	Lecture 1:	BRCA Testing and Treatment Decisions in BC
	Meeting:	Opinions in Breast Cancer Virtual
10/21/21	Lecture 1:	State of the Art Breast Cancer Treatment
	Meeting:	NCDOA (National Community Oncology Dispensary Association) Phoenix, AZ
10/29-11/1/21	Lecture 1:	Adjuvant Endocrine Therapy
	Lecture 2:	Metastatic HER2+ Breast Cancer
	Meeting:	19th Annual School of Breast Oncology Atlanta, GA
11/6/21	Lecture 1:	Consensus Panel
	Meeting:	Advanced Breast Cancer #6 (ABL) Lisbon (Virtual)
11/7/21	Lecture 1:	Treatment Standards for HER2+ MBC
	Meeting:	4th Shanghai International Medical Oncology Symposium Shanghai (Virtual)
11/11/21	Lecture 1:	Management Options in HER2+ Breast Cancer
	Meeting:	Pathways to Practive in Breast Cancer Aptitude Health (Virtual)

11/21/21	Lecture 1:	Advances in Metastatic Breast Cancer
	Meeting:	New Orleans Fall Cancer Meeting New Orleans, Louisiana
11/30/21	Lecture 1:	Cases in Breast Cancer
	Meeting:	Aptitude Health (Virtual)
12/3/21	Lecture 1:	Progress in Metastatic Breast Cancer
	Meeting:	ASCO Direct China China (Virtual)
12/12/21	Lecture 1:	Update on TNBC
	Meeting:	Treatment, Development and Future Directions in Breast Cancer China (Virtual)
1/29/2022	Lecture 1:	Advances in HER2+ Breast Cancer
	Meeting:	Annual Wisconsin Association of Hematology/Oncology Milwaukee, WI
1/29/2022	Lecture 1:	Biomarkers of Immunotherapy and Combination Therapy
	Meeting:	VIVI- Getting Better 2021 Beijing, China (Virtual)
2/11/2022	Lecture 1:	Management of HER2- Metastatic Breast Cancer
	Meeting:	2022 NCCN Breast Cancer Congress Chicago, (Virtual/ Live)
2/12/2022	Lecture 1:	Immune Therapy in the (neo) adjuvant setting
	Meeting:	Management of Breast Cancer in the new Millennium China, (Virtual)
3/10/2022	Lecture 1:	Update in Triple Negative Breast Cancer
	Meeting:	Institutional Perspectives in Breast Cancer Virtual
3/25/2022	Lecture 1:	Identification of Disease Early- Clinical Trial Design
	Meeting:	Grand Rounds Center of Clinical Excellence FDA (Virtual)
3/26/2022	Lecture 1:	Advances in Oral Therapy for HR- Positive Advanced BC
	Meeting:	Northside Hospital Cancer Institute 2022 Symposium Atlanta, GA
3/31/2022	Lecture 1:	Management of Patients with HER2- Breast Cancer
	Meeting:	Annual NCCN Conference Virtual
4/8/2022	Lecture 1:	PARP Inhibitors in Breast Cancer
	Meeting:	American Society of Breast Surgeons Las Vegas, NV
5/26/2022	Lecture 1:	Optimal Strategies for Adjuvant Therapy of HR Early Breast Cancer

	Meeting:	Best of St. Gallen Breast Cancer Consortium Shanghai, China (Virtual)
5/27/2022	Lecture 1: Meeting:	Clinical Development of CDK 4/6 Inhibitors International Breast Cancer Symposium on Endocrine Therapy (Virtual)
5/28/2022	Lecture 1: Meeting:	Neoadjuvant Therapy for HER2+ Early Stage Breast Cancer Horizon- Clinical Updates in Breast Cancer Delhi, India (Virtual)
6/13/2022	Lecture 1: Meeting:	Neoadjuvant and Adjuvant Approaches in HR+/ TNBC Practical Approaches to Treatment in Breast Cancer OncLive, (Virtual)
6/17-19/22	Lecture 1: Lecture 2: Meeting:	Planning: 25 Years of Progress in Breast Cancer New Approaches in ER+ Breast Cancer 6th Annual Chinese American Breast Cancer Summitt Guangzhou, China (Virtual)
7/9/2022	Lecture 1: Meeting:	Breast Cancer George Washington Oncology Update Symposium Washington, DC
7/15/2022	Lecture 1: Meeting:	Breast Cancer Annual Oncology Review Chair- NM Chicago
9/14/2022	Lecture 1: Meeting:	Adjuvant Endocrine Therapy Practical Approaches to Treatment in Breast Cancer Virtual
9/17/2022	Lecture 1: Meeting:	Management Challenges: HER2+ Breast Cancer Insights Into Breast Cancer Intercontinental Chicago
9/22-25/22	Lecture 1: Meeting:	Advances in HER2 Positive Breast Cancer 24th Annual Lynn Sage Breast Cancer Symposium Chicago, IL
9/30/2022	Lecture 1: Meeting:	Oligometastatic Disease AIN SHAMS University International Clinical Oncology Conference Cairo (Virtual)
10/12/2022	Lecture 1: Meeting:	New Agents in HER2 Disease Opinions in Targeting HER2 in Advanced Breast Cancer Curio (Virtual)
10/22/2022	Lecture 1: Lecture 2: Meeting:	Current + Emerging Treatments for Advanced Disease Practice Management; Tox-d, Olaparib Opinions in Breast Cancer Seattle, WA
10/27/2022	Lecture 1:	Adjuvant Treatment Decisions based on risk of Recurrence in ER+ disease

	Lecture 2:	New Therapies in Early Stage Breast Cancer
	Meeting:	2nd Annual Perspectives in Breast Cancer Care Chicago, IL
11/3-5/22	Lecture 1:	Adjuvant Endocrine Therapy
	Lecture 2:	Metastatic Her2 Positive Breast Cancer
	Meeting:	20th Annual School of Breast Oncology Atlanta, GA
11/29/2022	Lecture 1:	Endocrine Therapy Post CDK 4/6 Inhibitors
	Meeting:	China Oncology News China (Virtual)
12/6/2022	Lecture 1:	Standard of Care Options for HR+ MBC
	Meeting:	San Antonio Breast Cancer Symposium (CME) San Antonio, TX
12/10/2022	Lecture 1:	Update on NCCN Guidelines-Advanced Disease
	Meeting:	San Antonio Breast Cancer Society SABCS (Virtual)
1/11/23	Lecture 1:	Recent Advances in Management of HER2+ Breast Cancer
	Meeting:	Institutional Perspectives in Breast Cancer OncLIVE (Virtual)
1/13/23	Lecture 1:	HER2 Positive Early Breast Cancer, HER2 Low Disease
	Meeting:	Best of San Antonio Shenzhen, China (Virtual)
1/21/23	Lecture 1:	Advances in Treatment of HER2 Positive Metastatic Breast Cancer
	Meeting:	10th Annual USC Multidisciplinary Breast Cancer Symposium Los Angeles, CA
1/28/23	Lecture 1:	Advances in Treatment of HER2 Positive Breast Cancer
	Meeting:	Year in Review- Breast Cancer| Wisconsin Association of Hematology/Oncology Milwaukee, WI
1/28/23	Lecture 1:	Advances in Treatment of HER2 Positive Breast Cancer
	Meeting:	Nebraska Oncology Society Annual Review of Breast Cancer Omaha, NB (Virtual)
2/3/23	Lecture 1:	Advances in HER2+ Breast Cancer
	Meeting:	NCCN 2023 Breast Cancer Congress Chicago, IL
2/11/23	Lecture 1:	Fine Tuning Endocrine therapy for ER+ Early Stage Breast Cancer
	Meeting:	University of Kansas Breast Cancer Review Overland Park, KS
2/15/23	Lecture 1:	On the Horizon: New Drugs in Breast Cancer
	Meeting:	CVS National P/T Committee Chicago, IL

2/15/23	Lecture 1:	Update on NCCN Guidelines
	Meeting:	Molecular Tumor Board Guangzhou, China (Virtual)
2/24/23	Lecture 1:	Advances in Treatment for High-risk ER+ Breast Cancer
	Meeting:	Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Honolulu, HI
3/3-4/23	Lecture 1:	Advances in Treatment of Metastatic HER2+ Breast Cancer
	Meeting:	Miami Breast Cancer Symposium Miami, FL
3/15/23	Lecture 1:	Consensus panel
	Lecture 2:	Surgery for Stage IV Disease
	Meeting:	St. Gallen International Breast Cancer Conference Vienna, Austria
3/31/23	Lecture 1:	Advances in Treatment of Metastatic Disease
	Meeting:	Annual NCCN Meeting Orlando, FL
4/22/23	Lecture 1:	Practice Guideline Development
	Meeting:	1st Annual PRECIS Meeting Miami, FL
4/27/23	Lecture 1:	Adaptation of Practice Guidelines for Daily Practice
	Meeting:	ECO Breast Summit Madrid, Spain
4/28/23	Lecture 1:	Advances in HER2-directed Therapy
	Meeting:	Aptitude Health Breast Cancer CORE, Texas Oncology (virtual)
5/16/23	Lecture 1:	Advances in HER2-directed Therapy
	Meeting:	Aptitude Health Breast Cancer CORE, NW Georgia Oncology (virtual)
5/23/23	Lecture 1:	Advances in HER2-directed Therapy and PARP Inhibitors
	Meeting:	Aptitude Health Breast Cancer CORE, Advocate Health Chicago
5/24/23	Lecture 1:	Advances in HER2-directed Therapy
	Meeting:	Opinions in Targeting HER2 in MBC: An Interactive Workshop (virtual)
6/4/23	Lecture 1:	New Therapeutic Developments on Breast Cancer
	Meeting:	ASCO OncLive Chicago, IL
6/16-17/23	Lecture 1:	Keynote: Major Advances in Breast Cancer Management 2023
	Lecture 2:	Drug Development for HER2-low Disease
	Lecture 3:	PARP Inhibitors for BRCA Germline Mutation Carriers
	Meeting:	International Breast Cancer Summit Guangzhou, China
6/22/23	Lecture 1:	Advances in HER2-directed Therapy

	Meeting:	Aptitude Health Breast Cancer CORE Program, Tennessee Oncology & City of Hope (virtual)
6/28/23	Lecture 1: Meeting:	Clinical Decision-Making in HER2-negative Disease MD Outlook CME (virtual)
7/21/23	Lecture 1: Meeting:	Update on Management of MBC Annual Lurie Cancer Center Oncology Review Chicago, IL
8/15/23	Lecture 1: Meeting:	Update on Management of MBC Annual George Washington University Board Review Course (virtual)
8/16/23	Lecture 1: Meeting:	Update on Management of MBC Opinions in Metastatic Breast Cancer Michigan (virtual)
8/24/23	Lecture 1: Meeting:	ADCs in Breast Cancer Targeted Oncology Case-based Roundtable Chicago, IL
9/7-10/23	Lecture 1: Meeting:	Advances in Management of HER2-Positive Disease Lynn Sage Breast Cancer Symposium Chicago, IL
9/13/23	Lecture 1: Meeting:	Targeted Therapy in Breast Cancer Opinions in Breast Cancer: Interactive Workshop Chicago, IL
9/16/23	Lecture 1: Meeting:	Update on Guideline Development Shanghai International Breast Cancer Symposium
9/22/23	Lecture 1; Meeting:	Update on Breast Cancer Illinois Cancer Symposium at Carle Clinic Champaign, IL
9/29/23	Lecture 1: Meeting:	Treating Patients with HR+/HER2- Disease Medscape CME in Endocrine-sensitive Breast Cancer
10/10/23	Lecture 1: Meeting:	Sequencing Options in HER2+ Breast Cancer Daichi-Sanyo Advisory Meeting
10/12/23	Lecture 1: Meeting:	Conversations in TNBC Practice Point CME
11/2-5/23	Lecture 1: Lecture 2: Meeting	Adjuvant Endocrine Therapy Treatment of Metastatic HER2+ Disease School of Breast Oncology – Emory University Atlanta, GA
11/9-11/23	Lecture 1: Lecture 2: Meeting:	Consensus Panel Member New Approaches for Lobular Cancer Advanced Breast Cancer 7 Consensus Conference Lisbon, Portugal

11/12/23	Lecture 1:	ESMO Highlights in HR+ Metastatic Breast Cancer
	Meeting:	11th Chinese Advanced Breast Cancer Consensus Guideline Conference Beijing, China
11/14/23	Lecture 1:	Case-based Presentations
	Meeting:	Opinions in ADCs in MBC: An Interactive Workshop Chicago, IL
11/20/23	Lecture 1:	ADC in Breast Cancer
	Meeting:	Targeted Oncology Case-based Roundtable Chicago, IL
12/4/23	Lecture 1:	How has the management of the young, ER+ breast cancer patients changed over the years?
	Meeting:	Ovarian Function Suppression Summit - San Antonio Breast Cancer Symposium
12/6/23	Lecture 1:	Integrating PET Imaging into Metastatic HR+ Breast Cancer Care Settings
	Meeting:	PER CME Meeting - San Antonio Breast Cancer Symposium
2/2/24	Lecture 1:	Advances in Management of HER2-positive MBC
	Meeting:	NCCN Breast Cancer Congress (Chair) Chicago, IL
2/3/24	Lecture 1:	Advances in treatment of HER2-positive, metastatic breast cancer
	Meeting:	Wisconsin Association of Hematology/Oncology Milwaukee, WI
2/13/24	Lecture 1:	Updates on HER2+ Breast Cancer from San Antonio
	Meeting:	Aptitude Health Care Breast CORE – University of Kansas Cancer Center
2/26/24	Lecture 1:	PARP Inhibitor in Breast Cancer
	Meeting:	Targeted Oncology Breast Cancer Case-based Roundtable
3/5/24	Lecture 1:	Evolving Treatment Paradigms in ER-Positive, HER2-Negative Metastatic Breast Cancer
	Meeting:	MJ Life Sciences CME (virtual)
3/7/24	Lecture 1:	Crossfire: Optimizing and expanding toolbox in advanced HR+/HER2- MBC
	Meeting:	Miami Breast Cancer Symposium Miami, FL
3/28/24	Lecture 1:	Highlights of SABCS 2024
	Meeting:	DAVA's Best Practices in Breast Cancer
4/3/24	Lecture 1:	ADCs in Advanced Breast Cancer
	Meeting:	Targeted Oncology Breast Cancer Evolving Paradigms Roundtable (virtual)
4/4/24	Lecture 1:	Updates in the Treatment of Patients with HR+ Advanced Breast Cancer
	Meeting:	Virtual NANO
4/18/24	Lecture 1:	Ovarian Suppression for Breast Cancer
	Meeting:	Neil Love Breast Cancer Think Tank

5/1-3/24	Lecture 1:	NCCN Breast Cancer Guidelines
	Meeting:	NCCN Sub-saharan Guideline Development Meeting Nairobi, Kenya
5/15/24	Lecture 1:	Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
	Meeting:	Community Oncology Connections – Indiana Oncology Society
5/23/24	Lecture 1:	Treatment Sequencing for Patients With HER2-Low MBC
	Meeting:	Opinions in Targeting HER2 in MBC: An Interactive Local Workshop
5/29/24	Lecture 1:	The Advent of TROP2- Targeted Treatment Approaches in HR+/HER2- Breast Cancer and What You Need to Know
	Meeting:	Oncology Best Practice Grand Rounds Series Chicago, IL
6/12/24	Lecture 1:	ADCs in Breast Cancer
	Meeting:	Aptitude Health Breast CORE – Sidney Kimmel/Jefferson Health
6/13/24	Lecture 1:	ADCs in Breast Cancer
	Meeting:	Aptitude Health Breast CORE – Broward Health
6/13-16/24	Lecture 1:	Keynote: Major Advances in Breast Cancer 2024
	Meeting:	International Breast Cancer Summit Guangzhou, China and Macau
6/20/24	Lecture 1:	ADCs in Breast Cancer
	Meeting:	Aptitude Health Breast CORE – GA Cancer Specialists
6/21/24	Lecture 1:	Evaluating the Evolving Treatment Landscape for HR+ Breast Cancer - How to Personalize Care and Improve Patient Outcomes
	Meeting:	Wyoming/Montana State Oncology Society
7/12/24	Lecture 1:	ASCO Update on ER+ Breast Cancer
	Meeting:	12th Chinese Advanced Breast Cancer Consensus Guideline Conference Beijing, China
7/19/24	Lecture 1:	Late Stage Breast Cancer Update
	Meeting:	Annual Lurie Cancer Center Oncology Review (Chair) Chicago, IL
7/24/24	Lecture 1:	ADCs in Breast Cancer
	Meeting:	Aptitude Health HER2+ Breast CORE - Cancer Care of York
7/27/24	Lecture 1:	HER2+ Breast Cancer
	Meeting:	Opinions in Breast Cancer: An Interactive Regional Forum Chicago, IL
7/30/24	Lecture 1:	Current and emerging treatment options for patients with HR+/HER2- MBC
	Meeting:	Opinions in Targeted Therapies in HER2- Breast Cancer - Great Lakes
8/6/24	Lecture 1:	Treatment of HER2+ and HER2-low Disease
	Meeting:	Emerging Concepts in Breast Cancer Management
8/13/24	Lecture 1:	Adjuvant Therapy for Breast Cancer

	Meeting:	George Washington University Hem/Onc Board Review Course Washington, DC
8/15/24	Lecture 1:	Treatment of HER2-low Disease
	Meeting:	Aptitude Health HER2+ Breast CORE - Florida Cancer Specialists